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Abstract 
One of the major limitations of traditional organic chemical synthesis is the challenge of 
modifying a starting material with both stereoselectivity and regioselectivity to produce a single 
product. Nature has solved this problem by evolving enzymes that specifically bind ligands and 
orientate them for selective modification. Furthermore, enzymes are generally active under mild 
conditions, forgoing the harsh chemicals and byproducts often necessary in chemical synthesis. 
Therefore, there has been a growing interest to utilize enzymes as an alternative method for the 
production of a variety of compounds. 
Organic chemistry is limited is in the production of natural products. Natural products are 
broadly defined as compounds produced by living organisms that have bioactivity. With activities 
including antibacterial, antimycotic, antimalarial, cytotoxic, and immunosuppressive, natural 
products represent a plentiful source of medically relevant compounds. However, the synthesis of 
these molecules is often difficult due to their large size and complexity. For example, the common 
anticancer compound taxol is produced by isolating the immediate precursor from its natural 
source, the Pacific yew tree, because the total organic synthesis is prohibitively expensive. To 
effectively utilize enzymes in the production of complex natural products or biofuels, it is 
important to understand the molecular basis for their catalysis. This information can allow for the 
design of new enzymes that create novel compounds or the prediction of existing natural products 
by examining sequenced genomes. In this dissertation, I will present my efforts to understand both 
the ligand binding and catalytic mechanisms of proteins involved in the biosynthesis of RiPP 
natural products and polysaccharide degradation. 
RiPP (ribosomally synthesized and posttranslationally modified peptide) natural products 
represent a growing class of compounds. They are biosynthesized from a linear precursor peptide 
that was translated by the ribosome. A series of post translation modification transform the 
precursor peptide into the mature natural product. One of the common types of modifications 
observed in RiPP natural products is cyclization. My work in the RiPP natural product field has 
focused on three types of cyclization. In the first, thiazole and oxazole heterocycles are observed 
to be formed through the condensation of a serine, threonine, or cysteine residue and its backbone 
carbonyl in several classes of RiPPs including cyanobactins, thiopeptides, and linear azole 
containing (LAP) peptides. In Chapter 2, I discuss the crystallization of the putative 
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cyclodehydratase YcaO. My structural study of YcaO allowed for the identification and 
characterization of new ATP binding motif present in this family of enzymes.  
Head to tail macrocyclization is a second type of cyclization observed in serveral RiPP 
classes including orbitides, cyanobactins, and cyclotides. In Chapter 3, I discuss the structural and 
biochemical characterization of PCY1, the enzyme responsible for cyclization of the orbitide 
segetalin A1. My work identified both a new example of a RiPP precursor peptide binding mode 
and the mechanistic basis for the new cyclization activity discovered in the abundant S9 peptidase 
fold. 
Finally, the cyclization of the N-terminus of a peptide and a side chain through an 
isopeptide bond is observed in lasso peptide class. These natural products are noteworthy because 
the tail of the lasso peptide is threaded through the macrocyclic structure, producing a lasso shape. 
In Chapter 4, I discuss the structural elucidation and biochemical characterization of the leader 
peptide binding domain TbiB1. Though the use of in vitro activity assays and binding experiments, 
I was able to demonstrate a short, conserved motif is both necessary and sufficient for binding. In 
Chapter 5, I elaborate upon my work on the lasso peptide isopeptidase AtxE2. This enzyme, 
theorized to be a siderophore or mechanism of self-resistance in the lasso peptide-producing 
organism, was studied both structurally and biochemically to demonstrate that it constitutes a 
previously uncharacterized fold. Furthermore, its sparse interactions with the lasso peptide 
substrate may help to explain its substrate tolerance. Finally, we use the AtxE2 protein sequence 
as a tool to identify additional putative lasso peptide biosynthetic clusters, several of which would 
have been difficult to identify using other proteins as a probe. 
In addition to the production of natural products, enzymatic tools have been actively sought 
in the product of biofuels. One of the rate limiting steps in the production of biofuels in the 
degradation of complex sugar polymers such as hemicellulose and lignin from plant biomass into 
simple sugars. These sugar monomers can be utilized as a carbon source for biodiesel or ethanol 
producing microbes. In Chapters 6 and 7, I detail my efforts to structurally characterize several 
types of sugar binding domains present within sugar hydrolases. The structural analysis was then 
augmented with binding assays to confirm the binding determinants. 
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Chapter 1 Introduction 
 
 While organic synthesis has been and will continue to be a critical component in the 
production of useful chemicals, there has been a significant interest in using purified or in vivo 
enzymes as a complement for traditional chemical methods, collectively called biocatalysis.1 In 
fact, both enzyme catalysis and microbial fermentation are used extensively in industry. For 
example, enzymes are used to removed hydrogen peroxide during textile production2, production 
of polyester,2 and production of high fructose corn syrup,3 while microbes are used to produce 
citric acid,4 glutamate,5 and acrylamide.6 The rationale for this movement is based on the unique 
advantages that enzymes offer over organic synthesis. First, enzymes are typically extremely 
specific for the substrates they utilize and products they produce. Enzymes coordinate substrates 
in 3-dimensional space using a variety of amino acid residues in the active site. This mode of 
interaction ensures that only one position is properly oriented for catalysis, enabling even non-
chiral substrates to generate a stereochemically pure product. This contrasts with traditional 
organic synthesis wherein selectivity is a regular concern. Reactions are often able to occur on 
multiple moieties, forcing the use of protecting groups that need to be both added and removed. 
This increases the number of total steps required during a synthetic procedure, and may decrease 
product yield. Furthermore, reactants are not often coordinated in 3-dimenational space. This 
allows for production of enantiomeric products that need to be separated, decreasing overall yield. 
 Organic synthetic methods are often forced to make use of many biologically toxic 
compounds including solvents, heavy metals, and harsh pHs. Disposal of these byproducts is 
expensive and leaks can lead to environmental problems. Therefore, efforts have been make to 
investigate more environmentally safe methods of synthesis, called “green chemistry”.7 In addition 
to “greener” synthetic routes, biocatalysis and enzyme use are often considered as tools in this 
emphasis on green chemistry. Enzymes not only typically function most efficiently in aqueous 
solvents, near neutral pHs, and without extensive use of heavy metals, but they also have few side 
products that require disposal. 
 To completely and efficiently make use of enzymes as synthetic tools, it is important to 
both uncover novel enzymatic activities and understand their mechanism of action. With the 
exponential increase in sequencing data available, the abundance and diversity of unknown 
enzymatic functions has become apparent. Efforts, such as those in the Enzyme Function 
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Initiative,8 have sought to rapidly assign functions to these uncharacterized enzymes. With such a 
vast number of uncharacterized enzymes, a starting point to find new and unusual activities is 
critical. Based on the structural diversity of isolated compounds, it has become clear that enzymes 
involved in the production of secondary metabolites and natural products is both a rich and 
concentrated source of undiscovered enzymatic catalysis.9 Natural products are classified as any 
biologically produced compound with a useful bioactivity for humans, such as anticancer, 
antibacterial, antifungal, and immunosuppressive activities. Notably, they often contain chemical 
moieties not observed in primary metabolism, such as unusual epoxidations, halogenations, and 
cyclizations. The research presented in the first part of this dissertation describes my efforts to 
characterize unusual enzymatic activities observed in a variety of natural production biosynthesis 
or degradation pathways. In addition to finding unusual activities it is also import to discover and 
characterize enzymes that better utilize a target substrate. The second portion of this dissertation 
investigates the binding domains of new polysaccharide hydrolases that can utilize difficult to 
process hemicellulose substrates. 
  
RiPPs 
 Historically, natural products have generally been broken into five distinct classes: 
polyketide synthase (PKS) compounds, non-ribosomally peptide synthase (NRPS) compounds, 
alkaloids, saccharidess and isoprenoids. However, with the advent of genome sequencing it has 
become apparent that new class of natural products is commonly produced in nature, ribosomally 
encoded and post-translationally modified peptides (RiPPs).10 Members are this class are 
composed of amino acids with additional non-proteogenic modifications, similar to NRPS derived 
compounds. However, the biosynthetic routes used by NRPSs and RiPPs are completely 
dissimilar. NRPS compounds are assembly one amino acid at a time in an assembly line fashion. 
The added amino acids are often non-proteogenic in nature and often contain extensive 
modifications. In contrast, RiPP natural products encode a complete peptide precursor gene as part 
of the biosynthetic cluster.11 This gene is transcribed by RNA polymerase and translated by the 
ribosome, identical to typical proteins. This method of precursor peptide biosynthesis necessitates 
that only proteogenic amino are incorporated. To form the final natural product, a series of 
enzymes catalyze post-translational modifications, turning a linear peptide into a bioactive 
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compounds. These post-translation modifications are often extensive and can include 
macrocyclization,12–18 backbone heterocylization,19–21 halogenation,22,23 cycloaddition,19,24 and 
methylation.15,19,25  
 Analysis of many classes of RiPP natural products including lanthipeptides18, lasso 
peptides,26,27 cyanobactins,28 bottromycins,25 and thiopeptides19,24 has revealed that the precursor 
peptide often contains a similar structural organization.11 The N-terminal of the precursor often 
constitutes a “leader peptide”. This amino acid sequence contains conserved binding motifs that 
allow the post-translational modifying enzymes (tailoring enzymes) to recognize the precursor 
peptide. The “core peptide” follows the leader sequence. This core peptide is target of the 
modification enzymes and forms the basis of the final natural product. Notably, most tailoring 
enzymes have little affinity for the core peptide sequence and poorly utilize substrates lacking the 
leader sequence.29 The tight binding between the leader peptide and the modification enzymes 
localizes the core sequence to the promiscuous enzyme active site. This allows for a single cluster 
to contain only a single set of modification enzymes, but numerous precursor peptides that lead to 
diverse products due to differences in the core peptide.27,30,31 Following post-translation 
modification, the leader is cleaved by a protease and the product is often exported from the cell by 
a dedicated transporter. In certain systems, the precursor peptide are recognized by a “follower 
peptide” instead of a leader peptide. The follower peptide functions analogous to leader peptides, 
but it located C-terminal to the core sequence. 
 
Thiazole/Oxazole Modifications 
 While classes of RiPP natural products are distinguished by their final structures and routes 
of biosynthesis, some modifications are conserved across different families. For example, thiazole 
and oxazole post-translational modifications are observed in a wide range of RiPP classes 
including cyanobactins, linear azole containing peptides (LAPs)/thiazole or oxazole modified 
microcins (TOMMs), and thiopeptides.11 These modifications occur as the cyclization of the side 
chain of a serine, threonine, or cysteine with the neighboring amide carbon to form a five 
membered ring termed a thiazoline for a cysteine, oxazoline for a serine, and methyloxazoline for 
a threonine. In typical clusters, this heterocyclic ring is present in the oxidized form as a thiazole, 
oxazole, or methyloxazole modification. 
4 
 
 Initial efforts to elucidate the basis for the biosynthesis of these azole/azoline moieties were 
first completed using the E. coli produced LAP microcin B17, a 14 amino acid natural product 
containing four oxazole and four thiazole modifications.32–34 Sequencing of the plasmid-borne 
operon and transcriptional analysis suggested that only three enzymes were required for the 
cyclodehydration reaction, a B-protein, a C-protein, and a D-protein.35,36 Further purification of 
the “MccB17 synthase complex” and in vitro reconstitution demonstrated that these three enzymes 
can carry out the biosynthesis of all eight thiazole/oxazole rings in an ATP/dependent manner.37,38 
Further dissection of the activities of these three proteins showed that the B-protein is an FMN 
dependent dehydrogenase that oxidizes the azoline ring to an azole.39 The C- and D-proteins were 
demonstrated to form a complex that catalyzes the initial cyclodehydration reaction to form the 
azoline ring.40,41 However, the specific activities remained unclear. Sequence comparisons to the 
ATP utilizing microcin C7 synthase MccB42 suggested that the C-protein was responsible for the 
cyclization reaction, while the D-protein was an accessory protein that assisted with peptide 
binding or enhancement of activity. However, studies by Dunbar et. al. showed that the D-protein 
was indeed responsible for azoline biosynthesis.43 D-proteins represented a completely 
uncharacterized fold called a YcaO domain or domain of unknown function 181 (DUF181). My 
work, detailed in Chapter 2, describes structural characterization of the eponymous YcaO enzyme 
both APO and in complex with nucleotide substrates. Using this structural data, the ATP binding 
interactions were described for a previously unknown ATP binding motif present in many RiPP 
clusters. 
 
Orbitides 
 Orbitides, also called Caryophyllaceae-Type Cyclopeptides, are a recently recognized class 
of RiPP natural products.11 Members of this plant produced family are characterized by a 
macrocyclic structure composed of approximately 5-12 amino acids and contain only -amino 
peptide bonds. Furthermore, they do not contain disulfide bonds or the unusual tryptathionine 
residue observed in cyclotides and amatoxins respectively.11 The first orbitide, cyclolinopeptide 
A, was isolated from flaxseed (Linum usitatissimum) oil in 1959.44 Since then over 168 additional 
orbitides have been isolated with antimalarial,45 vasodilatory,46 immunomodulating,47 and 
xenoestrogenic48 bioactivities. While the structural composition of orbitides has been well 
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established, the biosynthesis pathway has only been recently identified.49 The cDNA of the orbitide 
producing plant Saponaria vaccaria was analyzed to look for peptides that contained the 
GVPVWA amino acid sequence found in the final segetalin A1 product. A 32 amino acid peptide 
was indeed found, along with precursor peptides correlating to an additional 11 orbitide products. 
Furthermore incubation of the amino acid precursor, presegetalin A1, with S. vaccaria seed extract 
demonstrated the production of cyclic segetalin A1, illustrating that orbitides are a member of the 
RiPP class of natural products. 
 Further biochemical studies identified biosynthesis could be achieved with only two 
enzymes.50 The first enzyme, oligopeptidase 1 (OLP1), cleaves the first 13 amino acid residues 
from the presegetalin A1 peptide to reveal an 18 amino acid peptide containing an N-terminal 
glycine residue. A second enzyme, peptide cyclase 1 (PCY1), catalyzes the N- to C-terminal 
cyclization of the first 6 amino acid residues and release of the linear 12-amino acid by product. 
Curiously, this enzyme is a member of the S9A protease/prolyl oligo peptidase family of proteins. 
While these proteins are known cleave peptide substrates, formation of cyclic products represents 
a completely new activity.51 In Chapter 3, I describe biochemical and structural efforts to explain 
the basis of this new cyclization activity. 
 
Lasso Peptides 
The first lasso peptide, microcin J25 was isolated in 1992 from E. coli.52 Initial structural 
analysis indicated that it was composed of 20 amino acid residues and a protected amino terminus. 
It took an additional 11 years before the 3-dimensional structure of microcin J25 to be completely 
elucidated.12–14 This natural product contained a macrolactam ring derived from the -amine of 
the N-terminal glycine and side chain carboxylate of Glu8. Most notably, the linear tail is threaded 
through the ring and locked in place by the bulky Phe19 and Tyr20 residues, creating a static 
“lassoed” or lariat structure characteristic of this class of natural products. This constrained 
structure has been found to be both heat stabile31,52–54 and protease resistant,26,31,55 making it as 
attractive target for drug discovery. 
Sequencing of the microcin J25 producing plasmid revealed that only four genes were 
present in the biosynthetic cluster and needed for biosynthesis.56 The first gene, mcjA (A-peptide), 
encodes a short 58 amino acid peptide. The C-terminal 21 amino acid residues are identical to 
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those found in the microcin J25 product, indicating that it is a member of the RiPP class of natural 
products. The final gene, mcjD (D-protein), was suggested to be an ABC transporter that exports 
the microcin J25 from the cell and is critical for self-immunity.56 Therefore, it was proposed that 
the two remaining genes, mcjB (B-protein) and mcjC (C-protein), were the only genes necessary 
for biosynthesis. Heterologous expression and purification of McjB and McjC demonstrated that 
complete in vitro processing of McjA to microcin J25 could be accomplished by the enzymes with 
only the addition of ATP and Mg2+.57 More detailed characterization revealed that McjB is likely 
a cysteine protease that cleaves the leader peptide from the core sequence.58 McjC then processes 
the linear core peptide by adenylating the carboxy side chain of Glu8 and subsequently facilitating 
the nucleophilic attack by the -amine of Gly1.58 Currently, the mechanistic basis for these 
reactions is unclear. 
Notably, many lasso peptide gene clusters deviate from this four protein arrangement. In 
these clusters, the full length B-protein is encoded by two separate open reading frames, a B1-
protein and a B2-protein. The B1-protein shows sequence similarity with the N-terminus of the 
full length B-protein and is responsible for leader peptide binding.59 The second protein, B2, 
contains sequence similarity to the C-terminal domain of the full length B-protein and is proposed 
to contain the protease activity that cleaves the leader peptide from the core. Structural and 
biochemical characterization of the B1-protein TbiB1 along with in vitro reconstitution of the B2-
protein TbiB2 is described in Chapter 4. 
While microcin J25 is the most studied lasso peptide, many others have been identified and 
isolated.27,55 Notably, the simplicity of the biosynthetic gene cluster has facilitated a genome 
mining approach wherein putative lasso peptides are first found in silico by genome mining and 
subsequently isolated using traditional methods. While many lasso peptides have been identified, 
the basis for any bioactivity is known for only three: microcin J25-ribosome inhibitor, capistruin-
RNA polymerase inhibitor60, and lassomycin-mycobacterial protease inhibitor61. 
Genome mining also revealed the presence of a conserved E-protein found in a large 
number of conserved lasso peptide biosynthetic clusters from alphaproteobacteria.62 These 
proteins share sequence similarity to the S9 protease family of proteins. Characterization of a 
homolog from Asticcacaulis excentricus, AtxE2, showed that these enzymes are isopeptidases that 
hydrolyze the characteristic isopeptide bond of lasso peptides.62 Furthermore, AtxE2 was shown 
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to be tolerant of mutations present in the lasso peptide substrate and only utilize properly threaded 
lasso peptides as substrates. The structural and biochemical characterization described in Chapter 
5 helps to explain both the mechanism of AtxE2 along with its substrate selectivity. 
 
Sugar Degradation 
 The growing threats of global warming and depletion of fossil fuels have incentivized the 
search for new and sustainable sources of energy. One of the methods actively being researched 
an implemented, is the production of biofuels. Biofuels constitute energy rich carbon compounds, 
such as ethanol, methane, or long-chain alkyl esters that are derived from renewable biological 
sources. In addition to being renewable, they also have low net carbon emissions as much of the 
carbon is derived from atmospheric CO2.
63 Combustion of the biofuel re-releases the CO2 into the 
atmosphere, allowing it to be subsequently synthesized into new biofuel. 
 While there are currently several methods being investigated for future biofuel production, 
the production of ethanol is the most common and is generated from plant cellulosic biomass, such 
as corn, wheat, or sugar beet.64 These plants, called feedstocks, contain high levels of cellulose, a 
simple sugar polymer composed exclusively of β(1→4) linked D-glucose monomers. The 
cellulose is treated enzymatically to hydrolyze it to simple sugars that are fermented by ethanol 
producing microorganisms. While this has shown to enable production of ethanol on the industrial 
scale, it has several drawbacks. First, the current methodologies are limited to plant feedstocks rich 
in cellulose. Analysis has shown that these crops are not ideal for ethanol production as they 
require significant amounts of energy to farm.63 Second, utilizing only cellulose from plants 
ignores a significant fraction of its biomass.65 In addition to cellulose, plants also contain 
hemicellulose (heterogeneous polymers containing xylan, glucomannan, arabinoxylan, 
glucomannan, xyloglucan, and glucuronoxylan)66 and lignin (heterogeneous crosslinked aromatic 
monomers).67  If methods could be discovered that could efficiently degrade hemicellulose and 
lignin, not only could more biomass be processed, but different and faster growing crops could 
serve as the basis for biofuels.63 
 Both chemical and enzymatic tools are being actively sought to breakdown the complex 
hemicellulose and lignin mixtures into simple sugars that could be used by ethanol producing 
microbes. Not only are enzymes viewed a “green chemistry”, but organisms has been known to 
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grown both on hemicellulose and lignin in nature, suggesting that suitable enzymes may already 
exist.68 Therefore, an enormous amount of research effort is being placed into the discovery and 
characterization of suitable enzymes that can hydrolyze these heterogeneous mixtures. My work, 
discussed in Chapter 6, investigates a hydrolase that can process branched -galactomannan 
sugars, a component of hemicellulose. In Chapter 7, I characterized a new carbohydrate binding 
module (CBM) from human gut flora that can tightly bind xylans, also a component of 
hemicellulose. 
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Chapter 2 Structural Studies on the Cyclodehydratase YcaOi 
 
Introduction 
The YcaO/DUF181 (domain of unknown function) family of proteins is currently 
comprised of nearly 5000 members distributed across the bacterial and archaeal domains. 
Disparate functions have been ascribed to members of the YcaO family. In Escherichia coli, the 
deletion or overexpression of the eponymous YcaO protein (Ec-YcaO) suggested that it 
potentiated the thiomethylation of ribosomal protein S12 (Figures 2.1A and B) and influenced 
biofilm formation, respectively.69,70 However, a molecular explanation for these observations is 
currently unavailable. Another YcaO-associated activity is the ATP-dependent cyclodehydration 
of Ser, Thr and Cys residues to azoline heterocycles, which is the defining modification of 
thiazole/oxazole-modified microcin (TOMM) natural products (Figure 2.1C).71 TOMMs display 
diverse structures and activities,11,71 with some implicated in bacterial pathogenesis,72 making the 
~1000 bioinformatically identifiable TOMM YcaO proteins noteworthy members of the larger 
superfamily. 
Although the TOMM YcaO domain was first implicated in cyclodehydration reactions in 
the mid-1990s,37 its exact role remains unclear.43,73 The function of the TOMM YcaO (D-protein), 
is intimately linked to members of the E1 ubiquitin-activating enzyme family (C protein) found in 
canonical TOMM biosynthetic clusters.37,41,74 Underscoring this linked function, roughly half of 
known TOMM clusters express the C- and D-proteins as a single polypeptide.41,71 Studies on both 
fused and unfused cyclodehydratases have demonstrated that these domains are necessary and 
sufficient for TOMM azoline formation.43,75 Consequently, the C- and D-protein complex is 
referred to as the TOMM cyclodehydratase (or alternatively, heterocyclase41,73). As early studies 
on the cyclodehydratase were unable to observe activity from either protein in isolation,37,39,74 the 
respective contributions of C- and D- proteins were inferred by bioinformatics. Based on the ATP 
dependence of the reaction,38 and the homology of the C-protein to the E1 superfamily, which 
includes other ATP-utilizing enzymes (e.g. MccB, ThiF and MoeB),75,76 it was assumed that the 
                                                          
i This chapter is adapted from the following published article: 
Dunbar, K. L.*, Chekan, J. R.*, Cox, C. L., Burkhart, B. J., Nair, S. K., and Mitchell, D. A. (2014) Discovery of a 
new ATP-binding motif involved in peptidic azoline biosynthesis. Nat. Chem. Biol. 10, 823–9. 
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C-protein was responsible for cyclodehydration, while the uncharacterized YcaO (D-protein) 
played a regulatory role.41,74  
In 2012, these assignments were challenged with the characterization of the TOMM 
cyclodehydratase from Bacillus sp. Al Hakam (Balh; Figure 2.1A).43 This YcaO protein (BalhD) 
displayed ATP-dependent cyclodehydratase activity in the absence of the cognate C-protein 
(BalhC); however, BalhC potentiated cyclodehydration by nearly 1000-fold. Considering that the 
C-protein had been implicated in precursor peptide recognition in streptolysin S biosynthesis,77 
and that BalhC dictated the regio- and chemoselectivity of the Balh cyclodehydratase,78 we 
hypothesized that the YcaO contained the active site residues while the C-protein was responsible 
for binding the peptide substrate. Although YcaO proteins lack recognizable ATP-binding motifs, 
the presence of one or more YcaOs in the bottromycin and trifolitoxin biosynthetic clusters, which 
lack recognizable C-proteins, supports these functional assignments.25,79–82  
While the above studies assigned a putative activity to TOMM YcaOs, a molecular 
understanding of cyclodehydratase catalysis remained elusive. Recently, the X-ray crystal 
structure of a fused cyclodehydratase was reported (TruD; Protein Data Bank, PDB code 4BS9), 
providing the first glimpse of a cyclodehydratase.73 The C-domain adopted the expected E1 fold 
while the YcaO fold was unique. As the structure lacked both the ATP and peptide substrates, no 
information regarding substrate engagement and catalysis could be gleaned. However, the lack of 
structural homology of YcaO to known ATP-binding proteins led to the reassertion that the C-
protein domain was responsible for ATP binding and carbonyl activation, while the YcaO domain 
catalyzed the requisite nucleophilic attack.73 
 Here, we report the structure of a non-TOMM YcaO from E. coli in various nucleotide-
bound and -free forms and demonstrate that the most conserved residues in YcaOs comprise a 
previously uncharacterized ATP-binding motif. We show that these ATP-binding residues are 
critical for catalysis in TOMM YcaOs using BalhD as a model cyclodehydratase. We further 
identified the active site of TOMM cyclodehydratases and demonstrated that the conserved, 
proline-rich C-termini are involved in active site organization and C-protein binding. Our results 
strongly support a model where ATP utilization is a universal feature of YcaOs (TOMM and non-
TOMM) and that TOMM C-proteins recognize the peptide substrate and potentiate the activity of 
the cognate YcaO. 
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Experimental Procedures 
ATP-binding site conservation 
The ligand interaction network for AMPCPP was generated using LigPlot plus using the 
standard parameters. A WebLogo83 frequency plot for the ATP-binding motif was generated from 
a Clustal Omega alignment of all of the sequences from the specified family using the standard 
parameters. The conservation map for the YcaO family was generated by aligning 150 unique 
YcaO sequences with at least 35% sequence similarity to Ec-YcaO (e-value < 10−5) and mapping 
the resulting conservation data onto the Ec-YcaO structure using ConSurf.84 The structure-based 
YcaO alignment was generated using Clustal Omega85 and ALINE,86 and the structural overlay of 
YcaO and TruD was generated using PyMOL version 1.5 (Schrödinger). 
 
Ec-YcaO crystallization 
Purified MBP-tagged Ec-YcaO was treated with TEV protease for 18 h at 4 °C. Successful 
cleavage was confirmed by SDS-PAGE, and Ec-YcaO was subsequently separated from the His6-
tagged MBP by subtraction Ni2+ affinity chromatography. Fractions with a purity of at least 90% 
were combined and purified by size-exclusion chromatography using a GE Superdex 200 column 
equilibrated in a buffer containing 300 mM KCl and 20 mM HEPES, pH 7.5. Fractions were 
collected and concentrated for crystallization screening experiments. The apo-Ec-YcaO crystals 
were obtained by sitting drop crystallization using a mother liquor containing 1.8 M ammonium 
citrate, pH 7.0, and 8 mg/ml Ec-YcaO in a 1:1 ratio. Incubation at 4 °C yielded crystals after several 
days. Soaking with 1 mM PCMBA for 4 h before vitrification was used to generate phases. 
Immediately before vitrification, crystals were soaked in a cyroprotectant containing 1.8 M 
ammonium citrate, pH 7.0, and 30% trehalose. AMP Ec-YcaO crystals were grown using hanging 
drop vapor diffusion with a mother liquor of 18% PEG 8,000, 0.1 M magnesium acetate and 0.1 
M sodium cacodylate, pH 6.5. An Ec-YcaO concentration of 8 mg/mL and a substrate 
concentration of 1 mM ATP and 1 mM MgCl2 was used for the formation of crystals at 4 °C. 
Directly before vitrification, crystals were immersed in a cryoprotectant containing the mother 
liquor supplemented with 30% MPD. AMPCPP Ec-YcaO crystals were grown and frozen in an 
identical manner with the exception of using 6 mg/mL Ec-YcaO, 1 mM AMPCPP instead of 1 
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mM ATP, and 20% PEG 8,000 instead of 18% PEG 8,000. All of the data were collected at LS-
CAT sector 21 of the Argonne Nation Labs Advanced Photon Source at 100 K using wavelengths 
of 0.97872 Å for the apo and AMP-bound structures and 0.97857 Å for the AMPCPP structure. 
 
Ec-YcaO structure solution and refinement  
Collected data were integrated and scaled using HKL2000 or autoProc.87 The PCBMA-
soaked apo-Ec-YcaO crystals were used as a source of anomalous signal in SAD phasing using 
the PHENIX software suite.88 Automated building of the structure was accomplished by the 
arp/wARP server.89 Manual refinement was performed using COOT90 and REFMAC5.91 For the 
AMP- and AMPCPP-containing structures, the apo-Ec-YcaO was used as a search model to obtain 
phases using the PHENIX software suite. PHENIX was also used for automated building of the 
structures. Manual refinement was again preformed using COOT and REFMAC5. Final 
Ramachandran statistics as determined by PROCHECK92 are as follows: 97.2% favored, 2.8% 
allowed and 0.0% outliers for the apo structure; 97.8% favored, 2.2% allowed and 0.0% outliers 
for the AMP-bound structure; and 96.3% favored, 3.7% allowed and 0.0% outliers for the 
AMPCPP-bound structure. 
 
Endpoint heterocycle formation assays 
For the reactions with the BalhD mutants, 50 μM MBP-BalhA1 was mixed with either 2 
μM MBP-BalhC/D (CD activity) or 25 μM MBP-BalhD (D-only activity) in synthetase buffer (50 
mM Tris (pH 7.5), 125 mM NaCl, 10 mM DTT, 20 mM MgCl2 and 3 mM ATP). The MBP tags 
were removed using 0.05 mg/mL of TEV protease and reactions were carried out for 18 h at 25 °C. 
Samples were desalted via C18 ZipTip (Millipore) according to the manufacturer’s instructions and 
analyzed on a Bruker Daltonics UltrafleXtreme MALDI-TOF spectrometer. Spectra were obtained 
in positive reflector mode using α-cyano-4-hydroxycinnamic acid as the matrix. 
 
PNP-based kinetic studies 
Substrate processing kinetics for the BalhD mutants were determined using a previously 
described purine nucleoside phosphorylase (PNP)-coupled assay.43,93 For BalhA1 kinetic 
experiments, variable concentrations of MBP-BalhA1 (1–120 μM) were reacted with 1–10 μM 
MBP-tagged BalhC and BalhD, and ATP was held constant at 3 mM. ATP kinetic experiments 
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were carried out in an identical fashion except that MBP-BalhA1 was fixed at 80 μM, and variable 
concentrations of ATP (0.1–5 mM) were used. Although this does not provide a saturating level 
of BalhA1 for all mutants, the KM for ATP does not change with varied BalhA1 concentration. For 
BalhD-A4LEH6 ATP kinetic assays, the rate of ATP hydrolysis was measured for 3 μM MBP-
tagged BalhD-A4LEH6 with and without 3 μM MBP-tagged BalhC. Reactions were carried out 
in triplicate. Regression analyses to obtain the kinetic parameters for both substrates were carried 
out with IGOR Pro version 6.12 (WaveMetrics). 
 
BalhC ‘KM’ for active BalhD mutants 
The affinity of catalytically active BalhD mutants for BalhC was determined using the PNP 
phosphate detection assay and a previously described procedure.39 25 μM MBP-BalhA1 was 
mixed with 1 μM MBP-BalhD in synthetase buffer, and reactions were initiated via the addition 
of 0.15–4 μM BalhC. All of the reactions were performed in triplicate. Regression analyses to 
obtain kinetic parameters for BalhC were carried out with IGOR Pro version 6.12 (WaveMetrics). 
 
Results 
E. coli YcaO hydrolyzes ATP to AMP and PPi 
With the ATP-dependent cyclodehydratase activity of BalhD previously established,43 we 
attempted to locate the ATP binding site in BalhD by 8-azido-ATP crosslinking; however, these 
experiments were unsuccessful (data not shown). Furthermore, the TruD crystal structure did not 
reveal an obvious ATP-binding site73 and BalhD was refractory to numerous crystallization 
attempts. We reasoned that since TOMM YcaOs evolved to interact with their cognate C-proteins, 
working with a non-TOMM (with no C-protein partner) might alleviate the previously encountered 
challenges. The local genomic environment of Ec-ycaO does not contain an E1 homolog (Figure 
2.1A), nor is Ec-YcaO known to interact with an E1 homolog, making it an attractive candidate 
for structural and biochemical characterization. Ec-ycaO was cloned into a tobacco etch virus 
(TEV) protease-cleavable maltose-binding protein (MBP)-fusion vector and expressed in E. coli. 
While the function of Ec-YcaO was unknown, characterized cyclodehydratases hydrolyze ATP in 
the absence of peptide substrates.43 Consequently, we measured the ATPase activity of Ec-YcaO 
using an established purine nucleoside phosphorylase assay.93 This assay revealed that Ec-YcaO 
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indeed hydrolyzed ATP, preferentially generating AMP and PPi (Figure 2). Although ATP 
hydrolysis was slow, perhaps because the native substrate was not present, Ec-YcaO displayed a 
KM for ATP of ~80 µM, comparable to several characterized cyclodehydratases (Figure 3).
38,43,75  
  
Crystallization of Ec-YcaO 
The structure of nucleotide-free Ec-YcaO (containing mercurial salt for phasing) was 
determined to a Bragg limit of 2.63 Å and revealed a circularly symmetric homodimer in the 
asymmetric unit (Figure 2.4 and Table 2.1). The overall structure consists of an N-terminal YcaO 
domain of ~400 residues and a 150 residue C-terminal domain resembling a tetratricopeptide 
repeat (TPR) that mediates dimerization. A structure-based comparison against the PDB revealed 
similarity solely with TruD, the only other solved YcaO structure (RMSD of 3.1 Å over 279 
aligned C atoms),94 confirming that YcaOs constitute a new structural fold.  
To identify the ATP-binding site, we determined the structure of Ec-YcaO in complex with 
multiple nucleotides. Co-crystallization of Ec-YcaO with ATP produced an AMP-bound structure 
(2.25 Å), suggesting that in situ hydrolysis had occurred (Figure 2.4A). To clarify the residues 
involved in ATP binding, we also determined the co-structure of Ec-YcaO with α, β-
methyleneadenosine 5’-triphosphate (AMPCPP, a non-hydrolyzable ATP analog).  These three 
structures facilitated the characterization of the ATP-binding site in the YcaO superfamily. 
 
Structural characterization of ATP-binding in Ec-YcaO 
Analysis of the 2.25 Å resolution AMP-bound and 3.29 Å resolution AMPCPP-bound co-
crystal structures revealed that the adenine ring is recognized by Glu191 and Asn187 via 
interactions through the N7 nitrogen and between Ser16 and the exocylic-N6 (Figure 2.4B). 
Additionally, Lys9 resides above one face of the adenine ring, while Ala70, Ser71, and Gly74 are 
found within an α-helix that extends below the adenine and ribose rings, forming a hydrophobic 
surface. The ribose of AMP and AMPCPP is oriented perpendicular to the adenine ring, with 
Ser184 and Glu78 coordinating the 2’- and 3’-hydroxyls, respectively. While Ser71 coordinates 
the α-phosphate in both structures, Arg286 coordinates to the α-phosphate in only the AMP-bound 
form (Figure 2.4C).  Surprisingly, two Mg2+ ions are found in the nucleotide-binding pocket in 
both structures. In the AMP structure, Glu199 and Glu78 ligate one Mg2+ ion while Glu290 and 
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Glu75 bind the second. The Mg2+ ions are coordinated in a similar fashion in the AMPCPP 
structure with the subtle difference that the second Mg2+ ion is coordinated by Glu202, rather than 
Glu75 (Figure 2.4D). This slight change in the coordination of the second Mg2+ ion positions the 
metal ions on opposite sides of the β- and γ-phosphates. 
 
The ATP-binding site is conserved in TOMM YcaOs  
Utilizing the nucleotide-bound structures of Ec-YcaO, we established the conservation of 
the ATP-binding residues across the superfamily. First, we generated a Cytoscape sequence 
similarity network95 of all YcaO members in InterPro (IPR003776).96 During assembly, redundant 
sequences were removed, leaving ~2000 sequences in the network. While the sequence of TOMM 
precursor peptide dictates the structure of the natural product, there is also a strong correlation 
between TOMM structure and the sequence similarity of the responsible YcaOs.71 For the network, 
all YcaO sequences were manually annotated based on neighboring genes. YcaOs were 
categorized as being involved in TOMM biosynthesis if there was a gene encoding for a 
recognizable C-protein in the local region (~10 kb on either side of the ycaO gene) or if the protein 
had an experimentally verified link to a known TOMM (e.g. bottromycin25,79,81 and trifolitoxin82). 
The remaining YcaOs were separated into two other categories, non-TOMM YcaOs (e.g. Ec-
YcaO) and TfuA-associated non-TOMM YcaOs. The latter were found within 10 kb of a gene 
encoding for the protein TfuA, which is implicated in trifolitoxin biosynthesis.97 Whenever 
possible, TOMM YcaOs were further subdivided by expected structural class. Based on these 
classifications, we determined that an expectation value of 10-80 gave an optimal separation of 
YcaO sequences into isofunctional clusters (Figure 2.3).  
Using the sequence similarity network as a guide, 349 of the ~2000 members in the non-
redundant network were selected from across all clusters and a maximum likelihood tree was 
generated (Figure 2.5A). Among the 349 were all singletons, defined as divergent family members 
not grouping with any other YcaO at an e-value of 10-80. Using this diversity-maximized tree, a 
sequence logo for each of the regions involved in ATP binding was generated using WebLogo 
(Figure 2.5B).83 The logos clearly demonstrate that the ATP-binding pocket is highly conserved 
in the YcaO family across all three groups (i.e. TOMM, non-TOMM, and TfuA-associated non-
TOMM).  The ATP-binding residues were found to be the most conserved in the YcaO superfamily 
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(Figure 2.5C). As this conservation is maintained in all characterized TOMMs (Figures 2.6 and 
2.7), the previously reported carbonyl activation mechanism is likely a universal biosynthetic 
feature.43,78  
 
The inferred ATP-binding site of BalhD is critical for activity 
Because the native substrate of Ec-YcaO is unknown, we validated the ATP-binding 
residues by conducting structure-function studies on BalhD. An alignment of BalhD and Ec-YcaO 
permitted the mapping of the nucleotide- and Mg2+-binding residues onto BalhD (Figure 2.7). 
Subsequently, an alanine mutagenesis scan was performed on the polar residues of BalhD 
predicted to bind ATP. Every mutation was well tolerated in terms of protein yield/stability. The 
effect on heterocycle formation on BalhA1 (the peptide substrate) by the mutant BalhD proteins, 
in the presence of BalhC, was monitored in a 16 h endpoint assay (Figure 2.8). Of the 11 mutated 
residues in the ATP-binding pocket, four were able to convert BalhA1 to the previously reported 
penta-azoline species,43 three showed intermediate levels of processing (2-4 heterocycles), while 
the remaining four generated no heterocyclic products within the limit of detection (Table 2.2). To 
quantify the effect of each mutation to BalhC/D activity, the rate of ATP hydrolysis was monitored 
using the KM concentration of BalhA1 (15 µM) and a concentration of ATP that would be 
saturating for wild-type BalhD (3 mM). Mutants unable to cyclize BalhA1, even after extended 
reaction times, displayed no detectable ATP hydrolysis over the assay background (Figure 2.9). 
Likewise, mutants that installed five azolines on BalhA1 in the endpoint assay had the highest 
ATP hydrolysis rates. These data are congruent with our earlier work showing that ATP hydrolysis 
is tightly coupled to heterocycle formation.43 The YcaO mutations examined here did not appear 
to disrupt this feature of TOMM cyclodehydration. 
While mutation of the BalhD ATP-binding pocket reduced cyclodehydratase activity, an 
alternative interpretation of the above data could be that these mutations interfered with the 
association of BalhC and BalhD. A unique feature of the Balh cyclodehydratase is that BalhD is 
catalytically active in the absence of BalhC.43 This permitted the use of BalhD-only activity 
measurements to determine if the alanine mutations affected the intrinsic cyclodehydratase 
activity. Heterocycle formation endpoint assays (16 h) were again conducted, but this time with 
50 µM BalhA1 and 25 µM BalhD mutant to account for the expected ~103 drop in catalytic activity 
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in the absence of BalhC.43 The resultant mass spectra confirmed that the decrease in 
cyclodehydration arose from a perturbation in BalhD activity (Table 2.2 and Figure 2.8).  
 For all BalhD mutants with measureable cyclodehydratase activity, we obtained the 
Michaelis-Menten kinetic parameters for BalhA1 and ATP (Table 2.2). Every mutation negatively 
affected the observed kcat (kobs), indicating that the selected residues were of catalytic importance. 
Apart from Lys281Ala, and to a lesser extent Ser72Ala, all ATP-binding site mutations of BalhD 
substantially increased the KM for ATP. In contrast, the only mutant in this series to substantially 
raise the KM for BalhA1 was Arg198Ala (Table 2.2). 
Four BalhD mutants (i.e. Glu76Ala, Glu79Ala, Glu194Ala, Glu197Ala) did not exhibit 
detectable cyclodehydratase activity. Potential explanations include an inability to bind the 
substrates (BalhA1 and/or ATP), hydrolyze ATP, or a structural perturbation with these mutants. 
Previous work demonstrated that BalhC potentiates the BalhA1-independent ATPase activity of 
BalhD;43 however, when the four inactive mutants were assayed, no potentiation was observed 
(Figure 2.10). This suggested that the lack of BalhD activity was due to a structural perturbation 
or the inability to bind/hydrolyze ATP. Unfortunately, attempts to directly measure ATP binding 
or a secondary structure perturbation of BalhD by isothermal titration calorimetry or circular 
dichroism spectroscopy, respectively, were problematic owing to the solubility characteristics of 
BalhD. However, we reasoned that the latter could be assayed indirectly by monitoring the 
interaction between BalhC and a mutant BalhD through a competition assay and affinity co-
purification. While all of the BalhD mutants were able to associate with the BalhC (Figures 2.11 
and 2.12), Glu76Ala and Glu194Ala did so with reduced affinity, suggesting that these mutations 
affected the BalhC-BalhD interaction surface. Conversely, the wild-type-like affinity that BalhD 
Glu79Ala and Glu197Ala displayed for BalhC suggested that these mutants were inactive due to 
inability to bind/hydrolyze ATP.  
 
Discussion 
We have discovered that Ec-YcaO contains a novel ATP-binding fold. Based on steric and 
electrostatic complimentary requirements, the YcaO strategy for binding ATP is reminiscent of 
other structurally characterized ATP-binding proteins. For example, the Lys/α-helix “sandwich” 
involved in adenine recognition is similar to the conserved Arg and Gly motif found in class I 
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amino acyl tRNA synthetases.98 Furthermore, select members of the ATP-grasp and PurM families 
have been shown to bind ATP through the use of multiple divalent cations;99,100 however, in these 
proteins, the Mg2+ ions are coordinated to all three phosphates, not just the β- and γ-phosphates. 
Since these similarities in ATP-binding occur despite a lack of structural and primary homology 
between YcaO and all other known ATP-binding proteins, this represents an example of 
convergent evolution in ATP-binding domains.  
The ATP-binding residues are the most highly conserved motifs in the YcaO superfamily 
and, appropriately, represent a prominent signature for the hidden Markov model that 
bioinformatically defines the YcaO/DUF181 family (IPR003776). Our extensive bioinformatics 
analysis, X-ray crystallographic data on Ec-YcaO, and biochemical characterization of BalhD 
confirm that ATP-utilization is a conserved feature in the superfamily. In spite of the low level of 
overall similarity between Ec-YcaO and BalhD, we were able to demonstrate that the YcaO ATP-
binding motif was critical for cyclodehydratase activity. While the mutations affected BalhD 
activity to differing extents, the impact of mutating a particular residue on Balh cyclodehydratase 
activity was proportional to the level of conservation within the YcaO family (Figure 2.6B).  
The capacity to bind ATP (or possibly other nucleotide triphosphates) appears to be 
ubiquitous in the YcaO superfamily, but it remains unclear whether the TOMM cyclodehydratase-
like direct activation of carbonyls is a universal feature. It is intriguing that YcaOs have recently 
been implicated in the formation of thioamides101 and macroamidine rings25,79–81, as both of these 
modifications could conceivably occur through carbonyl activation. In addition to providing 
significant insight into the mechanics of TOMM cyclodehydration, the results presented here 
provide an initial framework to explore the elusive functions of the 4,000 uncharacterized non-
TOMM YcaOs. 
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Figures 
 
Figure 2.1  (a) The local genomic environment for the E. coli non-TOMM YcaO (Ec-YcaO) 
and the Bacillus sp. Al Hakam TOMM YcaO (BalhD) is depicted along with the % amino acid 
identity for the YcaOs. Gene assignments are shown. (b) Ec-YcaO has been suggested to potentiate 
the S12 thiomethylation activity of RimO through an unknown mechanism. (c) Azole heterocycles 
in TOMM natural products are installed by the successive action of a cyclodehydratase (C- and D-
proteins) and a flavin mononucleotide (FMN)-dependent dehydrogenase (B protein). The 
cumulative mass change for each step is shown below the modification. X = S, O; R = H, CH3. 
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Figure 2.2 (a) The ATPase activity of Ec-YcaO was screened using the purine nucleoside 
phosphorylase (PNP)-coupled assay93 with and without 1 unit of pyrophosphatase (PPase). The 
addition of PPase increased the rate of chromophore production in the assay by 5-fold after the 
signal amplification achieved during PPi cleavage is taken into account. These data indicate that 
ATP is preferentially hydrolyzed to AMP and pyrophosphate by Ec-YcaO in vitro. This result is 
corroborated by the observation that co-crystallization of Ec-YcaO with ATP yielded an AMP-
bound structure (Figure 3A and B). Error bars represent the standard deviation from the mean 
(n=3). (b) An ATP kinetic curve was obtained for Ec-YcaO using the PPase-supplemented PNP 
assay. Error bars represent the standard deviation from the mean (n=3). Regression analyses to 
obtain Michaelis-Menten kinetic parameters were carried out in IGOR Pro version 6.12 
(Wavemetrics). The error on the kinetic parameters represents the standard deviation from the 
curve fitting.  
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Figure 2.3 A non-redundant Cytoscape sequence similarity network for the YcaO superfamily 
is displayed. Each node represents a unique YcaO protein, while lines between nodes exist if the 
proteins have an arbitrarily designated level of similarity. For this network, the similarity cut-off 
was a BLAST expectation value (e-value) of e-80. At this expectation value, YcaO proteins from 
characterized TOMM biosynthetic clusters appeared to primarily form isofunctional clusters. 
TOMM and non-TOMM YcaOs are defined as having a bioinformatically identifiable C protein 
within 10 kb of the YcaO protein, while a C protein could not be identified for the non-TOMM 
YcaOs. For simplicity, TfuA-associated non-TOMMs are labeled as non-TOMM YcaOs. Stand-
alone TOMM YcaOs are proteins found in a characterized TOMM biosynthetic cluster that lacks 
a C protein (e.g. bottromycin and trifolitoxin). It is noteworthy that many non-TOMM YcaOs 
appear to exist in a RiPP biosynthetic clusters; indicating that additional stand-alone YcaO 
cyclodehydratases may exist. Nodes are colored according to the legend and the clusters containing 
Ec-YcaO and BalhD are indicated. 
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Figure 2.4  (a) Structure of the Ec-YcaO homodimers with one monomer colored in purple 
(ATP-binding domain) and green (TPR domain) and the other monomer colored in gray. (b,c) 
Orthogonal views of the Ec-YcaO AMP-bound structure in the vicinity of the active site showing 
residues responsible for AMP and Mg2+ binding. The superimposed difference Fourier maps are 
contoured at levels of 2.0 (blue) and 8.0 (red). (d) AMPCPP (cyan) and Mg2+ (grey) bound in 
the Ec-YcaO active site coordinates with superimposed difference Fourier maps contoured at 
levels of 2.0 (blue) and 6.0 (red). Residues proposed responsible for Mg2+ binding are indicated. 
(e) A ligand interaction diagram for the AMPCPP-bound structure is shown. Putative hydrogen 
bonds are shown in orange with distances indicated, and red arcs denote hydrophobic interactions. 
Due to slight differences in residue orientation in the monomer subunits, only a subset of the 
interactions is displayed for clarity 
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Figure 2.5  (a) A diversity-maximized tree for the YcaO superfamily is displayed. YcaOs 
associated with a functionally or structurally characterized natural product clusters are denoted by 
a red asterisk, while the proteins used in this study are circled (blue). (b) WebLogo frequency plots 
for the YcaO ATP- and Mg2+-binding residues of YcaO domains for each subclass (TOMM, non-
TOMM, TfuA non-TOMM). Due to the high level of diversity in the sequences, WebLogos for 
the N-terminal ATP-binding residues could not be generated. The ATP-binding motif identified in 
Ec-YcaO is displayed above each of the ATP-binding regions with the number representing the 
residue in Ec-YcaO, and conserved residues colored orange.  
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Figure 2.6  The ATP-binding pocket is conserved in characterized TOMM YcaOs. All of the 
YcaO sequences from the indicated TOMM subclasses were aligned with Clustal Omega85 and the 
multiple sequence alignments were used to generate sequence logos (WebLogos)83 of the regions 
involved in ATP binding. The size of the letter is proportional to its level of conservation. The 
ATP-binding motif identified in Ec-YcaO is displayed above each of the ATP-binding regions. 
Residues that are similar to the ATP-binding motif identified in Ec-YcaO are colored orange. Due 
to the high level of diversity in the sequences, WebLogos for the N-terminal ATP-binding residues 
could not be generated. The number of sequences represented in each WebLogo is displayed in 
parentheses. The ATP-binding motif of Ec-YcaO is conserved in diverse TOMM YcaOs.  
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Figure 2.7 Multiple sequence alignment of Ec-YcaO with diverse TOMM YcaOs. Sequences 
of TOMM YcaOs from characterized natural product clusters were aligned with Ec-YcaO. The C 
domain of the naturally occurring CD fusion proteins (TruD, GodD, TsrH) was manually removed 
prior to alignment. Residues implicated in ATP- and Mg2+-binding in Ec-YcaO are highlighted in 
orange. Putative ATP-binding residues in BalhD were identified in this alignment. The conserved 
proline rich C-terminus of TOMM YcaOs is colored blue. A sequence identity matrix is displayed 
to show the divergence of the proteins in the alignment. The alignment indicates that the ATP-
binding site is under extensive selective pressure. McbD (microcin B17), YcaO (Ec-YcaO), TruD 
(trunkamide), GodD (goadsporin), TsrH (thiostrepton), SagD (streptolysin S), BalhD (unknown), 
PznD (plantazolicin). 
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Figure 2.8 Mutations to the BalhD ATP-binding site affect heterocycle formation. A MALDI-
TOF MS spectral overlay for BalhA1 treated with BalhC and either wild-type (WT) or mutant 
BalhD is displayed. Many of the mutations to the ATP-binding residues, which are listed on the 
right, decreased cyclodehydratase activity. The level of processing is summarized in Table 2. †, 
laser-induced deaminations. A loss of 90 Da indicates the formation of 5 azolines, a full in vitro 
processed BalhA1 substrate4. 
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Figure 2.9 Mutations to the BalhD ATP-binding site affect ATP hydrolysis. The rate of ATP 
hydrolysis was measured with BalhC and either wild-type (WT) or mutant BalhD using the PNP 
assay. Error represents the standard deviation from the mean (n ≥ 3). Mutations showing the 
slowest rate of ATP hydrolysis also installed fewer heterocycles on BalhA1 in an endpoint assay 
(Figure 2.8). 
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Figure 2.10 Mutations of the Mg2+-binding residues prevent background ATPase activity by 
BalhC. The background ATP hydrolysis rate of mutant BalhD proteins lacking the ability to 
modify BalhA1 was measured with and without BalhC. Although the ATPase activity of wild-type 
BalhD was increased 2.5-fold by the addition of BalhC, none of the mutants displayed similar 
increases in ATP hydrolysis. Combined with the decrease in D-protein only activity, this result 
suggested that mutation of the Mg2+-binding residues interferes with ATP-binding/hydrolysis. 
Error bars represent the standard deviation to the mean (n > 3). 
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Figure 2.11 Affinity co-purification of BalhC with mutant BalhD proteins. (a) A Coomassie-
stained SDS-PAGE gel of the BalhC affinity co-purification experiment with wild-type (WT) 
BalhD is shown. A MBP-tagged version of BalhC lacking a His6-tag was mixed with Ni-NTA 
resin with and without His6-MBP-BalhD. BalhC was retained by the Ni-NTA resin only when 
His6-BalhD was present. The level of interaction between mutant BalhD proteins and BalhC was 
visually compared to wild-type (WT) BalhD. Coomassie-stained SDS-PAGE gels of select ATP-
binding site (a) and PxPxP C-terminal (b) mutations are displayed. Apart from BalhD P429*, all 
mutant YcaOs lacked cyclodehydratase activity. Of the mutations to the ATP-binding pocket, 
E79A and E197A appeared to bind to BalhC with an affinity approximately equal to the WT 
protein. Both E76A and E194A displayed a lower level of binding. All of the mutations to the 
PxPxP motif of BalhD perturbed the interaction with BalhC. *, stop codons; ∆2 AA, BalhD 
(∆A418, K419); FT, flow through; W1, wash 1; W2, wash 2; E, elution.  
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Figure 2.12 Catalytically inactivate BalhD ATP-binding site mutants inhibit BalhA1 processing 
by a wild-type BalhC/D complex. To better quantify the BalhC binding affinity of of the mutant 
BalhD proteins, ATP hydrolysis rates were monitored for wild-type cyclodehydratase reactions 
with the addition of variable concentrations of an inactive BalhD mutants. As the reactions were 
carried out with 1 µM wild-type BalhD, mutants with an unperturbed BalhC interaction would 
display IC50 values of approximately 1 µM. Of the mutants tested, only E76A and E194A displayed 
drastic perturbations to BalhC binding. These results are consistent with the BalhC affinity co-
purification experiment (Figure 2.11). Together, these data indicate that the loss of 
cyclodehydratase activity in BalhD E79A, E197A and E286A is due to an inability to bind or 
hydrolyze ATP, rather than a loss of BalhC binding. Error bars represent the standard deviation 
from the mean (n ≥ 3). Regression analysis to determine the IC50 values for each inhibition curve 
was determined in IGOR Pro version 6.12 (Wavemetrics). The error on the IC50 values represents 
the standard deviation from the curve fitting. 
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Tables 
Table 2.1 Crystallographic Statistics for Ec-YcaO Structures.  
 Ec-YcaO APO Ec-YcaO AMP Ec-YcaO 
AMPCPP 
Data collection    
Space group P212121 P1 P1 
Cell dimensions    
    a, b, c (Å) 68.96, 140.33, 
163.49 
111.25, 112.95, 
132.89 
110.28, 112.40, 
130.68 
 ()  90.0, 90.0, 90.0 89.94, 73.51, 
77.23 
89.40, 73.62, 
77.62 
Resolution (Å) 50.0-2.65 (2.70-
2.65) 
127.14-2.25 
(2.26-2.25) 
125.20-3.29 
(3.30-3.29) 
Rsym 9.4 (68.2) 10.6 (71.0) 17.6 (59.3) 
I / I 16.5 (2.3) 10.6 (2.0) 7.0 (2.1) 
Completeness (%) 99.5 (99.6) 93.1 (66.1) 99.0 (98.2) 
Redundancy 6.0 (6.1) 3.8 (3.9) 2.5 (2.5) 
    
Refinement    
Resolution (Å) 50.0-2.64 127.14-2.25 125.20-3.29 
No. reflections 43,214 251,531 84,143 
Rwork / Rfree 0.1628/0.2185 0.2178/0.2500 0.1896/0.2377 
No. atoms    
    Protein 9,027 36,574 35,815 
    Nucleotide+Metal 4 182 174 
    Water 512 1,987 432 
B-factors    
    Protein 43.95 40.03 64.89 
    Nucleotide  29.62 51.83 
    Metal 88.88 25.93 23.18 
    Water 39.21 33.71 33.68 
R.m.s. deviations    
    Bond lengths (Å) 0.0141 0.0119 0.0113 
    Bond angles () 1.5489 1.4810 1.5215 
Each dataset was derived from one crystal. 
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Table 2.2 Mutations to the ATP-binding pocket of BalhD decrease activity. a% processing = 
(5P5 + 4P4 + 3P3 + 2P2 + 1P1)/(5); where Px is the percentage of the substrate with x number of 
azolines. The number of heterocycles formed in the assay is listed in parentheses. bApparent KM. 
cNot determined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      Ring Formationa                 BalhA1 Kinetics                    ATP Kinetics
Mutation Rationale CD D-only kobs,  min
-1 KM, µM
b kobs/KM, M
-1 s-1 kobs,  min
-1 KM, µM
b kobs/KM, M
-1 s-1
WT (5); 100% (2-3); 45% 12.9 ± 0.4 16 ± 2 13000 12.2 ± 0.3 240 ± 20 850
S72A α-PO4 binding (5); 100% (2); 40% 8.3 ± 0.2 11 ± 1 12500 8.0 ± 0.4 360 ± 60 370
E76A α-PO4 binding, Mg 2 binding (AMP), catalytic (0); 0% (0); 0% n.d.
c n.d.c n.d.c n.d.c n.d.c n.d.c
E79A Mg 1 binding (0); 0% (0); 0% n.d.c n.d.c n.d.c n.d.c n.d.c n.d.c
R80A Active site organization, catalytic (2-4); 63% (0-1); 10% 0.79 ± 0.05 16 ± 5 823 0.88 ± 0.02 620 ± 50 24
Q186A Adenine binding (5); 100% (0-2); 10% 3.9 ± 0.1 12 ± 1 5400 7.5 ± 0.3 2500 ± 200 50
N190A 3'-OH binding, active site organization (5); 100% (0-2);15% 5.1 ± 0.2 27 ± 3 3150 4.7 ± 0.2 920 ± 110 85
E194A Mg 1 binding (AMPCPP) (0); 0% (0); 0% n.d.c n.d.c n.d.c n.d.c n.d.c n.d.c
E197A Mg 2 binding (0); 0% (0); 0% n.d.c n.d.c n.d.c n.d.c n.d.c n.d.c
R198A γ-PO4 binding (2-4); 40% (0); 0% 3.3 ± 0.2 50 ± 8 1100 2.4 ± 0.2 760 ± 65 52
K281A α/β-PO4 binding (5); 100% (2-3); 45% 7.9 ± 0.2 16 ± 2 8200 6.1 ± 0.1 230 ± 20 440
E286A Mg 2 Binding (2-4); 64% (0); 0% 0.49 ± 0.03 27 ± 3 272 0.42 ± 0.01 1200 ± 100 6
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Chapter 3 Structural and Biochemical Studies of the Orbitide Cyclase PCY1 
Introductionii 
Macrocylic peptides have become appealing targets for drug discovery efforts, due to the 
emergence over the past decade of multiple routes for rapid synthesis and screening.102 The drug 
like properties of cyclic peptides arise from their constrained rigid structure, improved 
bioavailability, and membrane permeability relative to linear peptides, and resistance to 
degradation by host proteases.103–105 Peptide libraries generated using combinatorial synthesis can 
afford a striking diversity of scaffolds, up to a theoretical limit near 1013 compounds. However, 
organic synthesis of such large libraries is limited by practical concerns, thereby limiting the 
diversity of sequence variants that would be necessary to truly explore scaffold space. More recent 
approaches for macrocyclic peptide synthesis have focused on in vivo production, in which the use 
of genetic templates can provide a facile route towards the production of libraries of diverse 
structures.106 Enzymatic routes for macrocycle production include the use of isolated thioesterase 
domains from non-ribosomal peptide synthetases,107 glutathione S-transferase,108 or split 
inteins,106 as well as technologies based on reprogramming the genetic code.109 However, these 
approaches either require the use of conjugated biomimetics or are not sufficiently tolerant of 
substrates to thoroughly sample the diversity of possible structures. 
Ribosomally synthesized and post-translationally modified peptides (RiPPs) represent an 
abundant source of chemically and structurally diverse natural products.110 RiPPs are translated by 
the ribosome as linear peptides that are subsequently enzymatically modified to yield compounds 
with a range of biological activities.11 Many RiPPs undergo enzymatic macrocyclization, as 
observed in several diverse classes of compounds including bottromycins,15 cyanobactins,21 
lanthipeptides 17, streptides,111 lasso peptides,26 and thiopeptides.19 Understanding the biosynthetic 
pathways for RiPP macrocyclization continues to be important for biotechnological application, 
for the identification of new gene clusters, and for the production of novel RiPP derivatives.112 
Orbitides encompass a class of plant homodetic macrocyclic natural products, usually 5-
12 amino acids in size, which are characterized by the intramolecular condensation between their 
                                                          
ii This chapter is adapted from the following article manuscript: 
Chekan J. R., Covello P. S., and Nair S. K. Characterization of the Peptide Cyclase Involved in Plant Orbitide 
Biosynthesis. Manuscript in preparation. 
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N- and C-termini.11 The chemical structures of orbitides consists solely of -amide linkages and 
are distinguished from other macrocyclic plant peptide natural products such as cyclotides, which 
are further interlocked through multiple disulfide bonds,113 and amatoxins, which contain an 
unusual tryptathionine moiety formed by a crosslink between a Cys and Trp residue.114 The first 
macrocyclic orbitide, cyclolinopeptide A, was isolated in 1959 from flaxseed (Linum 
usitatissimum) oil and determined to be a cyclic peptide of ILVPPFFLI (Figure 3.1A).44 Since 
then, over 168 Caryophyllaceae-like non-redundant orbitides have been identified and encoding 
sequences have been confirmed in Annonaceae, Rutaceae, Euphobiaceae, and Linaceae 115. Many 
orbitides demonstrate biological activities including antimalarial,45 vasodilatory,46 
immunomodulating,47 and xenoestrogenic.48 
Analysis of expressed sequence tag libraries from developing seeds of Saponaria vaccaria 
(Vaccaria hispanica) identified genes that likely encode for peptides precursors of orbitides. 
Expression of cDNA encoding candidate precursors in the roots of a non-producing S. vaccaria 
strain resulted in the production of fully processed cyclic peptide products,49 confirming that 
orbitides are indeed RiPPs. Subsequent biochemical assays with seed extracts, using synthetic 
peptide substrates, revealed the order of post-translational modifications that generate the orbitide 
segetalin A1 (Figure 3.1A,B).50 Briefly, segetalin A1 is first produced ribosomally as a 32 amino 
acid peptide termed presegetalin A1. A conventional serine protease (oligopeptidase 1 or OLP1) 
cleaves the first 15 amino acids to yield a product containing an N-terminal glycine (termed 
presegetalin A1 [14-32]). A second enzyme (PCY1, short of peptide cyclase 1) acts on this product 
to excise the linear C-terminal thirteen residues (termed presegetalin A1 [20-32]), with the 
concomitant macrocyclization of the remaining N-terminal six residues to yield the 
cyclo[GVPVWA] segetalin A1 product (Figure 3.1B). The biosynthesis of cyclotides,116,117 
amatoxins,118 and cyanobactins119 employ similar biosynthetic strategies wherein a sequence-
specific peptidase catalyzes the transamidation of a linear peptide substrate to produce a 
macrocyclic product. 
Primary sequence analysis identifies PCY1 as a member of S9A protease family that 
includes several clades of prolyl oligopeptidases (POP). Proteases of the S9A class catalyze the 
hydrolytic cleavage of peptide substrates at the amide linkage C-terminal to Pro to yield two linear 
products. However, PCY1 is distinguished from canonical S9A proteases by its unique product 
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profile as the enzyme generates a macrocyclic product rather than the linear counterpart. In 
addition, PCY1 does not require a Pro in the sequence of the cyclized peptide. Analysis of the 
predicted primary sequences of dozens of putative orbitide precursor peptides reveal a striking 
pattern of conservation: residues within the core sequence that is cyclized are highly divergent, 
while residues in the preceding leader sequence (removed by OLP1) and the trailing follower 
sequence (excised as a linear peptide by PCY1) are highly conserved. Similar patterns of 
conservation for the sequences that are excised are observed for the precursors of other cyclic 
peptides including cyanobactins119 and amatoxins.114,120 Alanine scanning mutational analysis of 
presegetalin A1 demonstrate that the necessary elements for substrate recognition by PCY1 reside 
solely at the 12 residue follower sequence (hereafter, presegetalin A1 [20-32]) that is excised 
during the formation of the macrocylic product.50 Consequently, PCY1 may be used for the 
production of macrocycles of diverse sequences, provided that the conserved C-terminal follower 
sequence is present in the linear precursor.  A similar strategy  utilizes the peptide cyclase butelase 
1 to produce cyclic bacteriocins.121 
The structure of the unrelated cyanobactin transamidating protease (PatG) revealed a 
peptidase S8 (subtilisin-like) fold that is decorated with a “capping” domain, and biochemical 
studies suggest that this domain insertion likely facilitates macrocylization of the peptide 
substrate.122,123 The primary sequence of PCY1 fails to identify any such obvious insertions, 
relative to canonical S9A protease family members, raising the question of how an enzyme from 
a class of generic proteases can be adapted to produce a macrocyclic product. To address this issue, 
we have carried out biochemical and crystallographic characterization of PCY1. These studies 
reveal the mechanistic strategies employed by the enzymes to faciliates transamidation of the linear 
precursor peptide substrate to yield a macrocyclic final product. 
 
Methods 
Materials 
Peptides were purchased from GenScript with a purity of 90% or greater as verified by 
HPLC analysis. Chemicals were purchased from Fisher Scientific and Sigma-Aldrich. IPTG and 
antibiotics were purchased from Gold Biotechnology. 
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Enzyme Expression, Purification, and Mutagenesis 
The previously described overexpression vector for recombinant production of PCY150 
was transformed into a Rosetta E. coli expression strain (Novagen). PCY1 was expressed in 
Terrific Broth (BD Difco) by growing cell cultures to an OD600 of 1 at 37 °C. Cell cultures were 
cooled in an ice bath for 15 minutes prior to the addition of 0.5 mM IPTG. Cultures were further 
incubated at 18 °C for approximately 18 hours before harvesting. Cells were lysed (Avestin) and 
purified by His6 affinity purification (GE Healthcare Life Sciences). Fractions containing PCY1, 
as determined by SDS-PAGE, were collected and further purified using a Superdex 16/60 S200 or 
S75 size exclusion column (GE Healthcare Life Sciences) equilibrated with 100 mM KCl, 20 mM 
HEPES pH 7.5. PCY1 mutants were generated using the QuikChange methodology with the 
primers listed in Table 3.1. 
 
Protein Crystallization and Data Collection.  
Initial crystallization conditions were determined using sparse matrix screens using a 
Gryphon robot (Art Robbins). Optimized PCY1 crystals were obtained using hanging drop trays 
(Hampton) by incubating protein (concentration of 14 mg/ml) supplemented with 5 mM boric acid 
and 1 mM PSA1 [14-32] with an equal volume of precipitant containing 16% PEG 8,000, 0.2 M 
calcium acetate, and 0.1 M sodium cacodylate (pH 6.5), prior to equilibration against the same 
solution. Crystallization trays were incubated at 9 °C for at least four days. PCY1 His695Ala 
was crystallized using a protein concentration of 8 mg/mL and precipitant solution of 16 % PEG 
8,000, 50 mM calcium acetate, and 0.1 M sodium cacodylate (pH 6.5). Prior to crystallization, the 
PCY1 His695Ala variant was incubated with 1 mM presegetalin A1 [14-32]. For crystals of 
PCY1 with covalently bound ZPP, the protein was incubated with 1 mM ZPP for 18 hours at 4 °C. 
Crystals were grown by the hanging drop method at 9 °C with a presegetalin A1 [27-32] 
concentration of 1 mM and a protein concentration of 10 mg/mL using 20% PEG 8,000, 0.1 M 
calcium acetate, and 0.1 M sodium cacodylate pH 6.5 as the precipitant. The PCY1 Gly696 
insertion variant was crystallized by pre-incubation with 1 mM ZPP (as before) and 1 mM 
presegetalin A1 [27-32] at a concentration of 12 mg/mL. A precipitant solution of 18% PEG 8,000, 
0.2 M calcium acetate, 0.1 M sodium cacodylate pH 6.5 was used to form crystals at 9 °C. PCY1 
crystals were soaked in the crystallization buffer supplemented with 20% PEG 400 immediately 
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prior to vitrification by direct immersion into LN2. The PCY1 Tyr481Phe mutant crystals were 
produced by first incubating 1 mM presegetalin A1 [14-32] with protein at a concentration of 7 
mg/mL. Crystals formed at 289K using a 3:1 ratio of the protein sample mixed with a precipitant 
containing 23% PEG 3,350, 0.1 M magnesium chloride, and 0.1 M HEPES free acid pH 7.5, prior 
to equilibration against a solution of the same buffer. The cryo-preservation solution consisted of 
the crystallization buffer supplemented to a final concentration of 30% PEG 3,350 was utilized. 
Diffraction data was collected using CCD detectors, at LS-CAT Sector 21 of the Advanced Photon 
Source (Argonne National Labs, IL). 
 
Crystal Data Processing and Structure Refinement 
PCY1 data sets were integrated and scaled using the autoPROC software package.87 Using 
PDB code 1QFS as a search model, phases for wild type PCY1 data set was determined by 
molecular replacement using PHASER,124 as implemented in the PHENIX software suite.88 Initial 
model re-building was carried out using a combination of AutoBuild and Buccaneer.125 All 
crystallographic model building was preformed using Coot,90 followed by rounds of refinement 
using REFMAC5,91 and Phenix.refine. The refined wild type PCY1 structure was subsequently 
used to determine the phases of all mutants and covalently modified PCY1 structures. Data 
collection, scaling, and refinement statistics for all data sets can be found in Table 3.2. 
 
Fluorescence Polarization 
PCY1 was gel filtered into assay buffer (50 mM Tris base (pH 8.5), 100 mM NaCl, and 5 
mM DTT) with a Superdex 16/60 S200 column (GE Healthcare). To determine the Kd of the 
FITC(fluorescein isothiocyanate)-presegetalin A1 [27,32] fluorescent peptide, 100 nM of peptide 
was incubated with varying concentrations of PCY1 in a 115 L reaction. After a 1 hour incubation 
at 4 °C, 100uL of the solution was transferred to a 96-Well Low Fluorescence Assay Plate 
(Corning) and analyzed a Biotek Synergy H1 Hybrid Reader. Polarization data was fit according 
to Dunbar et. al.126 to determine the Kd of FITC-presegetalin A1 [27-32]. Competitive binding 
assays were performed using 100 nM FITC-presegetalin A1 [27-32], 2.3 M PCY1, and varying 
concentrations of either presegetalin A1 [27-32], presegetalin A1 [20-32], presegetalin A1 [27-32] 
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amide, or presegetalin A1 [27-32] N27A. Polarization data was fit to a one-site competitive 
binding curve to derive an IC50 value for each peptide. Ki values were derived from the IC50.
126 
 
Activity assays 
PCY1 activity assays were completed at 30 °C using 175 nM PCY1 and 30 M of peptide 
in a 100 L reaction containing 100 mM NaCl, 5 mM DTT, and 20 mM Tris base (pH 8.5). After 
the designated incubation time, the reactions were quenched with 1 equivalent (100 L) of 
methanol. Single turn over assays were completed using 30 M PCY1 and quenched after 5 min. 
Samples were centrifuged to remove protein precipitation. All reactions were completed and 
analyzed in triplicate. 
 
LC/MS Analysis 
LC/MS analysis was completed using an Agilent 1200 series HPLC, an Agilent G1956B 
mass spectrometer, and a Grace Davison Denali 250x4.6 mm 5 C18 HPLC column. Samples 
were analyzed using a following method with solvent A (10% ACN, 90% H2O, 0.1% Formic acid, 
and 0.1% ammonium formate) and solvent B (90% ACN, 10% H2O, 0.1% formic acid, and 0.1% 
ammonium formate) at 1 mL/min: 1 min at 0% B, linear gradient to 75% B for 14 min, linear 
gradient to 100% B for 1 min, 3 min at 100% B, linear gradient to 0% B for 1 min, and 5 min at 
0% B. 40 L of each reaction sample was analyzed using this method. Single ion mode was utilized 
to observe the following peptides: segetalin A1 (m/z=610.5, z=1), linear[GVPVWA] (m/z=628.5 
z=1), presegetalin A1 [14,32] (m/z= 993.2, z=2), presegetalin A1 [20,32] (m/z=669.2, z=2), 
cyclic[GKPVWA] (m/z= 639.5, z=1), cyclic[Ahx-VPVWA] (m/z= 666.6, z=1), and linear[Ahx-
VPVWA] (m/z= 684.6, z=1). 
 
Kinetics 
Kinetics assays were completed at 23 oC using 10 nM PCY1 and either 0.5 M, 1 M, 5 
M, 15 M, 30 M, or 60 M of the presegetalin A1 [14,32] substrate in a 100 L reaction 
containing 100 mM NaCl, 5 mM DTT, and 20 mM TRIS pH 8.5. After 2, 4, or 6 minutes, the 
reaction was quenched with 100 L of methanol. After centrifugation, 80 L of sample was 
analyzed using the LC/MS method and monitoring the abundance of the linear presegetalin A1 
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[20-32] byproduct (SIM m/z=669.2, z=2). A standard curve was created using synthetic 
presegetalin A1 [20-32] concentrations ranging from 10 nM to 400 nM. Reactions were completed 
triplicate. 
 
Fluorescent Monitoring of Conformational Change 
To monitor conformational changes, PCY1 was first labeled with the cysteine specific 
fluorophore N-(1-pyrene)maleimide. PCY1 was buffer exchanged into 200 mM NaCl, 20 mM 
HEPES free acid (pH 7.0) and concentrated to 1.25 mL of 50 M protein. TCEP and N-(1-
pyrene)maleimide were added to a concentration of 1 mM with the N-(1-pyrene)maleimide added 
dropwise. The reaction was stirred at 23 C for 2 hours and then quenched with a final concentration 
of 5 mM DTT. The protein was gel filtered and buffer exchanged into reaction buffer. Modification 
of PCY1 was confirmed by MALDI analysis to reveal a total of three N-(1-pyrene)maleimide 
added (Figure 3.2). To monitor the changes in the environment of the pyrenes, 4 M of labeled 
PCY1 was incubated with either buffer, 1 mM presegetalin A1 [27-32], or 1 mM presegetalin [27-
32] amide for 10 minutes. Using 338 nm excitation wavelength and excitation and emission slit 
widths of 5 nm, an emission scan was collected. 
 
Results and Discussion 
Incubation of recombinant PCY1 with a synthetic peptide corresponding to presegetalin 
A1 [14-32] resulted in a near complete conversion into cyclic[GVPVWA] segetalin A1 (and 
corresponding linear follower peptide) (Figure 3.3). The yield of linear core peptide was minimal, 
demonstrating that the enzyme favors production of macrocyclic products relative to the linear 
counterpart. In order to determine steady state kinetic parameters, we utilized a LC-MS-based 
assay to quantify rates of product formation. Complete Michaelis-Menten kinetics were carried 
out for the presegetalin A1 [14-32] substrate yielding a kcat value of 6.0 x 10
-2 s-1 ± 0.5 x 10-2 s-1 
with a KM of 0.77 M ± 0.35 M (Figure 3.4). In comparison, the transamidative protease involved 
in the biosynthesis of amatoxin (GmPOPB) has a similar KM value but is 100-fold faster (kcat of 
5.7 s-1),118 whereas the asparaginyl endipeptidases involved in cyclotide macrocyclization 
(butelase 1 and AEP) have similar kcat values, but with KM values that are 5 to 10-fold higher.
116,117  
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In order to elucidate how an S9A protease family can catalyze macrocyclization, we 
determined the crystal structure of PCY1 that had been incubated with the presegetalin A1 [14-32] 
substrate, in the presence of a protease inhibitor (Figure 3.5A, B).127 The 1.9 Å resolution structure 
of this PCY1 complex revealed an overall architecture similar to other prolyl oligopeptidase family 
members, such as the enzyme from porcine muscle (PDB Code: 1QFS; RMSD of 1.6 Å over 691 
aligned C atoms).94,128 The structure of PCY1 consists of an / hydrolase domain composed of 
residues Met1-Val77 and Asp437-Asp724, and a -propeller domain consisting of residues Cys82-
Glu432. A hinge region encompassing residues Asn78-Arg81 and Ser433-Pro436 links the two 
domains, and based on studies of other S9A family enzymes, presumably facilitates movement 
between an open form competent for binding substrate, and a closed form where chemistry is 
carried out.51,129 The PCY1-presegetalin A1 complex was crystallized in the closed form with a 
large internal cavity (10,317 Å3 as calculated by CASTp), which can accommodate the binding of 
large peptides.129,130 Enzyme residues Asp653, His695, and Ser562 make up the active site 
catalytic triad, and a hydrophobic pocket enriched in aromatic residues forms a binding pocket for 
the target peptide. Lastly, Tyr481 acts to stabilize the tetrahedral intermediate oxyanion that is 
formed following the attack of the Ser562 alkoxide onto the peptide substrate.  
While PCY1 crystallization was carried out using presegetalin A1 [14-32] and a protease 
inhibitor, the active site revealed unambiguous electron density only for the terminal six residues 
(NASAPV) of the follower peptide (Figure 3.5B). The residues within the follower sequence bind 
to PCY1 near the hinge region, and engage in hydrogen bonds with amino acids in both the / 
hydrolase and the -propeller domains. Hydrogen-bonding interactions can be observed between 
PCY1 residues Arg81, Asn97, Asn104, and backbone carbonyl and amide of Ala28 and Ser29, 
respectively, of the follower peptide. The only sequence-specific interaction with the follower 
peptide occurs between its side chain of Asn27, and the side chain of Asp104 and backbone 
carbonyl of Leu132 of PCY1. The binding of the carboxy terminus of the peptide is of particular 
interest, as it forms hydrogen bonds with PCY1 residues Ser495 and Ser493. This observation 
explains prior alanine-scanning mutational analysis of presegetalin A1 [14-32], which demonstrate 
that PCY1 is tolerant of mutation along the entirety of the primary sequence of the substrate but 
could not process a substrate with the deletion of the C-terminal Val32, indicating the importance 
of the follower peptide C-terminal carboxylate.50  
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In order to visualize a structure of PCY1 bound to intact presegetalin A1, we carried out 
cocrystallization with two different active site variants, His695Ala and Tyr481Phe. In both 
instances, electron density could only be observed for the six-residue follower sequence, despite 
the presence of the presegetalin A1 [20-32] peptide in the crystals (as determined by mass 
spectrometry), consistent with disorder/flexibility for the remainder of the substrate (Figure 3.6 
and 3.7). Hence, only the follower region of presegetalin A1 is engaged by PCY1, allowing for 
flexibility in the substrate N-terminal to the cleavage site. This flexibility explains how S. vaccaria 
can produce nine different orbitides of different ring sizes and sequence composition, as only the 
follower sequences are conserved in the precursor peptides progenitors of the macrocyclic 
products (Figure 3.8). 
Most RiPP biosynthetic enzymes utilize a PqqD domain (RiPP precursor peptide 
recognition element59) to engage the leader precursor peptide through a limited number of 
hydrophobic interactions. This has been observed in at least some of the enzymes involved in the 
biosynthesis of pyrroloquinoline quinone131, lantibioics132, lasso peptides59,  and cyanobactins29. 
In contrast, the follower peptide binding observed in PCY1 does not rely on hydrophobic 
interactions, but rather on hydrogen bonding interactions. Hydrogen-bonding interactions also 
mediate binding of leader peptides by microvirdin biosynthetic enzymes (citation) and of the 
follower peptide by PatG.122 
In order to determine the affinity of PCY1 for various follower peptides, we carried out 
competition binding measurements (Table 3.3). A six-residue presegetalin A1 [27-32] peptide 
conjugated to fluorescein isothiocyanate (FITC) bound to PCY1 with a dissociation constant (Kd) 
of 4.83 M as determined by fluorescence polarization (Figure 3.9A). Competitive binding 
between this labeled peptide and various unlabeled peptides was used to determine the Ki values 
for the unlabeled peptides. These competition experiments demonstrate that unlabeled presegetalin 
A1 [27-32] bound to PCY1 with a Ki of 31.0 M (Figure 3.9B). The longer, full-length linear 
byproduct of the cyclization reaction, presegetalin A1 [20-32], binds with a much higher affinity 
with a Ki of 0.40 M (Figure 3.9C). The nearly 80-fold greater binding affinity for the longer 
presegetalin A1 [20-32] peptide is curious given that only the last six residues of the peptide are 
involved in contacts with PCY1 in the cocrystal structure. The additional binding affinity, relative 
to presegetalin A1 [27-32], may be due to solvent exclusion or another non sequence-dependent 
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mechanism. The amino acids that make up the final cyclic product do not seem to contribute to 
binding as substrate presegetalin A1 [14-32] was measured to bind to the catalytically inhibited 
PCY1 H695A with a Ki of 1.10 M, very similar to that of presegetalin A1 [20-32] (Figure 3.9D). 
Therefore, it appears that the presegetalin A1 [27-32] follower peptide is the major determinant of 
binding, and while binding affinity is increased by the presegetalin A1 [20-26] linker region, it is 
unaffected by the residues that would form the cyclic product (i.e. presegetalin A1 [14-19]).  
In order to verify the roles of individual interactions observed observed in the structure, we 
measured the affinity of PCY1 for variants of the presegetalin A1 [27-32] peptide. Based on the 
crystal structure, the side chain of Asn27 of presegetalin A1 [27-32] is engaged in specific 
hydrogen-bonding interactions. Consequently, the Asn27Ala mutation in presegetalin A1 [27-
32] results in a reduction in the PCY1 binding affinity (Ki of 131 M) (Figure 3.9E). The C-
terminus of the follower peptide forms hydrogen bonds with PCY1 residues Ser495 and Ser493, 
and the binding affinity of PCY1 for the presegetalin A1 [27-32] variant with a C-terminal amide 
was diminished and outside the detection range of the assay (Figure 3.9F). Mutations were made 
to PCY1 residues Ser493 and Asn97, which both bind the follower peptide. Ser493Ala had 
minimal changes on product production during a 1 h activity assay while Asn97Ala greatly 
diminished activity (Table 3.3, Figure 3.10). 
Based on the kinetic studies, we hypothesized that the high affinity of PCY1 for the 
presegetalin A1 [27-32] follower peptide may ensure that the enzyme is maintained in the closed 
conformation throughout catalysis, and is only displaced after turnover. To test this, we 
fluorescently labeled PCY1 with thiol-specific probe N-1-pyrene maleimide. Addition of the 
presegetalin A1 [27-32] to labeled PCY1 resulted in the quenching of fluorescence compared to a 
buffer control (Figure 3.11). Conversely, addition of a control peptide that does not bind 
(presegetalin A1 [27-32] amide) showed no change in fluorescence. This is consistent with the 
notion that binding of presegetalin A1 [27-32] alone induces a conformational change in PCY1 to 
the closed state.  
 As presegetalin A1 [27-32] binding induces closure of the PCY1 structure, addition of 
exogenous peptide would be expected to inhibit productive turnover of the presegetalin A1 [14-
32] substrate. We tested this hypothesis using a 1h end-point reaction of PCY1 incubated with 30 
M of substrate in the absence or presence of stoichiometric and 10-fold excess of the presegetalin 
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A1 [27-32] follower peptide, as well as the presegetalin A1 [20-32] linker+follower peptide 
product (Figure 3.12). While PCY1 consumed nearly all of the presegetalin A1 [14-32] substrate, 
addition of the follower peptides resulted in a decrease in turnover in a concentration-dependent 
manner. These data are consistent with the follower peptide maintaining a closed state for PCY1. 
The role of the leader/follower peptide in stabilizing active conformations of biosynthetic enzymes 
is an emerging theme in RiPP biosynthesis. For example, during cyanobactin biosynthesis, binding 
of the PatE’ leader peptide to the LynD cyclodehydratase stabilizes the enzyme in a catalytically 
competent form29. 
Using the structural data as a guide, we generated and characterized mutants of several 
active site residues in order to test their roles in catalysis (Figure 3.13). As expected, both the 
Ser562Ala and His695Ala mutation of the catalytic triad residues produced inactive enzyme, 
confirming the necessity of these conserved residues. Lastly, Tyr481 is necessary to stabilize the 
oxyanion of the tetrahedral intermediate as the Try481Phe variant is catalytically inactive. 
We next interrogated the extent to which the enzyme could accommodate primary amines 
other than a peptide -amino group for transamidation. First, we utilized a variant presegetalin A1 
[14-32] substrate peptide that contained both the -amino terminus, as well as a side chain amine 
(Val15Lys). While PCY1 was able to completely convert this substrate to the cyclic product, 
tandem mass spectrometric (MS/MS) analysis revealed that only the -amino group was utilized 
for transamidation (Figure 3.14). We did not observe any products consistent with the use of the 
side chain of Lys15 as part of the macrocycle. We then tested whether PCY1 could generate a 
macrocyclic utilizing a non-proteinogenic amine. To this end, we used a presegetalin A1 [14-32] 
substrate that contained an N-terminal aminohexanoic acid (Ahx) in place of Gly14. PCY1 largely 
produced a linear product with this substrate, although minor amount of cyclic [AhxVPVWA] 
could also be detected (Figure 3.15). These data suggest that PCY1 catalyzed macrocyclization is 
most effective via the use of a peptide -amine. 
Prior studies on other macrocyclases, such as the PatG protease involved in cyanobactin 
biosynthesis, suggest a plausible route to cyclic peptide production.122,123 Briefly, following the 
formation of an acyl-enzyme intermediate during the first half protease reaction, hydrolysis of the 
intermediate is averted by solvent exclusion from the active site. Instead, the -amino terminus of 
the bound peptide substrate is oriented back towards the catalytic Ser, and deprotonation of the 
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amine could then facilitate a transpeptidation reaction to yield the cyclic peptide product. A 
comparison of the structure of PCY1 with other prolyl oligopeptidases reveals a strong 
conservation of overall structure and a near-identical alignment of putative active-site residues 
(Figure 3.16A). While nearly all of these features in the PCY1 active site superimpose with the 
structures of other S9A proteases, a notable exception is the approximately 2.4 Å displacement of 
His695 away from the catalytic Ser562.  As a result, His695 is located 3.5 Å away from Ser562, 
and two residues are not within the hydrogen bonding distance requisite for effective deprotonation 
of Ser562 to initiate catalysis.  
Studies of hydrolytic serine proteases have established that the catalytic His moves 
following formation of a tetrahedral intermediate, both to tune pKa and to serve as an effective 
proton donor to the leaving group.133–135  In order to determine if the misaligned His695 is 
reflective of a catalytically competent active site, we determined the 3.3 Å cocrystal structure of 
PCY1 covalently bound to an aldehyde inhibitor that mimics a tetrahedral intermediate (ZPP, Z-
Pro-prolinal) (Figure 3.16A). While the structure of ZPP differs from that of the true presegetalin 
substrate peptide, PCY1 is sufficiently tolerant for the sequence preceding the scissile bond to 
accommodate this inhibitor. The cocrystal structure shows that ZPP is covalently bound to Ser562, 
and adopts a conformation similar to that in canonical S9A enzymes, with the Pro oriented within 
the aromatic sidechain rich hydrophobic pocket. Surprisingly, the disposition of His695 relative to 
the unliganded enzyme remained unchanged (0.9 Å movement of N), and was outside the range 
of a hydrogen bonding interaction with Ser562. 
The obvious change in the orientation of the catalytic His695 suggested that it may play 
some role to direct the ability of PCY1 to catalyze macrocyclization. A cursory inspection of the 
PCY1 active site revealed a single residue deletion at a Gly that is normally adjacent to the catalytic 
His in canonical S9A proteases (Figure 3.16B). Surmising that this deletion may force the 
displacement of His695 away from Ser562, we generated a Gly insertion mutant in PCY1, which 
would mimic the canonical S9A protease active site. If the misalignment of His695 indeed plays 
a role in the macrocylase activity of PCY1, this insertion mutant should generate linear, hydrolytic 
products, similar to that of canonical S9A proteases. Notably, while these PCY1 mutants are still 
able to catalyze macrocyclization, they produce a much higher ratio of the hydrolytic product 
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(Figure 3.17). These data support the assertion that the altered position of His695 plays some role 
in macrocycle formation by PCY1.  
Although the insertion mutants showed the expected phenotype of production of both linear 
and cyclic products, the catalytic competency of the enzyme was severely compromised. In order 
to determine the basis for the diminished activity, we determined the 2.82 Å resolution structure 
of the PCY1 Gly696 insertion variant. The structure reveals significant disorder in the loop 
harboring His695. A more detailed comparison of PCY1 reveals additional structural deviations 
near the active site, relative to canonical S9A proteases, in addition to the single Gly deletion 
(Figure 3.18A). In particular, in canonical S9A enzymes, such as porcine prolyl oligopeptidase 
(PDB:1QFS), the loop of an adjacent -hairpin (encompassing Leu143 through Val156) is longer, 
and buttresses the orientation of the catalytic His in the active site. In PCY1, the equivalent loop 
is one residue shorter and is displaced away from the active site. The side chain of Tyr696 
(normally an Ala) occupies the volume created by this loop displacement. The Tyr696Ala/Gly 
insertion double mutant had a greatly compromised activity further underscoring that the 
repositioning of His695 in PCY1 involves a confluence of many local changes (Figure 3.18B).  
Based on the above structural and biochemical data, we hypothesized the His695 in PCY1 
may serve two roles: first, it could serve to deprotonate the catalytic Ser562 (as in other serine 
proteases), but additionally may also deprotonate the -amino terminus of the peptide substrate to 
facilitate transamidation. To further investigate the dual functionality of the catalytic His, we 
analyzed the PCY1 His695Ala variant under single turnover conditions (Figure 3.19A). If 
His695 does not play a role in the deprotonization of Ser562, this variant should still be functional 
but would yield hydrolytic, linear presegetalin A1 [20-32] as a product. However, this variant was 
inactive, indicating that His695 is necessary for activation of Ser562, despite the long distance 
between the two residues. Next, we sought to determine if His695 played a role in proton removal 
from the substrate -amino group by testing the activity of PCY1 His695Ala in the presence of 
imidazole. At the pH of the assay (pH=8.5), imidazole should be deprotonated and may be able to 
function as an imperfect, mobile surrogate for His. Surprisingly, the addition of 20 mM imidazole 
resulted in a gain of function for the His695Ala variant, which could generate both linear and 
cyclic[GVPVWA] segetalin A1 products from the presegetalin A1 [14-32] substrate (Figure 
3.19B). This result suggests that imidazole (and presumably His695 in the wild-type enzyme) can 
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both deprotonate Ser562 to facilitate formation of an acyl-enzyme adduct, and also deprotonate 
the -amino terminus of the substrate to facilitate transamidation. Competition between the mobile 
imidazole surrogate and solvent for attack onto the acyl-enzyme intermediate may account for 
observance of both linear and cyclic products in the His695Ala variant.  
 
Conclusions 
Although macrocyclic peptides have garnered significant interest as platforms for new 
therapeutics, emerging technologies for diverse libraries of molecules are limiting. Recent studies 
of various RiPP biosynthetic enzymes have provided several examples of biocatalysts that can 
generate a macrocyclic product from a linear peptide substrate.57,58,111,116,118,119,136 Such enzymes 
represent a next generation technological utility, but such many of these catalysts are often slow, 
or require sequence constraints on substrates.     
The biosynthesis of orbitides, as well as other RiPPs such as cyclotides,116,117 amatoxins,118 
and cyanobactins119 all utilize convergent strategies based on Ser proteases that can catalyze the 
formation of a cyclic product via transamidation, rather than a linear product via hydrolysis. 
Structural and biochemical studies of the cyanobactin macrocyclase PatG reveal that the enzyme 
has a helix-turn-helix insertion that sits above the active site, which presumably shields the acyl-
enzyme intermediate from solvent. Full enclosure of the PatG active site upon binding of substrate 
is completed by the AYDG follower peptide sequence necessary for substrate recognition. The 
structural and biochemical data presented here on the orbitide macrocyclase PCY1 reveals a more 
nuanced strategy of achieving the same result. Rather than containing obvious insertions, 
transamidation by PCY1 is facilitated by the binding of the follower peptide, which maintains the 
enzyme in a closed state that precludes solvent from the active site, potentially limiting the 
competing hydrolysis reaction. The selectivity for substrates is maintained via recognition of the 
follower sequence, while the lack of appreciable affinity for the residues to be cyclized (as 
demonstrated by fluorescence polarization data) allows for product diversity. Specificity dictated 
by recognition of the follower peptide is not common in RiPP biosynthetic enzymes, and the only 
other known cases are of enzymes involved in the biosynthesis of cyanobactins and bottromycin.122  
The active site of PCY1 is also altered to more efficiently catalyze the cyclization reaction, 
as the placement of His695 facilitates two roles: the canonical role of activating the Ser nucleophile 
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to help form an acyl-enzyme intermediate, and an unexpected role in deprotonating the -amine 
of the peptide substrate to facilitate transamidation (Figure 3.20). The dual functionality for His695 
is aided by its location in a mobile loop, which could accommodate the range of movements 
necessary for each function. Our biochemical studies provide a foundation for understanding the 
mechanistic basis for peptide macrocylization, an activity that is observed in growing classes of 
RiPP natural products. 
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Figures 
 
 
Figure 3.1 A) Structures of the orbitides segetalin A1, cyclolinopeptide A, and ribifolin. B) 
Scheme showing the biosynthesis of segetalin A1 by Saponaria vaccaria. 
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Figure 3.2 Extent of modification of PCY1 with a maleimide linked fluorescent dye. MADLI 
analysis of A) Unlabeled PCY1 and B) PCY1 labeled with N-(1-pyrene)maleimide. The 898 m/z 
mass difference, as measured by the z=2 peak, indicates three cysteines had been labeled. 
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Figure 3.3 SIM m/z=610.5, z=1 of the segetalin A1 product (green trace), SIM m/z=628.5 z=1 
of the linear [GVPVWA] product (red trace), and SIM m/z= 993.2, z=2 of the presegetalin A1 [14-
32] substrate (blue trace) are indicated. The wild type PCY1 utilized most of the presegetalin A1 
[14-32] substrate to produce almost exclusively cyclic segetalin A product after a 1 hour reaction. 
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Figure 3.4 Michaelis-Menten kinetic curve for PCY1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
52 
 
 
Figure 3.5 A) 1.9 Å PCY1 structure with the / hydrolase domain shown in green and -
propeller domain shown in red. B) The C-terminal 6 amino acids of the presegetalin A1 [14-32] 
substrate (orange) is bound near the hinge region of PCY1. A simulated annealing difference 
Fourier maps (Fo-Fc), calculated with the coordinates of the peptide omitted, is superimposed and 
contoured to 2.5 (blue). 
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Figure 3.6 Difference Fourier maps of PCY1 variant active sites. Electron density maps 
calculated with Fourier coefficients Fo-Fc and contoured at 2 over background within a 10 Å 
radius from the peptide binding sites illustrates that A) His695Ala and B) Tyr481Phe PCY1 
variants contained only PSA1 [27-32] (orange) visible in the crystal structure. 
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Figure 3.7 Integrity of the substrate peptide in PCY1 crystals. MALDI mass spectrometric 
analysis of the crystallization drop indicated the presence of the PSA1 [20-32] peptide (m/z= 
1375.183).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
55 
 
 
Figure 3.8 Sequences alignments of PCY1 substrates. Multiple sequence alignment of 
peptides with confirmed activity PCY1 activity.50 The follower sequence that is excised is strongly 
conserved, while the core sequence that is macrocyclized by the enzyme is divergent. 
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Figure 3.9 A) PCY1 was titrated into FITC-presegetalin A1 [27-32]. Competition between B) 
presegetalin A1 [20,32], C) presegetalin A1 [27-32], D) presegetalin A1 [14-32], E) presegetalin 
A1 [27-32] N27A, and F) presegetalin A1 [20-32] amide and the FITC- presegetalin A1 [27-32] 
was used to determine IC50 and Ki values for each ligand. 
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Figure 3.10 Activity of PCY1 follower peptide binding variants. Although Ser493 and Asn97 
both bind the follower peptide, the Asn97Ala variant had greatly diminished activity while the 
Ser493Ala variant was active in a 1 hour end-point assay. 
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Figure 3.11 Binding of the follower peptide change the conformation of PCY1. Fluorescence 
scan of pyrene labeled PCY1 after the addition of presegetalin A1 [27-32] (black), presegetalin A1 
[27-32]Amide (red), or buffer (blue). Presegetalin A1 [27-32] induced a quenching of 
fluorescence, indicative of a conformation change. 
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Figure 3.12  Product inhibition of PCY1 by the follower peptide. Competition assays between 
the presegetalin A1 [14-32] substrate and either 1 equivalents of presegetalin A1 [20-32], 10 eq. 
of presegetalin A1 [20-32], or 100 eq. of presegetalin A1 [27-32]. In each case substantial amounts 
of substrate remain, indicating that both presegetalin A1 [20-32] and presegetalin A1 [27-32] can 
act as inhibitors. 
 
 
 
 
 
 
60 
 
 
 
Figure 3.13 Biochemical activity of PCY1 variants. Liquid chromatograph/mass-spectrometry 
(LC/MS) analysis of PCY1 His695Ala, Ser562Ala, and Tyr481Phe variants indicated 
greatly reduced activity after a 1 hour incubation by monitoring the production of segetalin A1 
(green trace), presegetalin A1 [14-32] (blue trace), and linear[GVPVWA] (red trace). 
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Figure 3.14 PCY1 does not cyclize substrates through a Lys side chain amine. MS/MS analysis 
of product purified from the presegetalin A1 [14-32] V15K reaction gave no indication of product 
cyclized using the lysyl amine. Identified fragments are as follows: 639.3610 m/z = Segetalin A1 
(cyclic[GVPVWA]), 511.2674 m/z = [KPVW] or [PVWAG], 454.2445 m/z = [PVWA], 443.2474 
m/z = [WAGK],  383.2073 m/z = [PVW], 197.1283 m/z = [PV], 186.1244 m/z = [GK], 129.1021 
m/z = [AG ]or [K]. 
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Figure 3.15 Macrocyclase activity is dependent on the length of the N-terminal amine. An 18 h 
incubation of PCY1 with the N-terminal Ahx presegetalin A1 [27-32] mostly linear[Ahx-
VPVWA] (red trace) and small amounts of the cyclic[Ahx-VPVWA] (green trace). 
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Figure 3.16 A) Active site alignment of PCY1 (red, cream) and porcine muscle prolyl 
oligopeptidase (cyan, blue) with covalently bound Z-pro-prolinal. All residues are conserved and 
align well except for the catalytic histidine. Residues are labeled according to PCY1’s numbering. 
B) Sequence alignment of PCY1 and POP enzymes from Sus scorfa (domestic pig, NCBI: 
NP_001004050.1), Beta vulgaris (beet, NCBI: XP_010667346.1) and Morus notabilis (mulberry, 
NCBI: XP_010101294.1). 
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Figure 3.17 Activity profile of the PCY1 Gly696 insertion variant. The Gly696 insertion had 
minimal turnover after 1 hour. However, an 18 hour reaction produced a cyclic to linear product 
ratio of closer to one than wild-type PCY1. 
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Figure 3.18 Comparison of PCY1 with a canonical S9A protease. A) Changes in structures at 
regions distal to the active site between PCY1 (red) and porcine muscle POP (blue) indicate 
significant difference in the orientation of the hairpin loop. The hairpin is stabilized in PCY1 by a 
stacking interaction between His149 and Tyr696. B) The Tyr696Ala/Gly insertion double 
mutant still has greatly compromised activity. After an 18 h reaction, significant amounts of the 
PSA1 [14-32] substrate (blue trace) remains and no increase in linear hydrolysis product (red trace) 
compared to cyclic product (green trace) is observed. 
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Figure 3.19 A) Formation of presegetalin A1 [20,-32] was observed under single turnover 
conditions by LC/MS. After a 5 min incubation, wild type PCY1 was able to catalyze formation 
of the acyl enzyme intermediate, producing the presegetalin A1 [20-32] by product. The H695A 
mutant did not catalyze formation of presegetalin A1 [20-32], indicating it could not form the acyl 
enzyme intermediate. B) An 18 hour incubation of H695A with 20 mM imidazole allowed for the 
production of both linear [GVPVWA] and cyclic segetalin A1. Their ratio of production was much 
closer to one compared to the wild type PCY1 (Figure 3.3). 
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Figure 3.20 Proposed mechanism for PCY1. Unlike canonical S9A proteases, the active site His 
is mobile in PCY1, and may play a bifunctional role to facilitate the transamidation reaction. 
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Tables 
 
Table 3.1 Primers used for generating PCY1 variants 
 
Mutagenesis 
Primers 
Sequence 
Y481F For AAATGCATGGTTTTGGCGGGTTTGG 
Y481F Rev CCAAACCCGCCAAAACCATGCATTT 
S562A For TGAAGGTGGTGCTAATGGTGGCCTTCTCGTTGCTGC 
S562A Rev GGCCACCATTAGCACCACCTTCAATAGCCACTCTTCTAGC 
H695A For CGGATTCAGCGCAAAGCTGCAGCGTACGGACGTGCC 
H695A Rev CGCAAAGCTGCAGCGTACGGACGTGCCACAATGACCCAGATTGC 
G696Ins For CGCAAAGCTGCACATGGCTACGGACGTGCCAC 
G696Ins Rev GTGGCACGTCCGTAGCCATGTGCAGCTTTGCG 
G696Ins 
Y697A For 
CAAAGCTGCACATGGCGCCGGACGTGCCACAATG 
G696Ins 
Y697A Rev 
CATTGTGGCACGTCCGGCGCCATGTGCAGCTTTG 
S493A For GCGTGCCAACAAGTATTTTCACTTCTATGCTTCCGGCCTTCAAGC 
S493A Rev GCTTGAAGGCCGGAAGCATAGAAGTGAAAATACTTGTTGGCACGC 
N97A For GCATAAACATGATGCCAACTTTTGCCGCCAGTCGCA 
N97A Rev TGCGACTGGCGGCAAAAGTTGGCATCATGTTTATGC 
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Table 3.2 Data Collection and Refinement Statistics 
 
 Wild-type H695A ZPP complex 
696G –ZPP 
complex 
Y481F 
Data collection      
Space group P1 P1 P1 P1 P21 
Cell dimensions      
a, b, c (Å) 65.5, 85.6, 137.7 
65.0, 85.6, 
137.9 
65.5, 85.5, 138.1 65.0, 85.32, 137.9 87.0, 59.6, 134.1 
() 87.4, 78.3, 89.3 
87.5, 78.5, 
89.4 
87.6, 78.2, 89.4 87.7, 78.5, 89.6 90.0, 93.1, 90.0 
Resolution (Å) 
44.9-1.96 
(1.967-1.960) 
44.90-2.94 
(2.950- 2.940) 
45.2-3.3 (3.311-
3.300) 
45.70-2.82 
(2.829-2.820) 
86.90-2.37 
(2.381-2.373) 
Rsym 12.9 (52.5) 12.7 (50.6) 13.0(2.79) 12.6 (42.6) 9.2 (75.1) 
I / I 8.9 (3.3) 11.0 (2.8) 10.2 (5.0) 11.1 (3.3) 14.0 (2.1) 
Completeness (%) 95.8 (96.8) 98.8 (98.9) 98.9 (99.5) 98.3 (98.1) 99.2 (96.2) 
Redundancy 3.8 (3.9) 3.9 (3.9) 3.9 (3.9) 4.3 (4.4) 6.2 (6.5) 
      
Refinement      
Resolution (Å) 44.9-1.96 44.90-2.94 45.2-3.3 45.70-2.82 86.90-2.37 
No. reflections 191296 58051 41469 65404 52877 
Rwork / Rfree 0.224/0.189 0.227/0.186 0.220/0.172 0.270/0.223 0.284/0.236 
No. atoms 24731 22798 22866 22661 10789 
Protein 22670 22734 22814 22600 10754 
Water 2061 64 52 61 35 
B-factors      
Protein 19.68 33.16 33.43 29.66 51.74 
Water 24.87 19.19 17.08 13.30 32.58 
R.m.s. deviations      
Bond lengths (Å) 0.0166 0.0102 0.0107 0.0105 0.0104 
Bond angles () 1.6837 1.4070 1.4751 1.4454 1.3242 
 
1. Highest resolution shell is shown in parenthesis. 
2. R-factor = (|Fobs|-k|Fcalc|)/ |Fobs|and R-free is the R value for a test set of reflections consisting 
of a random 5% of the diffraction data not used in refinement. 
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Table 3.3 Binding constants for the follower peptide and mutants 
 
Ligand IC50 (M) Ki (M) 
Presegetalin A1 [20-32] 1.97 ± 0.34 0.40 
Presegetalin A1 [14-32]* 3.03  ±0.61 1.10 
Presegetalin A1 [27-32] 47.4 ± 1.0 31.0 
Presegetalin A1 [27-32] N27A 197± 8 131 
Presegetalin A1 [27-32] Amide > 1,000 > 650 
*Presegetalin A1 [14-32] binding experiments were completed with PCY1 H695A to prevent 
turnover. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
71 
 
Chapter 4 Structural and Biochemical Studies of the Lasso Peptide Leader Binding 
Protein TbiB1iii 
 
Ribosomally synthesized and post-translationally modified peptides (RiPPs) encompass a 
wide variety of chemical scaffolds that are generated through enzymatic modifications on linear 
ribosomal peptide precursors.11 These precursors may be demarcated into a highly conserved 
leader sequence that guides recognition by modification enzymes, and a highly variable core 
sequence where the modifications are actually installed. RiPP biosynthetic enzymes are specific 
for their corresponding leader sequence but tolerant for variations in the core sequence, which 
enables chemical diversity without sacrificing specificity. Lanthipeptide,137 cyanobactin,21 and 
lasso peptide138 biosynthetic clusters often encode for multiple precursor peptides that contain 
highly conserved leaders but divergent cores, which can all be post-translationally modified by the 
same set of enzymes to yield structurally divergent products.11 The leader sequences in RiPP 
precursors are engaged by domains that may exist as either a standalone protein or as fusions with 
catalytic domains of the modification enzymes. The binding domains often fall into the PqqD 
superfamily (PF05402), so named for a stand-alone protein responsible for binding the peptide 
precursor for the bacterial redox cofactor pyrroloquinoline quinone.59,139,140 Binding of the leader 
sequence is presumed to allow PqqD domains to present the core peptide to the catalytic 
domain/protein for modification.141,142 The prevailing proposal for RiPP biosynthesis suggests that 
substrates are recruited to the biosynthetic enzymes through specific recognition of the leader 
peptide, enabled by the leader-binding domain from the biosynthetic cluster.30,143 
Lasso peptides are a class of RiPPs characterized by an isopeptide bond between the N-
terminal -amine and side chain of an Asp or Glu 6-10 amino acids downstream,27 forming an 
internal lactam ring that encircles the remaining linear peptide to create a lasso-like shape. Over 
39 lasso peptides have been isolated and their activities include inhibition of bacterial RNA 
polymerase60,144 and ClpX protease.61 In vitro reconstitution of the lasso peptide microcin J25 
provides a plausible route for lasso peptides biosynthesis.57,58 First, a protease (B-protein) binds to 
                                                          
iii Part of this chapter is adapted from the following article manuscript: 
Chekan J. R. and Nair S. K. Characterization of a Prevalent Motif in Lasso Peptide Biosynthesis Reveals the Basis for 
Promiscuous Leader Sequence Binding. Manuscript in preparation. 
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and cleaves the leader peptide from the A-protein precursor peptide to yield the core peptide. Next, 
the side chain of a Glu/Asp C-terminal to the cleavage site (eight residues in the case of microcin 
J25) may be activated with ATP by the C-protein to form an adenylyl intermediate. Nucleophilic 
attack by the newly exposed -amine of the core peptide onto the Glu/Asp side chain adenylate 
may yield the mature product with the characteristic lasso structure. 
In most lasso peptide biosynthetic clusters, the B-protein is a single polypeptide but in 
some clusters, such as those that produce lassomycin,61 streptomonomycin,145 and lariatin,146 this 
gene split into two open reading frames, B1 and B2, which are similar to the N- and C-termini of 
full-length B. We investigated a putative and previously unidenitifed lasso peptide gene cluster 
from Thermobacculum terrenum ATCC BAA-798. Closer examination of the gene cluster 
revealed the unexpected arrangement of two putative precursor peptides (TbiA and TbiA), 
flanked by two isopeptide forming C-proteins (TbiC and TbiC), but containing only a single 
split B-protein (TbiB1 and TbiB2) (Figure 4.1a). Unexpectedly, both the leader sequence and the 
core sequence of the two precursor peptides are sequence divergent. This contrasts with other RiPP 
clusters containing multiple precursor peptides, in which the core sequences may be divergent but 
the leader sequences are highly conserved.30,31 The gene organization of this cluster suggests that 
the single split B-protein can process both precursor peptides, despite the divergence in their leader 
sequences. Further modification of the two processed precursors may be catalyzed by the two 
different C-proteins to yield the corresponding lasso products, hereafter named therbactin  and 
therbactin  (Figure 4.1b).  
To elaborate further the strategy underlying the biosynthesis of therbactins  and , we 
carried out reconstitution of the split B-protein activity using both precursor peptides as substrates. 
We hypothesized that TbiB1 would bind to the peptide substrate via the leader sequence and 
present the core sequence to TbiB2 for proteolysis. Using MALDI mass spectrometric analysis, 
we confirmed that the combination of both TbiB1 and TbiB2 is necessary for processing of the 
TbiA peptide, no activity was observed upon omission of either of the two proteins (Figure 4.1c 
and 4.1d). Surprisingly, the TbiB1-TbiB2 combination could also catalyze processing of the TbiA 
peptide (Figure 4.1e and 4.1f), in spite of the lack of significant sequence conservation among the 
leader sequences of the two peptides. Lastly, although ATP is a required cofactor for processing 
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by the two-domain B-proteins58, proteolysis by the therbactin split B-proteins does not require 
ATP. 
In order to provide additional evidence that the single leader-binding protein can engage 
the two sequence divergent leader peptides, we used fluorescence polarization assays to measures 
the affinities of TbiB1 for both TbiA and TbiA. Measurements of the binding to an N-terminally 
FITC labeled TbiA leader peptide yields a Kd of 266 nM (Table 4.1 and Figure 4.2). Competition 
assays with unlabeled TbiA gives a Ki of 359 nM, suggesting that the FITC tag did not 
significantly alter the peptide-binding affinities of TbiB1 (Figure 4.3a). The protein bound to the 
TbiA leader somewhat more tightly with a Ki of 227 nM (Figure 4.3b). Hence, even though the 
leader sequences of TbiA and TbiA are divergent, TbiB1 bindsboth peptides with comparable 
affinity.  
To elucidate the basis for the permissiveness of TbiB1 for divergent leader sequences, we 
determined the 1.43 Å resolution cocrystal structure of TbiB1 complexed with the TbiA leader 
peptide (Figure 4.3c). The structure of TbiB1 consists of a winged helix-turn-helix motif observed 
in the leader-binding domains of the cyanobactin heterocyclases TruD73 and LynD,29 the microcin 
C7 synthase MccB,42 the lantipeptide dehydratases NisB,132 as well as the standalone PqqD from 
Xanthomonas campestris.131 The first 16 residues of the TbiA leader are visible in the crystal 
structure, where Lys(-11) through Arg(-7) form an anti-parallel  sheet with Thr25 through Arp30 
of TbiB1 (the amino acids of the leader peptide were numbered relative to the excision site, starting 
with (-1) as the C-terminus of the leader) (Figure 4.3c and 4.3d). Binding of the leader is mediated 
largely through a “knobs-into-holes”147 strategy wherein select residues are packed into 
hydrophobic pockets located along the periphery of TbiB1 (Figure 4.4a). Three residues in the 
leader sequence are positioned in the following manner: Tyr(-17) and Pro(-14) are encapsulated in 
a pocket formed by Val32, Ile36, Ile53, Val59, and Phe71, and Leu(-12) is settled into a second 
pocket formed by Phe27, Phe71, Leu75, and Leu80 (Figure 4.3e). In addition to these contacts, 
limited hydrogen bond interactions are observed with the side chains of Tyr(-17), Ser(-15), and 
Glu(-10) of TbiA. Similar “knobs-into-holes” packing strategies are observed in other leader-
binding domains. In the lanthipeptide dehydratase NisA132 leader peptide structure, Leu16 and 
Phe18 from the conserved Phe-Asn-Leu-Asp motif occupy two hydrophobic cavities (Figure 4.4b). 
Likewise, the PatE’ leader peptide is engaged through the packing of Leu26 and Leu29 into 
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hydrophobic pockets in the cyanobactin heterocyclase LynD29 (Figure 4.4c). These Leu residues 
comprise the conserved Leu-(X)2-Leu-(X)2 motif abundant in cyanobactin leaders.
28,148 
A multiple sequence alignment of 27 different leaders from split B-protein lasso peptide 
gene clusters identifies a prevalent Y-(X)2-P-X-L-(X)3-G motif (Figure 4.5), and our structural 
data reconciles Tyr, Pro, and Leu as the “knobs” that fit into the hydrophobic “holes” in the leader-
binding TbiB1 protein (Figure 4.3c and 4.3d). The conserved Gly of this motif (Gly(-8) in TbiA), 
enables the leader sequence to form a kink around Tyr26 of TbiB1 (Figure 4.3e). The above data 
demonstrates that TbiB1 can engage leader peptides of seemingly disparate sequence through 
steric complementarity, i.e. by employing multiple hydrophobic pockets to engage appropriately 
spaced hydrophobic residues in the leader. An alignment of the leader sequences of TbiA and 
TbiA reveals that sequence similarity is generally limited to the Y-(X)2-P-X-L-(X)3-G motif 
(Figure 4.1b).  
In order to verify the importance of the “knobs-into-holes” packing criterion for leader 
engagement, we carried out binding assays with TbiA leader derivatives against wild-type TbiB1 
and variants. The binding affinity of TbiB1 for the Tyr(-17)Ala and Pro(-14)Ala variants of the 
TbiA leader peptide were too low to be accurately determined, indicating the importance of two 
residues in this conserved motif (Table 1 and Figure 4.2). Of the seven mutations of TbiB1 tested, 
alteration to residues in the hydrophobic pockets had the greatest impact on the binding affinity 
for the TbiA leader peptide (Table 1 and Figure 4.2). A sequence alignment of 25 other putative 
B1 proteins illustrates that the residues significant for leader binding (Asp67, Phe71, Leu75, and 
Leu80) are largely conserved (Figure 4.6). Although Tyr26 was completely conserved in every 
sequence, the Tyr26Ala variant of TbiB1 did not significantly affect binding affinity (Table 1). 
Mapping the sequence alignment of these 26 B1 proteins onto the TbiB1 structure reveals that the 
areas that interact with the peptide have the highest degree of sequence conservation, enforcing a 
conservation in the mode of peptide binding across split B-protein gene clusters (Figure 4.7). 
To probe if through steric complementarity was sufficient to instill leader-binding, we 
engineered the Y-(X)2-P-X-L-(X)3-G motif into the leader sequence of McjA, which is the 
precursor peptide for the unrelated lasso peptide microcin J25 (Figure 4.8). McjA is produced from 
a single B-protein microcin J25 lasso peptide cluster,56 and can neither bind to TbiB1 (Figure 4.9b 
and Table 1), nor is a substrate for the TbiB1+TbiB2 protease reaction (Figure 4.10a and 4.10b). 
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Insertion of this motif into the McjA leader required only three mutations, Pro(-10)Tyr, Lys(-
14)Pro, and Lys(-8)Gly and yielded the variant that we termed McjAYxxP (Figure 4.9a). 
Remarkably, while wild-type McjA leader peptide failed to demonstrate any detectable binding to 
TbiB1 (Figure 4.9b), the McjAYxxP leader peptide triple-mutant variant bound to TbiB1 with low 
micromolar affinity (Ki = 13.3 M), (Figure 4.9c and Table 1). We next sought to investigate 
whether installation of the binding motif into this non-cognate precursor could also facilitate 
processing by the TbiB2 protease. Incubation of McjAYxxP variant with both TbiB1+TbiB2 
resulted in proteolytic processing, whereas the wild-type precursor peptide was unprocessed 
(Figure 4.10a and 4.10b). Importantly, this reaction required the presence of both TbiB1 and 
TbiB2, indicating the reaction did not procced due to spurious background hydrolysis by TbiB2 
(Figure 4.11). These studies demonstrate that the changes at only three mutations into an otherwise 
inert peptide substrate resulted in both tight binding of the leader sequence and subsequent 
processing by an orthogonal biosynthetic system.  
Although we demonstrated that the Y-(X)2-P-X-L-(X)3-G motif is critical for binding of 
the leader peptide to TbiB1, we sought to elucidate whether this trend is operative across other 
lasso peptide B1-protein orthologs. To this end, binding affinities were determined between the 
FITC-TbiA leader peptide and two B1-proteins, AC529_00730 from Thermobifida 
cellulosilytica TB100 and SNA_19735 from Streptomyces natalensis ATCC 27448. These 
divergent B1-proteins shared low sequence identity with each other and with TbiB1 (<40% 
sequence identity in each case) (Figure 4.12a). Additionally, each of these proteins were found in 
complete lasso peptide gene clusters that contained precursor peptide with the identified Y-(X)2-
P-X-L-(X)3-G motif, but with significant sequence variation both in the core and non-conserved 
leader residues (Figure 4.12b). Both TbiB1 orthologs bound the FITC-TbiA peptide with 
affinities in the low micromolar regime, Kd = 11.1 M for AC529_00730 and Kd = 13.8 M from 
SNA_19735 (Figure 4.13). This tight binding further demonstrates that the observed motif is not 
only necessary and sufficient for peptide binding in TbiB1, but across diverse B1-protein family 
members. Notably, these values are similar to the binding affinity observed between TbiB1 and 
McjAYxxP peptide, suggesting that the basal dissociation constant between B1-proteins and the 
Y-(X)2-P-X-L-(X)3-G motif is approximately 12 M. 
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RiPP biosynthetic pathways provide highly flexible platforms for generating chemical 
diversity since the post-translational processing enzymes are guided by the leader sequence and 
are permissive for alterations to the core peptide. Our data illustrate that leader recognition does 
not require sequence specificity, but rather is guided by motifs that facilitate steric 
complementarity. Although the studies here are specific for leader binding for the split B-protein 
lasso peptide biosynthetic systems, it is likely that these tenets extend to other RiPP clusters as 
well. Engineering of a non-cognate leader sequence for processing by the split B-protein enzymes 
provides a proof of concept that this and other RiPP systems are amenable for future substrate 
engineering efforts. Knowledge of motif specificity for RiPPs can facilitate the design of artificial 
leader sequences, assembled via “mix-and-match” strategies, which may be processed by substrate 
promiscuous enzymes from diverse RiPP clusters.30,143,149 
 
Methods 
Cloning, Protein Expression, and Purification 
Primers used for cloning are listed in Table 4.2. TbiB1 (ACZ43715.1), TbiA 
(ACZ43711.1), and TbiA (ACZ43707.1) were obtained using PCR from T. terrenum genomic 
DNA (ATCC BAA-798D-5) and primers designed based on the published sequence. TbiB2 
(ACZ43714.1) was obtained as a codon optimized gene (Table 4.2) from Integrated DNA 
Technologies, Inc. All genes were cloned into a pET His6 MBP TEV LIC cloning vector (gift from 
Scott Gradia, Addgene plasmid # 29656) and transformed into E. coli BL-21 cells containing the 
Rosetta plasmid (Novagen) for protein expression. TbiB1 and TbiB1 mutants were expressed in 
LB media and allowed to grow at 37 °C to an OD600 of 0.6 before cooling in an ice bath ice for 15 
minutes. IPTG was added to a concentration of 500 M and the cells were incubated for an 
additional 18 hours before harvesting in a buffer of 500 mM NaCl, 20 mM Tris (pH 8.0), and 10% 
glycerol. TbiA and TbiA were expressed and harvested in a similar manner except the 
corresponding cultures were not chilled, but were instead induced with 500 M IPTG at an OD600 
of 0.6, and incubated for another 3 hours at 37 °C before harvesting. McjA and McjAYxxP were 
grown to an OD600 of 1.5 and induced with 1 mM IPTG for 1 hour at 37 °C prior to harvesting. 
TbiB2 was grown in TB media (BD Difco) in cultures that reached an OD600 of 1.0 before, cooling, 
addition of 500 M IPTG, and incubation at 18 °C. 
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Cells harboring protein expression constructs were lysed with five passes through a French 
press (Avestin) using a pressure of 5000 psi. Prior to lysis, 1 mM PMSF was added to cells that 
expressed McjA and McjAYxxP. The crude lysate was centrifuged at 14,000 rpm for 50 minutes 
to clear insoluble cell debris. The cleared lysate was passed through an MBPTrap column (GE 
Healthcare Lifesciences) equilibrated in 1 M NaCl and 20 mM Tris (pH 8.0). The column was 
washed with 50 mL of equilibration buffer and protein was eluted with equilibration buffer 
supplemented with 10 mM maltose. Fractions were checked for purity using an SDS-PAGE gel. 
TbiB1 for binding assays and TbiB1 mutants were further purified by size exclusion 
chromatography using Superdex 75 or 200 columns (GE Healthcare Lifesciences) equilibrated 
with 100 mM NaCl, 1 mM ZnCl2, 20 mM Tris base (pH 7.0) while MBP-TbiB2 was purified with 
a column equilibrated with 100 mM NaCl and 20 mM Tris base (pH 7.0). Pure fractions were 
collected, concentrated, and aliquoted for later use. 
For TbiB1 used in activity assays and crystallization, MBP was first cleaved from TbiB1 
fusion protein with the addition of TEV, followed by incubation at 23 °C for 18 hours. TbiB1 was 
further purified by incubation at 60 °C to precipitate MBP and TEV. The heated purified solution 
was concentrated to 500 L and further heated at 60 °C to remove additional MBP and TEV. 
TbiB1 was further purified by a Superdex 75 equilibrated with 100 mM KCl and 20 mM HEPES 
free acid (pH 7.5). The purest fractions, as determined by SDS-PAGE, were either concentrated to 
13 mg/ml and frozen (for TbiB1 used for crystallography) or first diluted into 100 mM NaCl, 20 
mM Tris base (pH 7.5), and 5% glycerol prior to flash freezing and storage (for protein used in 
assays).  
 
Full Length Peptide Production 
The MBP tag was removed from TbiA TbiA, McjA and McjAYxxP by incubation with 
TEV at 23 °C for 18 hours. The MBP-tagged peptides were first concentrated to 10 mg/mL before 
treatment with TEV. Addition of a TEV cleavage site resulted in the appendage of a Ser-Asn-Ala 
sequence to the N-terminus of the native peptide. After tag cleavage, 1 eq. of 50% ACN and 0.1% 
formic acid was added to the reaction to precipitate MBP and TEV. After centrifugation to pellet 
the insoluble proteins, the supernatant was concentrated by vacuum. The dried powder was re-
78 
 
suspended in reaction buffer (100 mM NaCl and 20 mM Tris base pH 7.0) and centrifuged to 
remove any insoluble particles. 
 
Peptides used for Experimental Assays 
Peptides used in this study are listed in Table 4.3. All TbiA leader peptides used for binding 
assays were purchased from GenScript with 90% purity and were used directly. Full length 
peptides were expressed as described above and were further purified by HPLC using a YMC 250 
mm X 4.6 mm, 5  C4 column and a Shimadzu LC-20AD HPLC  system. Chromatographic 
separations utilized a linear gradient (solvent A composed of H2O and 0.1% formic acid and 
solvent B composed of ACN and 0.1% formic acid), starting at 5% B and going to 95% B over 30 
minutes. Fractions were monitored by absorbance at 280 or 275 nm, and collected fractions were 
analyzed by MALDI (Figure 4.14). McjA was purified using a linear gradient from 15% B to 45% 
B over 30 minutes. The TbiA leader used for crystallography was purchased in in its crude form 
and purified by HPLC instead using a Grace Davison Denali 250x4.6 mm 5 C18 HPLC column. 
TbiA, TbiA, McjA, and McjAYxxP  concentration were determined using a Nandrop (Thermo 
Fisher Scientific) by measuring the absorbance at 280 nm and using extinction coefficients of 6085 
M-1cm-1, 4595 M-1cm-1, 4470 M-1cm-1, 2980 M-1cm-1 respectively. 
 
Crystallization, Data Collection, Phasing and Refinement 
Initial crystallization conditions for TbiB1 incubated with 1 mM TbiA were established 
using sitting drop sparse matrix screening. Initial hits were optimized to a final condition consisting 
of 8% isopropanol, 0.3 M zinc acetate, 0.1 M sodium cacodylate (pH 6.5). Diffraction quality 
crystals were grown by the hanging drop method.  Briefly, a 1 L solution of 10 mg/mL TbiB1 
and 1 mM TbiA were mixed with 1 L of the above precipitant and incubated over a solution of 
the same at 9 °C. Large crystals grew over 5 days and were transiently soaked in the precipitant 
solution supplemented with 15% MPD immediately prior to vitrification by direct immersion into 
LN2. Diffraction data were collected at the Advanced Photon Source Sector-21 LS-CAT at 
Argonne National Labs.  
All diffraction data were indexed, scaled, and integrated using autoPROC.87 
Crystallographic phases were determined with the PHENIX.autosol88 package of the PHENIX 
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software suite using zinc (bound by the protein from the crystallization media) as source of 
anomalous diffraction (FOM=0.319). PHENIX.Autobuild was used to generate an initial model, 
which was further improved through manual model building using with COOT90. The model was 
subject to rounds of model building followed by refinement using REFMAC591, and 
PHENIX.Refine until convergence. Crystallographic statistics are listed in Table 4.4. 
 
Binding Assays 
The FITC-TbiA leader (50 nM) was incubated with varying concentrations of MBP-
TbiB1 and variants for 30 minutes in a buffer containing 100 mM NaCl, 20 mM Tris pH 7.0, and 
1 mM ZnCl2. The addition of zinc was found to increase the signal to noise of the polarization 
measurements (Fig. S2i). Binding was monitored by the change in the polarization of FITC-TbiA 
as measured on a BioTek Synergy H1 Hybrid Reader using the yellow polarization filter and a 96-
Well Low Fluorescence Assay Plate (Corning). Data was fit according to Dunbar et. al.,126 to 
obtain Kd values for FITC-TbiA binding to MBP-TbiB1 and MBP-TbiB1 variants.  Competition 
assays were completed with 50 nM FITC-TbiA, 250 nM MBP-TbiB1, and varying 
concentrations of unlabeled TbiA leader, TbiA, and TbiA mutants. Competition assay with 
the full length peptides was done in a 398-Well Black Assay Plate (Corning) instead. Data was fit 
to a dose response curve to obtain IC50 values for each ligand. The IC50 values were converted to 
Kd values as listed in Dunbar et. al.
126 All binding assays were completed in triplicate. 
 
Activity Assay 
To test for protease activity with the TbiA and TbiA substrates, a reaction containing 5 
M peptide, 0.2 M TbiB1, 0.2 M MBP-TbiB2, 1 mM DTT were incubated at 37 °C for 18 hours 
in a buffer composed of 100 mM NaCl and 20 mM Tris base (pH 7.0). Assays utilizing the McjA 
and McjAYxxP substrates contained 50 M peptide, 2 M TbiB1, and 2 M MBP-TbiB2 and 
were incubated at 37 °C for 18 hours using the same buffer. Samples were desalted with C18 Zip 
Tips (Millipore) and analyzed by MALDI (Bruker Daltonics UltrafleXtreme MALDI TOF/TOF) 
using 2,5 dihydroxybezonic acid TFA as the matrix. 
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Figures 
 
 
 
Figure 4.1 a) Therbactin gene cluster of T. terrenum with the canonical lasso peptide 
biosynthetic proteins shown. b) Proposed biosynthetic route for therbactin  and therbactin . 
Conserved residues are indicated in black while the blue and orange residues are specific to 
therbactin  and therbactin  respectively. NCBI accession codes are as follows: TbiB1 
(ACZ43715.1), TbiB2 (ACZ43714.1), TbiA (ACZ43711.1), TbiA (ACZ43707.1), TbiC 
(ACZ43712.1), and TbiC (ACZ43709.1). MALDI analysis of the TbiB1 and TbiB2 mediated 
protease reaction observing formation of c) TbiA leader: 2730.3 m/z, d) TbiA core: 3970.9 m/z, 
e) TbiA leader: 2602.4 m/z, and f) TbiA core: 4459.1 m/z. Blue traces are reactions with TbiB1 
and TbiB2, red traces are reaction without TbiB1, and green traces are reactions without TbiB2. 
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Figure 4.2 Binding affinity was determined utilizing FITC-TbiA leader and varying 
concentrations a) WT MBP-TbiB1, b) MBP-TbiB1 L19A, c) MBP-TbiB1 Y26A, d) MBP-TbiB1 
F27A, e) MBP-TbiB1 D67A, f) MBP-TbiB1 F71A, g) MBP-TbiB1 L75A, h) MBP-TbiB1 L80A, 
and i) WT MBP-TbiB1 without ZnCl2. Competition assay were completed with j) TbiA Y4A 
and k) TbiAP7A. Each point represents an average of three trials. 
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Figure 4.3 Fluorescent polarization binding experiments demonstrate that both a) TbiA 
leader and b) TbiA leader bind tightly to TbiB1. c) Structure of TbiB1 (copper) with TbiA 
leader peptide bound. d) The TbiA leader peptide interacts through steric complementarity 
through insertion of hydrophobic residues into corresponding pockets found in TbiB1. e) 
Simulated annealing omit map (contoured at 2 above background) calculated with Fourier 
coefficients (Fobs-Fcalc) with phases from the final model but with the coordinates of the leader 
peptide omitted prior to calculations. The coordinates of the final model are superimposed.   
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Figure 4.4 Surface models of a) TbiB1 (copper) and TbiA leader (blue), b) NisB PqqD 
domain (purple) and NisA leader (orange), and c) LynD PqqD domain (green) and PatE’ (silver) 
indicate a conserved binding mode. Cartoon depiction of the “knob” and “hole” binding modes of 
leader consensus motifs into the binding domains of d) TbiB1, e) NisB, and f) LynD. 
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Figure 4.5 a) Sequence alignments from putative split B-protein lasso peptide gene clusters. 
Sequence alignment were generated with Clustal Omega85. The identified motif is indicated by red 
arrows. NCBI accession codes: Thermobacillus composti KWC4:AGA59244.1; Bacillus simplex: 
AMM93994.1; Clostridium butyricum DORA_1: ETI90266.1; Thermobaculum terrenum ATCC 
BAA-798 : ACZ43711.1; Haloarcula hispanica N601:AHB67463.1; Salinibacter ruber 
M8:CBH23198.1; Rhodothermus marinus DSM 4252: ACY47863.1; Streptomyces 
diastatochromogenes: WP_054228348.1; Streptomyces leeuwenhoekii: ALT06552.1; 
Roseobacter denitrificans OCh 114: CP000362.1 3722626-3722561; Nocardia transvalensis: 
WP_040748650.1; Streptomyces aurantiacus JA 4570: EPH46496.1; Streptomonospora alba: 
KIH99826.1; Xylanimonas cellulosilytica DSM 15894:ACZ29130.1; Sulfurovum sp. NBC37-1: 
WP_041672763.1; Streptomyces roseosporus NRRL 11379:EWS93464.1; Hassallia byssoidea 
VB512170: KIF29240.1; Blastococcus saxobsidens DD2: CCG01339.1; Erythrobacteraceae 
bacterium HL-111: KPP94413.1; Chloracidobacterium thermophilum B: CP002514.1 1207252-
1207130; Methanobacterium paludis strain SWAN1: CP002772.1 1486684-1486755; 
Rhodococcus jostii: BAL72546.1; Thermobaculum terrenum ATCC BAA-798 : ACZ43707.1; 
Moorea producens 3L: EGJ30460.1; Erythrobacter sp. NAP1:EAQ28228.1; Crinalium 
epipsammum PCC 9333:AFZ15083.1; Tolypothrix bouteillei VB521301: KIE10878.1 b) Weblogo 
analysis83 highlights the conserved Y-(X)2-P-X-L-(X)3-G motif. 
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Figure 4.6 Sequence alignment of B1 proteins generated from putative lasso peptide gene 
clusters indicate that the residues important for binding in TbiB1 and highly conserved. The 
residues mutated in this study are indicated with a red arrow. The sequence alignment was 
completed with Clustal Omega85. NCBI accession codes: Streptomonospora alba: KIH99640.1; 
Xylanimonas cellulosilytica DSM 15894:ACZ29132.1; Rhodococcus jostii: BAL72548.1; 
Streptomyces roseosporus NRRL 11379: EFE76493.1; Streptomyces aurantiacus JA 
4570:EPH46495.1; Streptomyces leeuwenhoekii: ALT06554.1; Streptomyces 
diastatochromogenes: WP_054228346.1; Nocardia transvalensis: WP_040748649.1; 
Salinibacter ruber M8: CBH23195.1; Clostridium butyricum DORA_1: ETI90267.1; 
Thermobacillus composti KWC4:AGA59242.1; Bacillus simplex: AMM93992.1; Blastococcus 
saxobsidens DD2:CCG01342.1; Roseobacter denitrificans OCh 114:ABG33313.1; 
Chloracidobacterium thermophilum B: AEP11779.1; Erythrobacter sp. NAP1:EAQ28226.1; 
Haloarcula hispanica N601:AHB65687.1; Thermobaculum terrenum ATCC BAA-
798:ACZ43715.1; Erythrobacteraceae bacterium HL-111: KPP94417.1; Sulfurovum sp. NBC37-
1:BAF73017.1; Moorea producens 3L: EGJ30457.1; Rhodothermus marinus DSM 
4252:ACY47866.1; Methanobacterium paludis strain SWAN1: AEG18393.1; Crinalium 
epipsammum PCC 9333:AFZ15086.1; Hassallia byssoidea VB512170:KIF30015.1; Tolypothrix 
bouteillei VB521301:KIE10880.1 
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Figure 4.7 Sequence conservation of the 26 B1 sequences was mapped onto the TbiB1 
structure using the ConSurf serverConsurf84. Areas of highest sequence conservation (red) are 
localized to regions that interact with the TbiA leader peptide. 
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Figure 4.8 McjA aligned to TbiA and TbiA using the conserved threonine as the alignment 
point. The McjAYxxP peptide was created by generating three mutations (red arrows) to create 
the Y-(X)2-P-X-L-(X)3-G motif. The indicated Ile (blue arrow) was left unmutated as isoleucine is 
similar to the consensus leucine and seen in place of leucine in several leader sequences (Figure 
4.5). 
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Figure 4.9 Sequences of a) the McjA peptide and b) the engineered McjAYxxP peptides. The 
three mutated residues in McjAYxxP are indicated in red. Competitive binding assays for c) McjA 
leader peptide and d) McjAYxxP leader peptide indicate that the orthogonal McjA leader peptide 
cannot bind and insertion of the conserved binding motif is sufficient to enable high binding 
affinity to TbiB1. 
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Figure 4.10 MALDI analysis of protease action observing a) McjA and McjAYxxP leader 
peptide and b) McjA and McjAYxxP core peptide. Blue traces are reactions with the McjA peptide 
and the red traces are reaction with McjAYxxP. a) McjA leader expected= 4365.4 m/z and 
McjAYxxP leader expected= 4400.4 m/z b) McjA core: expected= 2125.0 m/z and McjAYxxP 
core: expected= 2125.0 m/z. 
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Figure 4.11 MALDI analysis of protease action indicates both TbiB1 and TbiB2 are required 
for processing into a) McjAYxxP leader peptide and b) McjAYxxP core peptide. Blue traces are 
reactions with the both TbiB1 and TbiB2, the red traces are reactions omitting TbiB1, and green 
traces are reactions with TbiB2. a)McjAYxxP leader expected= 4400.4 m/z b) McjAYxxP core: 
expected= 2125.0 m/z. 
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Figure 4.12 Sequence alignments between the a) TbiB1, AC528_00730 and SNA_19735 B1-
protein indicates high levels of sequence diversity. Alignment of the cognate leader peptides shows 
little conservation apart from the Y-(X)2-P-X-L-(X)3-G motif. 
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Figure 4.13 Fluorescent polarization binding assays between the FITC-TbiA leader peptide 
TbiB1 orthologs a) AC528_00730 and b) SNA_19735 indicated tight binding to the noncognate 
leader peptide. 
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Figure 4.14 Purity of peptides confirmed by MALDI analysis. a) TbiA: expected= 6683.2 m/z 
observed= 6683.8 m/z b) TbiA: expected= 7043.4 m/z observed= 7044.7 m/z   c) McjA 
expected= 6472.4 m/z observed= 6475.8  d) McjA: expected= 6508.4 m/z observed= 6510.7 m/z 
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Tables 
Table 4.1 Binding affinity values were derived from fluorescent polarization experiments and 
indicate the importance of conserved residues both in the TbiB1 protein and TbiA leader peptide. 
TbiB1 
Variant 
FITC-
Peptide 
Competitor Kd 
 (nM) 
IC50 
(nM) 
Ki  
(nM) 
Amino Acid 
Function 
WT TbiA 
leader 
 266 ± 59    
WT TbiA 
leader 
TbiA - 878 ± 60 359  
WT TbiA 
leader 
TbiA - 613 ± 73 227  
WT 
 
TbiA 
leader 
McjA Leader - >100,000 >50,000  
WT 
 
TbiA 
leader 
McjAYxxP 
Leader 
- 24,700 ± 
2,034 
12,300  
WT TbiA 
leader 
TbiA Y(-17)A - >250,000 >125,000 Fits into hydrophobic 
pocket 
WT TbiA 
leader 
TbiA P(-14)A - >50,000 >25,000 Fits into hydrophobic 
pocket 
L19A TbiA 
leader 
 332 ± 79    Hydrophobic interaction 
with V-6 
Y26A TbiA 
leader 
 283 ± 60   Interacts with Gly from 
leader peptide 
F27A TbiA 
leader 
 3,940 ± 520   Forms hydrophobic 
pocket 
D67A TbiA 
leader 
 7,140 ± 
2,590  
  Hydrogen bond with 
Tyr(-17) and Ser(-15) 
F71A TbiA 
leader 
 >50,000   Forms divide between 
the two hydrophobic 
pockets 
L75A TbiA 
leader 
 950 ± 197   Forms hydrophobic 
pocket 
L80A TbiA 
leader 
 7,330 ± 550   Forms hydrophobic 
pocket 
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Table 4.2 Primers and genes synthesized for this study. 
Primer/Gene Sequence 
TbiB1 For TACTTCCAATCCAATGCAATGAAGATAAGTGATGCGGTGGTGTCAGCC 
TbiB1 Rev TTATCCACTTCCAATGTTATTAAGCTTCATCAGCGTAGCCCTCCAGC 
TbiB1 L19A For GATGAGGTGGTGTTGGCGCACCTGCAGACCGG 
TbiB1 L19A Rev CCGGTCTGCAGGTGCGCCAACACCACCTCATC 
TbiB1 Y26A For TGCAGACCGGCACGGCCTTTGGCCTGGACG 
TbiB1 Y26A Rev CGTCCAGGCCAAAGGCCGTGCCGGTCTGCA 
TbiB1 F27A For AGACCGGCACGTACGCTGGCCTGGACGCTG 
TbiB1 F27A Rev CAGCGTCCAGGCCAGCGTACGTGCCGGTCT 
TbiB1 D67A For CACAGTGGAGAGAGCCCTGCGGGACTTCC 
TbiB1 D67A Rev GGAAGTCCCGCAGGGCTCTCTCCACTGTG 
TbiB1 F71A For AGACCTGCGGGACGCCCTGCGCGCGCTG 
TbiB1 F71A Rev CAGCGCGCGCAGGGCGTCCCGCAGGTCT 
TbiB1 L75A For CTTCCTGCGCGCGGCGGCCAACAAGGAG 
TbiB1 L75A Rev CTCCTTGTTGGCCGCCGCGCGCAGGAAG 
TbiA For TACTTCCAATCCAATGCAATGAAGGAGTACAGGAGCCCCGAGCTCAAGG 
TbiA rev TTATCCACTTCCAATGTTATTATTAGAAGCGCACGCACGCGCCGTACG 
TbiA For TACTTCCAATCCAATGCAATGACCAAGACGTATACAGCACCCACACTAGTGG 
TbiA Rev TTATCCACTTCCAATGTTATTATTACACCGAGCCGGTCAGGCAGACGAAAGG 
McjA pt1 ATGATTAAACACTTCCACTTTAACAAGTTAAGCTCCGGCAAGAAGAACAACGTCCCA 
McjA pt2 CTGGCTGGCGCTCTTCTTAATCTGAATGACTCCTTTCGCCGGAGATGGGACGTTGTT 
McjA pt3 CCCAACGAAGTACTCTGGGACATGGCCTGCGCCCCCCTTAGTCAACTGGCTGGCGCT 
McjA pt4 ACCATAAAAAGAGATCGGAGTGCCAATCCCAACGAAGTA 
McjAYxxP CTGGCTGGCGCTGCCCTTAATCTGAATGACCGGTTTCGCATAAGATGGGACGTTGTT 
McjA For TACTTCCAATCCAATGCAATGATTAAACACTTCCACTTTAACAAGTTAAGC 
McjA Rev TTATCCACTTCCAATGTTATTAACCATAAAAAGAGATCGGAGTGCCAATCCCAACG 
TbiB2 For TACTTCCAATCCAATGCAATGAAACTGCGCCTGGCCGATCTGC 
TbiB2 Rev TTATCCACTTCCAATGTTATTATCACAGATCGTATGCAGCTTCACGATCCACACG 
TbiB2 Gene ATGAAACTGCGCCTGGCCGATCTGCAACTGATTGCCAAAGCATGGTCAGATCTGATTCTCATTG
ACCGTCGCCTGAGCCATGAAGGTCTGGACCCAATTTTGATTAAAATCGAAAGTGAGGCAGCAC
CGCCCCAAGACGTGTCGCGTGAACACTTGCGCCTGGCCCGTCGTTACGCTCGCCGTATTGCTTT
AGCGGCGCATATTTGCCCTGTAGGCGCCCGTTGCTTGCATCGTTCATTGGTATTGCATATGTGG
TTACGGCGTCAGGGGTTACCAAGTCGTCTGCGTTTCGGAGTGTGGAAGGCGGAAGAAGACCTG
CGTGCGCATGCATGGGTTGAACTTGCAGGCGTGCCTGTGAATGACGACCGTCGGAGTCTCCAA
GGTATCTCGCCGATGACAAGTCCCCGCCGTGTGGATCGTGAAGCTGCATACGATCTGTGA 
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Table 4.3 Peptides used in this study. 
Peptide Name Sequence Source 
TbiA Leader MKEYRSPELKEYGRVEDRTAG Genscript 
TbiA Leader- FITC (FITC)-(Ahx)-MKEYRSPELKEYGRVEDRTAG Genscript 
TbiA Leader MTKTYTAPTLVEYGGLTRLTLG Genscript 
TbiA Full Length SNAMKEYRSPELKEYGRVEDRTAGATGNKPDYVVSN
NQLVIDNNNPTCTNNVPYGACVRF 
Purified 
TbiA Full Length SNAMTKTYTAPTLVEYGGLTRLTLGQHGNLPDYNVK
GQVVANNNCSLPEEGPGSSGNSNPFVCLTGSV 
Purified 
TbiA Leader Y4A MKEARSPELKEYGRVEDRTAG Genscript 
TbiA Leader P7A MKEYRSAELKEYGRVEDRTAG Genscript 
McjA Asn(-21) through 
Gly(+1)  Leader 
NVPSPAKGVIQIKKSASQLTKG Genscript 
McjAYxxP Asn(-21) 
through Gly(+1)  Leader 
NVPSYAKPVIQIKGSASQLTKG Genscript 
McjA SNAMIKHFHFNKLSSGKKNNVPSPAKGVIQIKKSASQ
LTKGGAGHVPEYFVGIGTPISFYG 
Purified 
McjAYxxP SNAMIKHFHFNKLSSGKKNNVPSYAKPVIQIKGSASQ
LTKGGAGHVPEYFVGIGTPISFYG 
Purified 
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Table 4.4 Crystallographic Statistics for TbiB1. 
 
 TbiB1-TbiA leader 
Data collection  
Space group P212121 
Cell dimensions  
a, b, c (Å) 48.1, 60.2, 62.5 
() 90.0, 90.0, 90.0 
Resolution (Å) 48.1-1.35 
(1.355-1.351) 
Rsym 6.1 (85.0) 
I / I 19.7 (2.3) 
Completeness (%) 99.8 (95.1) 
Redundancy 6.8 (6.7) 
  
Refinement  
Resolution (Å) 25.0-1.35 
No. reflections 38,331 
Rwork / Rfree 0.211/0.227 
No. atoms 1859 
Protein 1697 
Water 157 
B-factors  
Protein 21.5 
Metal 23.76 
Water 31.76 
R.m.s. deviations  
Bond lengths (Å) 0.005 
Bond angles () 1.06 
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Chapter 5 Structural and Biochemical Studies of the Lasso Peptide Isopeptidase AtxE2iv 
 
Introduction 
The knowledge base on the biosynthesis of ribosomally synthesized and post-
translationally modified peptide (RiPP) natural products is quickly growing.11 However, little is 
known about the breakdown or degradation of RiPPs. A new mechanism for RiPP catabolism was 
recently identified in a subset of biosynthetic clusters encoding for lasso peptides,62 a class of 
bioactive peptides characterized by a threaded structure resembling a slipknot.12 The characteristic 
structure of lasso peptides is defined by an isopeptide bond between the N-terminal -amine and 
the side chain carboxylate of an Asp or Glu residue, with the linear C-terminal tail threaded through 
the resultant macrolactam ring (Figure 5.1A). The biosynthesis of lasso peptides requires a gene 
encoding the peptide precursor (A-gene) and two enzymes (encoded for by the B-gene and C-gene) 
necessary for installing the post-translational modifications. In particular, the B-protein excises the 
leader sequence from the precursor peptide, and the C-protein installs the isopeptide linkage. Many 
lasso peptide gene clusters also include an ABC transporter for export of the mature peptide, 
serving as an immunity factor.56–58 Previous genome mining efforts in our laboratory identified 
additional genes often located adjacent to lasso peptide gene clusters, notably genes annotated as 
proteases located downstream of the two lasso biosynthetic clusters in the freshwater bacterium 
Asticcacaulis excentricus.62 The atxE1 protease gene is located adjacent to the biosynthetic cluster 
for astexin-1, while the atxE2 gene is found adjacent to the cluster for astexin-2 and astextin-3. 
Notably, these clusters lack the ABC transporter found in many lasso peptide clusters.  
The organization of a putative protease adjacent to the lasso peptide biosynthetic 
machinery suggested that the enzyme might play a role in the catabolism of lasso peptides. 
Incubation of the cognate lasso peptides astexin-2 and astexin-3 with purified AtxE2 resulted in 
an increase in mass of the peptide by 18 Da and mass spectral analysis of the product confirmed 
that the lasso peptide had been linearized. These, and additional biochemical data, demonstrated 
that AtxE2 is an isopeptidase that can hydrolyze the lasso peptides astexin-2 and astexin-3, 
                                                          
iv This chapter is adapted from the following article manuscript: 
Chekan J. R., Koos, J.D., Zong C., Maksimov, M. O., Link A. J., and Nair S. K. The Structure of a Lasso Peptide 
Isopeptidase Identifies a New Protein Fold. Manuscript in revision. 
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encoded within the same biosynthetic cluster, into linear products (Figure 5.1B).62 Hydrolysis of 
a lasso peptide into a linear species by isopeptidases may be a self-protection mechanism to limit 
the build-up of intracellular concentration of the bioactive lasso product. Alternatively, we have 
previously proposed that lasso peptides with associated isopeptidases may be functioning 
analogously to siderophores.26,62 In this scenario, the isopeptidase may serve as a factor that 
releases cargo bound to the lasso peptide. Presumptive homologs of the AtxE2 isopeptidase are 
found in other proteobacterial lasso peptide clusters, and likely represent a canonical catabolism 
gene for these natural products.62  
The isopeptidases seemingly have strict specificity for their substrates, as AtxE1 and 
AtxE2, encoded within two different biosynthetic clusters in Asticcacaulis excentricus, do not 
function on the lasso substrates produced by the other cluster.62 However, analysis of the substrate 
tolerance of AtxE2 against a panel of Ala variants of astexin-2 and astexin-3 shows the 
isopeptidase to be broadly tolerant of mutations within the substrate.150 AtxE2 cleaved all alanine 
variants of astexin-2 and -3 with the exception of the Val11Ala variant of astexin-3. This broad 
substrate tolerance is seemingly contradictory to the fact that AtxE2 cannot use astexin-1 as a 
substrate. Lastly, the isopeptidases are only functional on threaded substrates, i.e. lasso peptides 
in which the C-terminal tail is inserted through the isopeptide bond.62 AtxE2 does not process 
peptides that contain a macrolactam but without a threaded C-terminal tail. 
Sequence analysis using fold-recognition software identifies AtxE2 as a member of the S9 
peptidase family, whose members include prolyl oligopeptidases (POPs), dipeptidyl peptidase IVs, 
and acylamino-acid-releasing enzyme.51 However, S9 peptidases generally hydrolyze peptide 
bonds within linear, not macrocyclic, substrates, and there are no known family members that can 
cleave isopeptide bonds. Moreover, the active site cavity of many S9 peptidases would be far too 
small to accommodate a threaded lasso peptide substrate. In order to reconcile these seemingly 
contradictory perspectives on substrate recognition and tolerance, we determined the crystal 
structure of AtxE2 both in isolation, and in complex with an astexin-3 substrate. Surprisingly, the 
AtxE2 structure does not represent a S9 peptidase, but rather consists of a new protein fold with a 
/ hydrolase domain appended to an open -propeller domain. Binding of the lasso substrate 
occurs through topological, rather than sequence, complementarity. Substrate binding by AtxE2 
results in a deformation near the isopeptide bond, and a reorganization of the active site into a 
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conformation that is productive for hydrolysis. Kinetic characterization and mutational analysis 
provide a rationale for the range of substrate tolerance for this new class of isopeptidases. The 
presence of the isopeptidase gene may be used to demarcate new lasso peptide biosynthetic 
clusters, and a network-based genome mining approach identified 87 potential biosynthetic 
clusters, greatly expanding the list of this subfamily of lasso peptides. 
 
Methods 
Protein Expression and Purification 
atxE2 was previously cloned into a pQE-60 vector.62 Mutations were made to atxE2 using 
the QuikChange methodology and the primers listed in Table 5.1. E. coli BL21 cells transformed 
with the atxE2 containing pQE-60 plasmid were grown to an OD600 of 1 at 37 
oC in a shaking 
incubator. After addition of 1 mM IPTG, cells were incubated at 37 oC for an additional 3 hours 
before the cells were pelleted and resuspended in 500 mM NaCl, 20 mM Tris base (pH 8.0), and 
10% glycerol. AtxE2 variants were grown in a similar manner except E. coli BL21 cells co-
transformed with the Rosetta plasmid (Novagen) were used.  
Expression of AtxE2 Ser527Ala with selenomethionine (SeMet) was carried out by 
growing cells in M9 minimal medium (500 mL) supplemented with 40 mg/L of all amino acids 
besides Met and at 50 mg/L SeMet. When the cell culture reached an OD600 of 0.45, 5 mL of a 
solution of Ile, Leu, Val, Lys, Phe, and Thr (10 mg/mL each) was added to the culture to suppress 
Met biosynthesis. After 20 min, the culture was induced with 1 mM IPTG to begin protein 
production. After 3 h at 37 °C, the cells were collected by centrifugation and frozen at -80 °C. 
Cells were lysed using a cell homoengizer (Avestin) and the insoluble cell debris was 
pelleted by centrifugation at 14,000 x g. The cleared lysate was loaded onto a HiTrap Nickel 
column (GE Healthcare Life Sciences). The column was washed and protein was eluted by a linear 
gradient from 30 mM to 250 mM imidazole. Pure fractions, as judged by SDS-PAGE, were 
combined and concentrated. The protein was further purified using a S200 Superdex gel filtration 
column (GE Healthcare Life Sciences) that was equilibrated with 300 mM KCl and 20 mM HEPES 
pH 7.5. Fractions were collected and concentrated to 4 mg/mL before vitrification in liquid 
nitrogen. Protein used for kinetics and activity assays was supplemented with 10% glycerol prior 
to vitrification. 
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Peptide Production 
The expression and purification of astexin-3 has been previously described, with 
expression performed at room temperature to maximize full length peptide.62 Briefly, E. coli BL21 
cells harboring the gene cluster for astexin-3 production on a pASK-75 derivative were induced 
with anhydrotetracycline at room temperature for 21 h. The cells were lysed with methanol, and 
the crude methanol extract was cleaned up using a C8 solid-phase extraction column. For the 
astexin-3ΔC4 peptide, the methanol extract (which contains mostly full length peptide) from 4.5 
L of expression was digested with 30 units of carboxypeptidase Y (USB Corporation) in 3 mL of 
50 mM sodium acetate buffer, pH 6.0, with 5% acetonitrile at 25 oC for 18 hours. The reaction was 
stopped by dilution to 40 mL with water and purified on a Strata 100 mg/1 mL C8 column 
(Phenomenex). The sample was dried and purified to homogeneity using a Zorbax 300-SB 9.4 x 
250 mm, 5 m, C18 column on an Agilent 1200 system and lyophilized. The identity of the purified 
product was confirmed by MALDI mass spectrometric analysis (ABI 4800 MALDI-TOF-MS). 
 
Crystallization, Data Collection, Structure Solution, and Refinement 
The AtxE2 selenomethionine labeled Ser527Ala variant (4 mg/mL) was incubated with 1 
mM full length astexin-3 for 15 mins and screened for crystallization using a sparse matrix screen. 
Crystals, obtained using 16% (w/v) PEG 8000, 0.04 M potassium phosphate, and 20% (v/v) 
glycerol as a precipitant, were vitrified by direct immersion into liquid nitrogen. Wild-type AtxE2 
(4 mg/mL) was crystallized using 21% PEG 3350, 0.4 M NaCl, and 0.1 M Bis-Tris (pH 5.5) as a 
precipitant. Prior to vitrification, the crystals in briefly submerged in the crystallization media 
supplemented to 30% PEG 3350 to serve as a cryoprotectant. To obtain the binary complex 
crystals, Ser527Ala AtxE2 (3.7 mg/mL) was incubated with 2 mM astexin-3C4, and 10% 
glycerol. Crystals of the complex, grown using 18% PEG 3350, 0.3 M ammonium citrate dibasic, 
were supplemented with 10% glycerol and 2 mM astexin-3C4, prior to vitrification. All 
diffraction data was collected at the Advanced Photon Source Sector-21 LS-CAT at Argonne 
National Labs. 
Diffraction data was indexed, scaled, and integrated using a combination of HKL-2000 and 
autoPROC87 packages. Crystallographic phases were obtained from selenomethionine labeled 
AtxE2 using the autosol.PHENIX88 package. Initial model building was completed with 
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autobuild.PHENIX.88 This model was used to obtain crystallographic phases for both the ligand-
free AtxE2 and the astexin-3C4 complex. Manual refinement was completed with iterations of 
COOT90 and REFMAC5.91 Refinement parameters are listed in Table 5.2. 
 
Kinetic Assay 
Kinetic constants for AtxE2’s use of astexin-3C4 were determined similar to full length 
astexin-3. Briefly, the decrease of substrate concentration was monitored by a decrease in 
fluorescence (Excitation = 274/5 nm and Emission= 355/20 nm). 50 L reactions containing 10 or 
30 nM AtxE2 and varying concentrations of astexin-3C4 in PBS were completed in triplicate on 
a black 384-well plate (Corning). Fluorescence was recorded 4 times per minute on a Biotek 
Synergy H1F instrument at 24 oC. As fluorescence was not linear with concentration, a standard 
curve was fit to a second order polynomial to obtain astexin-3C4 concentrations. 
 
End Point Assays 
Reactions (40 L) containing 75 nM WT AtxE2 or AtxE2 variants were incubated with 75 
M full length astexin-3 in PBS buffer at 30 °C. After 1 hour, reactions were quenched with 1 
equivalent (40 L) of methanol. 50 L of each reaction was injected on a YMC 250 mm X 4.6 
mm, 5  C18 column using a Shimadzu LC-20AD HPLC system. Product formation was 
monitored at 280 nm using a 30 minute linear gradient starting at 20% ACN and 0.1% formic acid 
and ending at 45% ACN and 0.1% formic acid. The identity of the substrate and product peaks 
was confirmed by MALDI mass spectrometric analysis (Bruker Daltonics UltrafleXtreme MALDI 
TOF/TOF) (Figure 5.2). Reactions were completed and analyzed in triplicate. 
 
Results 
Overall structure of the lasso isopeptidase 
The crystal structure of AtxE2 was determined to a Bragg limit of 2.4 Å, using 
crystallographic phases determined from data collected on selenomethionine labeled protein 
(Figure 5.3A). The structure reveals a new fold, despite the prior software prediction of homology 
to S9 peptidases. The overall structure consists of two domains with residues Ala25 through 
Tyr397 forming an N-terminal open -propeller domain, and residues Arg398 through Gln686 
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forming a C-terminal /hydrolase domain. The N-terminal open -propeller domain of AtxE2 
(Figure 5.3A and 5.3B) consists of approximately five repeats of stacked -strands that form an 
enclosure that resembles an inverted cup. A helical insert (helix -1, numbered according to Figure 
5.4), consisting of Arg189 through Ile229, forms one side of the cup and defines an open cavity 
adjacent to the active site triad. A short loop containing helix -2 connects the next blade of the 
propeller to complete the circular shape.  
The arrangement of the secondary structural elements in the AtxE2 open -propeller 
domain contrasts with the typical seven-bladed propeller observed in canonical S9 peptidase 
family members. A topology diagram of AtxE2 (Figure 5.5) indicates the location of both the -1 
and -2 helices and their absence in the structurally similar S9-peptidase family member 
puromycin hydrolase from Streptomyces morookaense (PDB Code:3AZQ).151 The additional 
helices increase the amino acid length of the third blade of the propeller. Furthermore, the fourth 
blade of propeller is completely absent in AtxE2 and is replaced by a short linker to connect the 
fifth blade. These modifications in the secondary structure produce the substantial structural 
changes that alter the canonical -propeller to generate the newly observed open -propeller fold 
(Figure 5.6).  
The expectation that AtxE2 would form an S9-like protein fold was likely due to the 
presence of the C-terminal hydrolase domain, as structure-based analysis of this domain using the 
DALI server94 identifies similarities with the hydrolase domains of puromycin hydrolase from 
Streptomyces morookaense151 (RMSD 2.9 Å over 249 C atoms) and a prolyl tripeptidyl 
aminopeptidase from Porphyromonas gingivalis152 (PDB Code: 2DCM , RMSD 2.4 Å over 240 
C atoms) (Figure 5.3D). The hydrolase domain houses the Ser527-His638-Glu610 catalytic triad 
that forms the active site. In spite of the overall conservation of the C-terminal hydrolase domain, 
there are significant differences in the orientation of secondary structural elements (Figure 5.7). 
Specifically when AtxE2 is superimposed upon puromycin hydrolase, loop-1, and helices -3, -
4, and -5 are pushed back from the catalytic Ser. These movements presumably are necessary to 
accommodate the bulky threaded lasso peptide substrate. The extended helix -1 establishes 
immediacy between the N- and C-terminal domains, and the interaction interface between the three 
establishes the large substrate-binding pocket (Figure 5.3C). 
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Molecular basis for lasso peptide specificity 
In order to understand the basis of specificity for isopeptide hydrolysis, we sought to 
determine the structure of an inactive Ser527Ala AtxE2 variant62 in complex with the lasso peptide 
astexin-3. Attempts to obtain cocrystals of AtxE2 with full-length astexin-3 were unsuccessful. 
Prior experiments demonstrated that AtxE2 could process astexin-3 substrates that were truncated 
at the C-terminal tail, which is the most flexible region of the lasso peptide.62,150 Treatment of 
astexin-3 with carboxypeptidase Y yielded a truncated lasso peptide that lacked the C-terminal 4 
amino acids (astexin-3C4) (Figure 5.8). We obtained kinetic parameters for AtxE2 using astexin-
3C4 as a substrate by monitoring a decrease in fluorescence that occurs upon lasso peptide 
hydrolysis (Figure 5.9). The KM of 75 M ± 23 M for astexin-3C4 was similar to the previously 
determined KM of 131 M ± 34 M for the full length astexin-3. The kcat of 1.36 ± 0.16 s-1 was 
approximately three-fold higher compared to full-length astexin-3. These kinetic parameters 
suggest that the catalytic efficiency of AtxE2 is not compromised upon removal of the 4 residues 
at the C-terminus of astexin-3. 
Crystallization efforts of inactive AtxE2 in complex with astexin-3C4 yielded the 2.2 Å 
structure of the binary complex (Figure 5.10A and 5.10B). A comparison of the unliganded AtxE2 
structure with that of the astexin-3C4 complex reveals that a small active site loop, encompassing 
Gln437 through Gly442, shifts towards the substrate, resulting in a movement of Tyr438 to within 
3.3 Å of the carbonyl oxygen of the isopeptide bond (Figure 5.11). The orientation of Tyr438 upon 
binding substrate suggests that this residue may stabilize the oxyanion in the tetrahedral 
intermediate that forms upon attack of the catalytic Ser onto the isopeptide carbonyl carbon. To 
probe the role of this residue, we generated the Tyr438Phe variant, which lacked any detectable 
activity (Figure 5.12). The movement of this loop to orient Tyr438 appears be induced by binding 
of the substrate, specifically by the threaded C-terminal tail. In the AtxE2 cocrystal structure, the 
first few residues that are threaded through the lasso (Trp16 and Asp17) form a solvent-excluded 
pocket that directs Tyr438 towards the isopeptide linkage.  
In the cocrystal structure, the entirety of the lasso peptide is contained within the large 
binding pocket adjacent to the catalytic triad in AtxE2 (Figure 5.10A). The isopeptide bond 
between Gly1-Asp9 of astexin-3C4 is located within the active site of the / hydrolase domain, 
where the catalytic Ser527 alkoxide would be poised for nucleophilic attack and the 
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aforementioned Tyr438 would act to stabilize the negative charge on the oxyanion that develops 
in the transition state (Figure 5.10C). The Ser10-Gln14 loop of the substrate fits into a pocket 
(Figure 5.13) lined with residues Asn121, His214, Thr531, Thr553, Ala558, Asn562, Ile566, 
Leu570, and Ala572 (Figure 5.10A and 5.10B), explaining further why AtxE2 cannot process 
unthreaded substrates.62 The loop region of an unthreaded lasso would lack shape complementarity 
while the extended tail would clash with the binding pocket of the macrolactam ring.   
Inspection of the isopeptidase-peptide interface reveals only a few specific interactions 
between astexin-3C4 and AtxE2 (Figure 5.10D). Trp111 and Ile113 of AtxE2 create a 
hydrophobic pocket for Pro4 of astexin-3C4 while Leu570, Ile575, and Tyr573 of AtxE2 form a 
pocket for Leu8 of the peptide; Asn121 and Asn562 form hydrogen-bonding interactions with the 
backbone of Gly13 and Val11 of astexin-3C4, respectively. Lastly, Trp116 can hydrogen bond 
with the backbone oxygen of Gly13 and may form stacking interactions with Tyr15 of the 
substrate. Several residues within astexin-3C4, including Met5 and Val6 are entirely solvent 
exposed. The absence of extensive side-chain specific interactions explains the tolerance AtxE2 
for the panel of astexin-3 Ala variants, almost all of which are substrates for the enzyme.150 
To confirm the importance of the observed interactions, we generated the Trp111Ala, 
Trp116Ala, Asn121Ala, and Asn562Ala variants of AtxE2, and tested both the wild-type and 
enzyme variants for product formation in an endpoint assay (Figure 5.12 and 5.14). The hydrolytic 
product for each variant was observed by HPLC, the corresponding peaks were integrated, and 
normalized with respect to product formation by wild-type AtxE2. Surprisingly, the Trp111Ala 
variant has activity comparable to wild type AtxE2 whereas the Asn121Ala variant appeared to 
even enhance activity. These data indicate that mutations within the AtxE2 hydrophobic pocket 
that engage Pro4 of the substrate, and at residues that hydrogen bond with Gly13 of the substrate 
do not inactivate the enzyme. However, both Trp116Ala and Asn562Ala AtxE2 variants had 
greatly reduced activity indicating the importance of the hydrogen-bonding interactions provided 
by these residues. 
A superposition of the previously determined solution NMR structure of astexin-362 with 
that of astexin-3C4 bound in the AtxE2 cocrystal structure reveals major differences in the 
structure of the lasso peptide (Figure 5.15). In the solution structure, Val11, Ser12, and Gly13 of 
the loop protect the isopeptide bond. As a result of these interactions, the isopeptide bond of 
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astexin-3C4 in the solution conformation would be inaccessible to AtxE2. The cocrystal structure 
illustrates how AxtE2 opens the lasso peptide to expose the isopeptide bond for hydrolysis. 
Specifically, the Ser10-Gln14 loop is moved away from the isopeptide bond and positioned into a 
pocket in the /hydrolase domain, while the threaded tail is similarly directed away for the 
isopeptide bond. Similarly, the structure of the loop of microcin J25 is altered upon binding to the 
ferric citrate transporter FhuA, which is responsible for its cellular import.153 
 
Distribution of Lasso Peptide Isopeptidases 
In order to determine the incidence of the isopeptidase in lasso peptide biosynthetic 
clusters, we created a sequence similarity network of homologs8 using the AtxE2 sequence as a 
query (Figure 5.16). A network was derived using an alignment score of e-85, corresponding to at 
least 30% sequence identity between connected nodes. This result was then used for a genome 
neighborhood network analysis, in order to identify those sequence similar clusters that contained 
an isopeptidase homolog adjacent to lasso peptide biosynthetic machinery. A total of 98 unique 
putative lasso peptide isopeptidase homologs with <95% sequence identity were identified using 
this criterion and they clustered into three groups within the sequence similarity network (Figure 
5.16). The persistence of the isopeptidase as a regulatory or catabolic mechanism appears to be 
most prevalent amongst the Alphaproteobacteria with some examples in Gammaproteobacteria 
as well.55  
In order to analyze the conservation of important sequence elements across these 
homologs, we mapped the alignment of sequences onto the structure of AtxE2. Notably, these 98 
sequences showed very few regions with high sequence conservation (Figure 5.17). As expected, 
the catalytic Ser-His-Asp/Glu is highly conserved, as is the catalytically important Tyr438. 
Otherwise, there is little conservation in the sequence of residues that form the binding pocket for 
the lasso peptide. This lack of sequence conservation is consistent with the broad range of 
sequences, as well as macrolactam ring sizes, found in lasso peptides that may be catabolized by 
isopeptidase homologs.  
 
Isopeptidase as a Query Seed for Identifying New Lasso Clusters 
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Previous genome mining efforts to discover lasso peptides in our laboratory have relied on 
pattern matching to the lasso peptide precursor followed by searches for conserved motifs in the 
B- and C-enzymes in the vicinity of the precursor.27,154 B-enzymes are comprised of N-terminal 
domain that resembles the PqqD protein fused to cysteine protease domain, and are responsible 
for the cleavage of the leader peptide from the core peptide. C-enzymes are homologous to 
asparagine synthetase and form the isopeptide bond in the lasso peptide. Marahiel and co-workers 
have used an approach that relies on the relatively unique B-protein as the seed for genome mining 
searches.55 We sought to determine if the presence of the catabolic isopeptidase gene could be used 
as an alternative seed in genome mining. To this end, we carried out a comparative search effort 
to explore whether the isopeptidase-centric mining approach could identify clusters not previously 
detected. Manual inspection of the genomic context of all 98 the isopeptidases in these three 
clusters revealed that 87 contained a complete cluster with an A-peptide precursor, B-protein, C-
protein, and a TonB-dependent transporter (Table 5.3). However, 19 of the 87 clusters contain a 
mis-annotation of either the B- or C-protein (Table 5.3). Three examples are shown and re-
annotated in Figure 5.18. The original improper annotation would have precluded identification of 
these putative lasso peptide clusters using the biosynthetic enzymes as a search sequence. Of the 
87 clusters identified, 65 have not been previously described.  
Nearly all of the 87 gene clusters share the architecture found in the astexin-2 and -3 gene 
cluster with the A-, B-, and C-genes found in one operon and the isopeptidase and TonB-dependent 
transporter in a separate divergently transcribed operon. We have previously demonstrated62 that 
these proteobacterial gene clusters form a phylogenetic clade distinct from antimicrobial lasso 
peptide gene clusters. The finding of dozens of new proteobacterial clusters, nearly all with the 
same architecture, underscores how well conserved these clusters are in Proteobacteria. Despite 
the homogeneity in cluster architecture, some of the newly identified clusters exhibit features that 
have not been observed before in lasso peptides. In Sphingopyxis sp. 113P3, the cluster has the 
canonical architecture, but also includes a second isopeptidase and TonB-dependent transporter. 
In Sphingopyxis sp. H071, the precursor gene is not located upstream of the B- and C-genes, but 
is located instead between the C-gene and the isopeptidase E-gene. Lastly, the cluster from 
Sphingomonas hengshuiensis remarkably includes a HipA/HipB toxin/antitoxin pair sandwiched 
between the two operons in the lasso peptide gene cluster. 
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Our data suggest that the genome mining efforts using the protein sequences of catabolic 
genes may serve as another useful tool for the identification of RiPP biosynthetic clusters, 
especially in cases such as lasso peptides where the biosynthetic enzymes are distantly related to 
metabolic enzymes. To validate this approach, we carried out the heterologous expression of the 
two lasso peptides predicted to be expressed by the organism Asticcaucalis benevestitus (Figure 
5.19); we have named these compounds benenodin-1 and benenodin-2. Given that robust 
heterologous expression systems exist for proteobacterial lasso peptide gene clusters,27,55 many of 
the additional clusters found here can likely be expressed in a similar fashion. 
 
Discussion 
The lasso peptide isopeptidase is a unique member of the serine protease family as it carries 
out the hydrolysis of an isopeptide (rather than peptide) bond, and only on threaded lasso peptide 
substrates. The structure represents a new protein fold that is uniquely constructed to accommodate 
the complex substrate. The comparison of the cocrystal structure of the substrate astexin-3C4 
with the structure of the lasso peptide in solution illustrates how the enzyme remodels the substrate 
to access the isopeptide bond for hydrolysis. The Ser10-Gln14 isopeptide loop, which is converted 
from a linear to a loop topology during lasso maturation, is proposed to play a role in the 
biosynthetic process.150 Our studies indicate this loop also plays an important function in the 
catabolism of lasso peptides, as binding to the isopeptidase repositions this loop away from the 
isopeptide bond and into a binding pocket. Hence, it is likely that both the RiPP biosynthetic and 
catabolic enzymes utilize the same epitope in the substrate for recognition. 
The tolerance of AtxE2 to substitutions at nearly all residues within the substrate is 
accommodated by the lack of extensive specific contacts between the enzyme and substrate. The 
interactions observed in the crystal structure show that the shape of the lasso peptide rather than 
the composition of individual residues may be the primary recognition motif. Thus, AtxE2 may 
only engage substrates based on the number of amino acid residues within the lasso macrolactam 
ring and the size of the loop. Enzymes involved in the biosynthesis of RiPPs are shown to be 
tolerant of substitutions within the core peptide,28,30,155 and this tolerance is thought to provoke 
diversity in the resultant scaffolds. While the biosynthetic enzymes can process substrates with 
mutations along the core, they generally are not permissive to changes in the size of the ring. One 
exception are the caulosegnins I-III, for which the identical biosynthetic enzymes generate rings 
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of 8 and 9 residues.31 The broad tolerance of the isopeptidase likely is necessary to allow for 
hydrolysis of point mutants that may occur in the substrate, which is also gene encoded.150  
Hydrolysis of linear peptide substrates by canonical serine proteases occurs through an 
acyl-enzyme intermediate and substrate specificity is partially mediated by the complementarity 
between the enzyme specificity pocket and the amino acid located at the P1 position,156 i.e. the 
residue preceding the labile peptide bond.157 Although AtxE2 does not hydrolyze a peptide bond, 
the enzyme may use a similar means for substrate specificity. Specifically, formation of an acyl-
enzyme adduct at Ser527 via the side chain of Asp9 of astexin-3 would result in the deposition of 
the Ser10-Gln14 isopeptide loop in a large pocket analogous to the specificity pocket of serine 
proteases, suggesting complementarity between the isopeptide loop of the substrate determines the 
specificity of the lasso isopeptidase. Lastly, reorganization of the region harboring Tyr438 to 
position this residue for transition state stabilization is partially facilitated by the threaded tail of 
the lasso substrate. Similar active site reorganizations are observed in the structurally and 
chemically unrelated ubiquitin cysteine isopeptidase USP7, where the active site His-Cys dyad is 
oriented only upon substrate binding.158 
Our bioinformatic studies showed that isopeptidase homologs are quite common across 
Alphaproteobacteria, facilitating the identification of 87 lasso biosynthetic clusters using the 
AtxE2 isopeptidase sequence as a search query, and suggesting a further strategy to quickly 
identify lasso peptide gene clusters in Proteobacteria. Mining efforts using motifs from 
biosynthetic enzymes have been fruitful for RiPP genome mining of lanthipeptides,159,160 
cyanobactins,161 and thioazole/oxazole modified microcins,162,163 largely because of the unique 
nature of some of their constituent modification enzymes. In contrast, the lasso biosynthetic 
enzymes are not unique in sequence and show moderate sequence similarity to transglutaminase 
(B-protein) and asparagine synthetase (C-protein), which complicates straightforward 
identification of putative clusters. Another complication is that the B- and C-proteins are 
commonly misannotated, whereas the larger isopeptidase gene with its conserved  hydrolase 
domain is more commonly correctly annotated. The identification of multiple new biosynthetic 
clusters by this method suggests that an approach using sequences of precursor peptides, 
biosynthetic enzymes, as well as those of catabolic genes, should produce more candidates and 
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eliminate false positives in genome mining. The validation and further characterization of the 87 
biosynthetic clusters identified through this work is currently underway. 
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Figures 
 
 
Figure 5.1 A) Schematic of representative lasso peptides microcin J25, astexin-1, and astexin-
3. B) AtxE2 hydrolyzes the isopeptide bond of astexin-3. 
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Figure 5.2 MALDI mass spectral analysis of the two peaks observed by HPLC (Figure 5.14) 
from the AtxE2 WT and AtxE2 variant activity assays. The 22 minute peak (Top panel) correlates 
with the lassoed astexin-3 substrate (expected mass= 2524.17 m/z), while the 19 minute peak 
(Bottom panel) is consistent with the linear astexin-3 hydrolysis product (expected mass= 2542.17 
m/z). Oxygenated species (+16 m/z) are also observed for both astexin-3 and linear astexin-3. 
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Figure 5.3 A,B) Ribbon diagram of ligand-free AtxE2. C) The surface model of AtxE2 reveals 
the large lasso peptide-binding pocket. D) The catalytic triad of AtxE2 (gold) is well conserved 
when compared to puromycin hydrolase (purple). Residues were numbered according to AtxE2. 
However, nearby -helices and loops are moved away from the triad in AtxE2. 
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Figure 5.4 Sequence alignment of AtxE2 and three homologs with secondary structure of 
AtxE2 indicated. The NCBI access codes for the aligned sequences are: ADU14095.1 
(Asticcacaulis excentricus CB 48), ABF54307.1 (Sphingopyxis alaskensis RB2256), ABZ74310.1 
(Caulobacter sp. K31), and KFD26161.1 (Sphingobium yanoikuyae). 
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Figure 5.5 Secondary structure topology diagrams for AtxE2 and puromycin hydrolase as 
generated by PDBsum.164 The -1 and -2 helices and the missing blade unique to AtxE2 are 
indicated. 
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Figure 5.6 Structural comparison of the open -propeller domain of AtxE2 and the -propeller 
domain of puromycin hydrolase reveal topological differences. 
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Figure 5.7 Superimposition of / hydrolase domains of AtxE2 (gold) and puromycin 
hydrolase (pink). Helices and loops near to the catalytic triad are moved away in AtxE2, likely to 
accommodate the bulky lasso peptide substrate. 
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Figure 5.8 Sequence alignment of the astexin-1, astexin-2, and astexin-3C4 lasso peptides 
with conserved residues indicated. 
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Figure 5.9 Kinetic constants for astexin-3C4 hydrolysis were similar to value of full length 
astexin-3, indicating the tail of the lasso peptide does not enhance activity.  
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Figure 5.10 A) Overall structure of AtxE2 with astexin-3C4 bound (green) indicates that the 
lasso peptide binds into the large pocket of AtxE2. B) The structure of the binary complex was 
refined without astexin-3C4 and the Fo-Fc difference maps scaled to 2  (green mesh) was 
overlaid into astexin-3C4. C) The catalytic triad of AtxE2 is well positioned for hydrolysis of the 
isopeptide bond (green). D) Interactions between astexin-3C4 (green labels) and AtxE2 (black 
labels). 
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Figure 5.11 Structural alignment of APO AtxE2 (purple) and AtxE2 with astexin-3C4 bound 
(blue and green) reveals a flipping of the Tyr438 containing loop. This Tyr438 moves to point 
toward the isopeptide bond of astexin-3C4. 
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Figure 5.12 A) Analysis of production formation of AtxE2 variants after 1 hour revealed that 
Trp116 and Asn562 are important for activity in AtxE2. Substitution of Tyr438, important for 
stabilization of the alkoxide intermediate, leads to loss of detectable activity. Amounts of product 
were monitored by HPLC, integrated, and normalized to WT production. 
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Figure 5.13 Surface view of AtxE2 with astexin-3C4 bound illustrates the pocket that binds 
the lasso peptide, in particular the loop region. 
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Figure 5.14 Representative HPLC traces monitoring the hydrolysis of astexin-3 by AtxE2 and 
AtxE2 variants after 1 hour. 
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Figure 5.15 Overlay of astexin-3 from NMR structure (orange) and astexin-3C4 (green) as 
observed in the crystal structure. The residues Ser12 within the loop and Asp17 in the tail are 
moved away from the isopeptide bond in the crystal structure form, allowing access to the 
isopeptide bond. 
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Figure 5.16 A sequence similarity network was derived from AtxE2 using a similarity score of 
e-85, where connected nodes represent genes that are related by at least 30% at the primary sequence 
level. Red nodes indicate proteins located near complete putative lasso peptide clusters, while blue 
nodes indicate proteins not located near complete putative lasso peptide clusters. Examples of three 
isopeptidases located near known lasso peptide clusters are indicated: astexin-3 (green), 
caulonodin I (pink), and sphingopyxin II (yellow). 
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Figure 5.17 Mapping of sequence conservation of lasso isopeptidases onto the AtxE2 structure 
using ConSurf84 shows low levels of conservation around the astexin-3C4 lasso peptide (green) 
apart from the catalytic triad near the isopepeptide bond.  
 
 
 
 
 
 
128 
 
 
Figure 5.18 Three of the incorrectly annotated clusters were re-annotated by searching for open 
reading frames. The original and updated annotations are listed for Novosphingobium barchaimii 
LL02 25411_4, Sphingobium baderi strain DE-13, and Sphingopyxis sp. H071. The A-peptide is 
the linear precursor that is transformed into the lasso peptide. The B- and C-proteins work in 
tandem to generate the lasso peptide. TonB-dependent transporters (labeled TonB above) are very 
frequently associated with lasso peptide isopeptidases. The NCBI accession numbers for the 
isopeptidases are: KMS56018.1 (Novosphingobium barchaimii LL02 25411_4), ALR20106.1 
(Sphingobium baderi strain DE-13), and KTE56667.1 (Sphingopyxis sp. H071). 
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Figure 5.19 MALDI mass spectral analysis of crude extracts of E. coli producing the two 
putative lasso peptides from Asticcaucalis benevestitus, benenodin-1 and benenodin-2. Full-length 
peptide products are observed as well as C-terminal tail truncation products. 
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Tables 
 
Table 5.1 Primers used in this study. 
 
Primer Sequence 
AtxE2 W111A 5' CGATGTCGGTGGCGAGTATCTGTTCGCGACGATACCCAGTTGG 
AtxE2 W111A 3' CCGTATGGGGGTTGACCCATAGCAGCGCTTGTCTATGAGCGGT 
AtxE2 W116A 5' CTGTTCTGGACGATACCCAGTGCGGGGTATGCCC 
AtxE2 W116A 3' GGGCATACCCCGCACTGGGTATCGTCCAGAACAG 
AtxE2 N121A 5' GTTGGGGGTATGCCCGAGCCGCCCCGTC 
AtxE2 N121A 3' GACGGGGCGGCTCGGGCATACCCCCAAC 
AtxE2 N562A 5' ACCGCATCGGTCATGGCTGGACCGCGGATCTC 
AtxE2 N562A 3' GAGATCCGCGGTCCAGCCATGACCGATGCGGT 
AtxE2 Y438F 5' GAAAGCCGCGCGAACTAAATTGCACGATCACAAGCGGCAG 
AtxE2 Y438F 3' TATTTGCCCTGTAGGCGCCCGTGCGTTGCATCGTTCATTGG 
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Table 5.2 Crystallographic Refinement Parameters. 
 
 AtxE2 S527A SeMet AtxE2 AtxE2 S527A –AstexinC4 
Data collection    
Space group C222 C222 C222 
Cell dimensions    
a, b, c (Å) 151.0, 203.1, 109.5 150.5, 201.7, 109.1 151.3, 202.9, 110.4 
() 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 
Resolution (Å)1 50.0-2.65 (2.70-2.65) 50.0-2.40 (2.44-2.40) 29.817-2.20 (2.207-2.20) 
Rsym 16.1 (93.6) 13.8 (74.9) 10.7 (73.7) 
Rpim 6.7 (40.0) 7.1 (41.4) 3.9 (26.9) 
CC1/2 (highest shell)          0.686           0.625             0.817 
I / I 10.8 (1.7) 16.0 (4.3) 16.2 (2.8) 
Completeness (%) 100.0 (100.0) 98.6 (83.8) 99.9 (99.9) 
Redundancy 6.7 (6.4) 4.6 (3.8) 8.4 (8.4) 
    
Phasing    
Figure of Merit 0.251   
    
Refinement    
Resolution (Å)  49.7-2.40 121.26 –2.20 
No. reflections  62464 81764 
Rwork / Rfree2  0.197/0.236 0.155/0.198 
No. atoms  10881 11501 
Protein  10316 10591 
Water  565 910 
B-factors    
Protein  42.77 34.69 
Water  40.42 37.29 
R.m.s. deviations    
Bond lengths (Å)  0.008 0.017 
Bond angles ()  1.076 1.748 
 
1. Highest resolution shell is shown in parenthesis. 
2. R-factor = (|Fobs|-k|Fcalc|)/ |Fobs|and R-free is the R value for a test set of reflections consisting of a random 5% of 
the diffraction data not used in refinement. 
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Table 5.3 Lasso peptide gene clusters containing an isopeptidase. The NCBI codes or 
nucleotide ranges are given for the A-, B-, C-, and E-genes along with TonB-dependent transporters 
found in the same operon as the isopeptidase E-genes. Previously identified clusters are indicated 
in the last column. Entries in red were manually annotated. 
 
Organism A B C 
TonB-
dependent 
transporter 
E Reference 
Altererythrobac
ter sp. Root672 
NZ_LMHH
01000001.1|
1855787...1
855912 
KRA84104.1 KRA84105.1 KRA84107.1 KRA84106.1 This study 
Asticcacaulis 
benevestitus 
DSM 16100 
ESQ92588.1 ESQ92587.1 ESQ92586.1 ESQ92584.1 ESQ92585.1 This study 
Asticcacaulis 
benevestitus 
DSM 16100 
ESQ87019.1 ESQ87018.1 ESQ87017.1 ESQ87015.1 ESQ87016.1 This study 
Asticcacaulis 
excentricus 
ATCC 15261 
ADU14099.
1 
ADU14097.1 ADU14096.1 ADU14094.1 ADU14095.1 27 
Asticcacaulis 
sp. AC466 
ESQ84213.1 
AWGE01000
008.1|291495
...290839 
ESQ84209.1 ESQ84207.1 ESQ84208.1 This study 
Asticcacaulis 
sp. YBE204. 
ESQ79309.1 ESQ79308.1 ESQ79307.1 ESQ79305.1 ESQ79306.1 This study 
Brevundimonas 
abyssalis TAR-
001. 
GAD58271.
1 
BATC010000
05.1|67774...
67115 
GAD58269.1 GAD58267.1 GAD58268.1 This study 
Caulobacter sp. 
AP07 
EJL37542.1 EJL37543.1 EJL37544.1 EJL37546.1 EJL37545.1 55 
Caulobacter sp. 
K31 
ABZ74314.
1 
ABZ74312.1 ABZ74311.1 ABZ74309.1 ABZ74310.1 27 
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Table 5.3 (cont.) 
Organism A B C 
TonB-
dependent 
transporter 
E Reference 
Caulobacter sp. 
Root342 
LMDD0100
0013.1|2714
6...27322 
KQV54656.1 KQV54657.1 KQV54659.1 KQV54658.1 This study 
Croceicoccus 
naphthovorans 
NZ_CP0117
70.1|352509
2...3525226 
NZ_CP01177
0.1|3525287..
.3525898 
AKM11371.1 
NZ_CP01177
0.1|3532112..
.3529758 
AKM11372.1 This study 
Erythrobacter 
citreus LAMA 
915 
KNH00953.
1 
JYNE010000
28.1|393055..
.393693 
KNH00954.1 KNH00957.1 KNH00956.1 This study 
Luteimonas sp. 
FCS-9 
LASZ01000
002.1|37487
8...375018 
KLJ02548.1 KLJ02549.1 KLJ02590.1 KLJ02550.1 This study 
Luteimonas sp. 
FCS-9 
LASZ01000
003.1|29915
5...298994 
KLJ02114.1 KLJ02113.1 KLJ02176.1 KLJ02177.1 This study 
Novosphingobiu
m barchaimii 
LL02 
JACU01000
004.1|60605.
..60736 
JACU010000
04.1|60736...
61470 
JACU010000
04.1|61470...
63161 
KMS56019.1 KMS56018.1 This study 
Novosphingobiu
m 
lindaniclasticu
m LE124 
EQB08408.
1 
EQB08407.1 EQB08406.1 EQB08404.1 EQB08405.1 This study 
Novosphingobiu
m malaysiense 
JTDI010000
09.1|31234...
31368 
KHK89070.1 
JTDI0100000
9.1|32082...3
3884 
KHK89072.1 KHK89071.1 This study 
Novosphingobiu
m resinovorum 
EZP82446.1 EZP82445.1 EZP82444.1 EZP82442.1 EZP82443.1 This study 
Novosphingobiu
m resinovorum 
EZP82440.1 EZP82439.1 EZP82438.1 EZP82436.1 EZP82437.1 This study 
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Table 5.3 (cont.)    
Organism A B C 
TonB-
dependent 
transporter 
E Reference 
Novosphingobiu
m resinovorum 
EZP80709.1 EZP80708.1 
JFYZ010000
15.1|10314...
8575 
EZP80705.1 EZP80706.1 This study 
Novosphingobiu
m sp. AAP1 
LJHO01000
009.1|72380.
..72246 
LJHO010000
09.1|72177...
71521 
KPF52738.1 KPF52737.1 KPF52777.1 55 
Novosphingobiu
m sp. AAP1 
LJHO01000
007.1|17161
2...171496 
KPF53238.1 
LJHO010000
07.1|170775..
.169036 
KPF53236.1 KPF53237.1 55 
Novosphingobiu
m sp. Fuku2-
ISO-50 
LLZR01000
022.1|10372
6...103580 
KUR75369.1 KUR75368.1 KUR75366.1 KUR75367.1 This study 
Novosphingobiu
m sp. P6W 
JXZE01000
003.1|23243.
..23374 
KIS32912.1 KIS32913.1 KIS33506.1 KIS33505.1 This study 
Novosphingobiu
m sp. PP1Y 
NC_015580.
1|1723970...
1724122 
CCA92512.1 CCA92513.1 CCA92515.1 CCA92514.1 55 
Novosphingobiu
m sp. PP1Y 
FR856860.1|
34952...347
88 
CCA89845.1 CCA89844.1 CCA89842.1 CCA89843.1 55 
Novosphingobiu
m sp. Rr 2-17 
EIZ78128.1 EIZ78129.1 EIZ78130.1 EIZ78132.1 EIZ78131.1 This study 
Novosphingobiu
m subterraneum 
KHS45261.
1 
KHS45260.1 KHS45259.1 KHS45257.1 KHS45258.1 This study 
Novosphingobiu
m subterraneum 
KHS42581.
1 
KHS42580.1 KHS42579.1 KHS42577.1 KHS42578.1 This study 
Rhodanobacter 
denitrificans 
AGG87603.
1 
AGG87602.1 AGG87601.1 AGG87599.1 AGG87600.1 This study 
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Table 5.3 (cont.)    
Organism A B C 
TonB-
dependent 
transporter 
E Reference 
Rhodanobacter 
thiooxydans 
LCS2 
AJXW0100
0057.1|1073.
..1234 
EIL98304.1 EIL98302.1 EIL98304.1 EIL98303.1 55 
Sphingobium 
baderi 
NZ_CP0132
64.1|141607
5...1416227 
NZ_CP01326
4.1|1416288..
.1416935 
NZ_CP01326
4.1|1416938..
.1418686 
ALR20107.1 ALR20106.1 This study 
Sphingobium 
chlorophenolicu
m 
KEQ53303.
1 
KEQ53304.1 KEQ53305.1 KEQ53307.1 KEQ53306.1 This study 
Sphingobium 
chlorophenolicu
m 
KEQ51823.
1 
KEQ51822.1 KEQ51821.1 KEQ51819.1 KEQ51820.1 This study 
Sphingobium 
czechense LL01 
KMS58843.
1 
KMS58842.1 KMS58841.1 KMS58311.1 KMS58312.1 This study 
Sphingobium 
herbicidovorans 
ATCC 700291 
KFG89440.
1 
KFG89439.1 KFG89438.1 KFG89436.1 KFG89437.1 This study 
Sphingobium 
lactosutens 
DS20 
EQB11375.
1 
EQB11376.1 EQB11377.1 EQB11379.1 EQB11378.1 This study 
Sphingobium 
lactosutens 
DS20 
ATDP01000
089.1|41920.
..42072 
ATDP010000
89.1|42014...
42781 
ATDP010000
89.1|43438...
44514 
ATDP010000
89.1|49239...
46660 
EQB14871.1 This study 
Sphingobium 
sp. Ant17 
JEMV01000
094.1|1141...
1281 
EXS68240.1 EXS68241.1 EXS68243.1 EXS68242.1 This study 
Sphingobium 
sp. Ant17 
JEMV01000
036.1|6055...
6186 
JEMV010000
36.1|6245...6
910 
EXS69379.1 EXS69381.1 EXS69380.1 This study 
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Table 5.3 (cont.) 
Organism A B C 
TonB-
dependent 
transporter 
E Reference 
Sphingobium 
sp. ba1 
KFL46753.1 
JPPQ010000
69.1|1431689
...1431030 
KFL46751.1 KFL46749.1 KFL46750.1 This study 
Sphingobium 
sp. SYK-6 
NC_015976.
1|2167027...
2166872 
NC_015976.1
|2166809...21
66138 
BAK66648.1 BAK66646.1 BAK66647.1 27 
Sphingobium 
sp. SYK-6. 
NC_015976.
1|2901725...
2901597 
BAK67366.1 BAK67365.1 BAK67363.1 BAK67364.1 27 
Sphingobium 
sp. YBL2 
NZ_CP0109
54.1|382348
8...3823631 
AJR25278.1 AJR25279.1 AJR25283.1 AJR25282.1 This study 
Sphingobium 
sp. YBL2 
NZ_CP0109
54.1|444042.
..444158 
NZ_CP01095
4.1|444118...
444867 
AJR22755.1 AJR22757.1 AJR22756.1 This study 
Sphingobium 
yanoikuyae 
JPOU01000
050.1|33730.
..33590 
KFD26163.1 KFD26162.1 KFD26160.1 KFD26161.1 55 
Sphingobium 
yanoikuyae 
JFFT010000
48.1|22722...
22853 
KMW28608.
1 
KMW28609.
1 
KMW28611.
1 
KMW28610.
1 
55 
Sphingobium 
yanoikuyae 
KEZ21066.1 KEZ21065.1 KEZ21064.1 KEZ21062.1 KEZ21063.1 55 
Sphingobium 
yanoikuyae 
KEZ17948.1 KEZ17947.1 KEZ17946.1 KEZ17944.1 KEZ17945.1 55 
Sphingobium 
yanoikuyae 
ATCC 51230 
EKU73625.
1 
EKU73624.1 EKU73623.1 EKU73621.1 EKU73622.1 55 
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Table 5.3 (cont.) 
Organism A B C 
TonB-
dependent 
transporter 
E Reference 
Sphingomonas 
hengshuiensis 
NZ_CP0108
36.1|451161
1...4511489 
AJP73681.1 AJP73680.1 AJP73676.1 AJP73677.1 This study 
Sphingomonas 
parapaucimobil
is NBRC 15100 
BBPI01000
030.1|33410.
..33538 
GAM00331.1 GAM00332.1 GAM00334.1 GAM00333.1 This study 
Sphingomonas 
paucimobilis 
EZP70610.1 EZP70609.1 EZP70608.1 EZP70606.1 EZP70607.1 This study 
Sphingomonas 
paucimobilis 
EZP68912.1 EZP68913.1 EZP68914.1 EZP68916.1 EZP68915.1 This study 
Sphingomonas 
sanxanigenens 
DSM 19645 
AHE55571.
1 
AHE55570.1 AHE55569.1 AHE55567.1 AHE55568.1 This study 
Sphingomonas 
sp. LH128 
ALVC0100
0003.1|2559
6...25727 
EJU15100.1 EJU15101.1 EJU15103.1 EJU15102.1 55 
Sphingomonas 
sp. SKA58 
EAT10634.1 EAT10633.1 EAT10632.1 EAT10628.1 EAT10629.1 27 
Sphingopyxis 
alaskensis DSM 
13593 
NC_008048.
1|2674126...
2673995 
ABF54241.1 ABF54240.1 ABF54238.1 ABF54239.1 27 
Sphingopyxis 
alaskensis DSM 
13593 
NC_008048.
1|2746426...
2746256 
ABF54309.1 ABF54308.1 ABF54306.1 ABF54307.1 27 
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Table 5.3 (cont.)    
Organism A B C 
TonB-
dependent 
transporter 
E Reference 
Sphingopyxis 
fribergensis 
NZ_CP0091
22.1|298004
6...2979873 
AJA09673.1 AJA09672.1 AJA09670.1 AJA09671.1 This study 
Sphingopyxis 
fribergensis 
CP009123.1|
121593...12
1468 
AJA11698.1 AJA11697.1 AJA11695.1 AJA11696.1 This study 
Sphingopyxis 
fribergensis  
NZ_CP0091
22.1|305071.
..305208 
AJA07217.1 AJA07218.1 AJA07220.1 AJA07219.1 This study 
Sphingopyxis 
granuli 
CP012199.1|
3538300...3
538142 
AMG75570.1 AMG75569.1 AMG75567.1 AMG75568.1 This study 
Sphingopyxis 
macrogoltabida 
ALJ15626.1 ALJ15625.1 ALJ15624.1 ALJ15622.1 ALJ15623.1 This study 
Sphingopyxis 
macrogoltabida 
ALJ15513.1 ALJ15512.1 ALJ15511.1 ALJ15509.1 ALJ15510.1 This study 
Sphingopyxis 
macrogoltabida 
NZ_CP0127
00.1|438169.
..438306 
NZ_CP01270
0.1|438254...
439012 
ALH79216.1 ALH79218.1 ALH79217.1 This study 
Sphingopyxis 
macrogoltabida 
ALJ16607.1 ALJ16608.1 ALJ16609.1 ALJ16611.1 ALJ16610.1 This study 
Sphingopyxis 
macrogoltabida 
ALJ14063.1 ALJ14062.1 ALJ14061.1 ALJ14059.1 ALJ14060.1 This study 
Sphingopyxis 
sp. 113P3 
ALC11308.
1 
ALC11309.1 ALC11311.1 ALC11313.1 ALC11312.1 This study 
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Table 5.3 (cont.)    
Organism A B C 
TonB-
dependent 
transporter 
E Reference 
Sphingopyxis 
sp. C-1 
GAO78960.
1 
BBRO01000
001.1|235170
2...2351055 
GAO78959.1 GAO78957.1 GAO78958.1 This study 
Sphingopyxis 
sp. C-1 
GAO77431.
1 
BBRO01000
001.1|769678
...770391 
BBRO01000
001.1|770394
...772112 
GAO77435.1 GAO77434.1 This study 
Sphingopyxis 
sp. C-1 
GAO78077.
1 
GAO78078.1 GAO78079.1 GAO78081.1 GAO78080.1 This study 
Sphingopyxis 
sp. H050 
LNRZ01000
001.1|60382
0...603939 
KTE22836.1 KTE22837.1 KTE22839.1 KTE22838.1 This study 
Sphingopyxis 
sp. H050 
LNRZ01000
002.1|33137.
..33274 
KTE21701.1 KTE21702.1 KTE21704.1 KTE21703.1 This study 
Sphingopyxis 
sp. H071 
LNSF01000
002.1|90958.
..90827 
LNSF010000
02.1|90762...
90124 
LNSF010000
02.1|90121...
88412 
KTE56666.1 KTE56667.1 This study 
Sphingopyxis 
sp. HIX 
LNSB01000
024.1|21120.
..21245 
KTE37760.1 KTE37761.1 KTE37763.1 KTE37762.1 This study 
Sphingopyxis 
sp. LC363 
KGB55906.
1 
KGB55905.1 KGB55903.1 KGB55901.1 KGB55902.1 This study 
Sphingopyxis 
sp. LC363 
KGB53706.
1 
JNFC010000
45.1|84936...
84298 
KGB53705.1 KGB53703.1 KGB53704.1 This study 
Sphingopyxis 
sp. LC363 
KGB59315.
1 
KGB59316.1 KGB59317.1 KGB59319.1 KGB59318.1 This study 
Stenotrophomo
nas 
acidaminiphila 
ALJ29423.1 ALJ29424.1 ALJ29425.1| ALJ29427.1 ALJ29426.1 165 
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Table 5.3 (cont.)     
Organism A B C 
TonB-
dependent 
transporter 
E Reference 
Xanthomonas 
arboricola pv. 
pruni 
JHUQ01000
175.1|1737...
1880 
KCW98619.1 KCW98620.1 KCW98622.1 KCW98621.1 This study 
Xanthomonas 
campestris pv. 
cannabis 
JSZE010000
94.1|14190...
14047 
KHL53485.1 KHL53453.1 KHL53451.1 KHL53452.1 This study 
Xanthomonas 
citri pv. 
mangiferaeindic
ae LMG 941 
CAHO0100
0029.1|4132
0...41174 
CCG37616.1 CCG37615.1 CCG37613.1 CCG37614.1 55 
Xanthomonas 
gardneri 
JZJS010000
33.1|18064...
18201 
KLB01418.1 KLB01419.1 KLB01420.1 KLB01441.1 27 
Xanthomonas 
sp. Leaf131 
LMOG0100
0002.1|1943
61...194501 
KQQ84666.1 KQQ84667.1 KQQ84669.1 KQQ84668.1 This study 
Xanthomonas 
sp. Mitacek01 
LKIT01000
002.1|12533
62...125350
8 
KPN20492.1 KPN20493.1 KPN21401.1 KPN20494.1 This study 
Xanthomonas 
sp. Nyagatare 
JRQI010000
07.1|15033...
15206 
KGK59232.1 KGK59370.1 KGK59372.1 KGK59371.1 This study 
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Chapter 6 Structural and Biochemical Basis for Mannan Utilization by Caldanaerobius 
polysaccharolyticus Strain ATCC BAA-17v 
 
Introduction 
Hemicellulose represents the second most abundant biopolymer on the planet, and harbors 
a reservoir of polysaccharides that can be fermented to bioenergy products such as ethanol 166. In 
softwoods (gymnosperms), mannans are the major constituents of hemicellulose 167, and are 
widely distributed throughout the plant tissues.168 Mannan polymers are heterogeneous and consist 
of a linear backbone of -1,4-linked mannose sugars (mannans) or a combination of glucose and 
mannose sugars (glucomannans) that may be substituted with galactosyl groups (i.e., 
galactomannans or galacto-glucomannans).66 This structural complexity presents a challenge for 
both the import and subsequent enzymatic degradation of decorated mannans into constituent 
monosaccharides for fermentation into ethanolic biofuels.169  
Multiple enzymatic activities are required for mannan degradation, including -
mannanases (which cleave the 1,4-linked mannose backbone), -mannosidases (which hydrolyze 
1,4--D-mannopyranosides), and -glucosidases (which cleave 1,4-linked glucopyranoses from 
the nonreducing ends of oligosaccharides released by -mannanases) (Figure 6.1).170–172 In 
addition, the debranching activities of acetyl esterases and -galactosidases are required to process 
acetyl and galactosyl substituents, respectively. Multiple examples of each of these activities have 
been discovered from microbial sources, and the individual enzymes have been characterized in 
detail.173 Consequently, enzymatic cocktails of mannan degrading enzymes have biotechnological 
applications for the in vitro saccharification of lignocellulosic biomass into fermentable sugars. 
Current efforts in industrial-scale lignocellulosic biomass deconstruction are shifting away 
from the use of expensive enzyme cocktails for in vitro processing and towards engineering of 
microbial organisms for metabolic fermentation in vivo.174–176 In such efforts, ethanologenic 
organisms that can already ferment glucose are genetically transformed with the necessary genes 
                                                          
v This chapter is adapted from the following published article: 
Chekan, J. R.*, Kwon, I. H.*, Agarwal, V.*, Dodd, D., Revindran, V., Mackie, R. I., Cann, I., and Nair, S. K. (2014) 
Structural and Biochemical Basis for Mannan Utilization by Caldanaerobius polysaccharolyticus Strain ATCC BAA-
17. J. Biol. Chem. 289, 34965–34977 
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for metabolism of other hexoses, as well as pentose sugars.177 In some applications, the 
introduction of membrane integral ATP-dependent oligosaccharide transporters allows facile 
import of short chain sugars, which can be further metabolized within the engineered strain.178,179 
We have previously characterized a xylan utilization gene cluster consisting of a xylan-specific 
transporter and the necessary hydrolytic enzymes for xylose metabolism, which may be used as a 
cassette to engineer xylan fermentative capacity into ethanologenic organisms.180 However, 
mannan-specific ATP-dependent transporters have not been characterized in detail, thus limiting 
the utility of cassette-based engineering approaches for the bioprocessing of mannan-rich 
softwoods. As mannans are decorated with branched substituents, enzymes for both the import and 
catabolism of manno-oligosaccharides must accommodate these decorations, a feature not 
commonly observed with the solute-binding components of similar transporters. 
Here, we describe the identification of a mannan utilization cluster in the thermophilic 
bacterium Caldanaerobius polysaccharolyticus, the gene products of which target manno-
oligosaccharide transport and degradation. The cluster encodes six genes, including man5b, a -
mannosidase predicted to be intracellularly located, a transcriptional regulator, which likely senses 
the presence of manno-oligosaccharides, a putative multi-component ATP-dependent membrane 
integral complex that is predicted to import the end products of extracellular mannan degradation, 
and a member of GH130, a newly described glycoside hydrolase family.181 Based on sequence 
comparison and genomic context, a putative solute-binding component (CpMnBP1) was 
identified, which may be a component of the ABC transporter complex. We have carried out 
calorimetric analyses on CpMnBP1, which reveal a tolerance for both linear and decorated manno-
oligosaccharides. We also present the co-crystal structures of CpMnBP1 in complex with 
mannobiose (to 1.4 Å resolution) and mannotriose (to 2.2 Å resolution), which represent the first 
structural views of a manno-oligosaccharide-specific solute-binding protein. The structural data, 
and previous biochemical analysis of gene products encoded in the mannan utilization gene cluster 
allow for an understanding of the specificity for manno-oligosaccharide binding by CpMnBP1. 
 
Experimental Procedures 
Materials  
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Manno-oligosaccharides (mannobiose (M2), mannotriose (M3), mannotetraose (M4), 
mannopentaose (M5), mannohexaose (M6), and α-galactosyl mannotriose) and cello-
oligosaccharides (cellotriose (G3), cellotetraose (G4), cellopentaose (G5), and cellohexaose (G6)) 
were purchased from Megazyme (Bray, Ireland).  Cellobiose (G2) was purchased from Sigma-
Aldrich (St. Louis, MO).  Protein molecular mass markers for sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) were obtained from Bio-Rad (Hercules, CA).  
High-performance liquid chromatography (HPLC) grade sodium acetate trihydrate was purchased 
from EMD Chemicals (Darmstadt, Germany). All other reagents were purchased from Fisher 
Scientific (Hanover Park, IL) and were of the highest purity available. 
 
Growth of C. polysaccharolyticus and RNA extraction.  
C. polysaccharolyticus was cultured anaerobically at 65 C in butyl rubber-stoppered Balch 
tubes using a previously reported defined medium180 in an atmosphere consisting of 5% H2 and 
95% CO2.  As sole carbohydrate source, glucose, mannose, glucomannan (Megazyme), or 
galactomannan (Megazyme) was added at 0.2 % (w/v). The cells were adapted to the respective 
media by culturing for 24 hours three times in succession. Subsequently, 0.2 ml of pre-culture was 
inoculated into 10 ml of fresh medium and the optical density at 600 nm (OD600nm) values were 
monitored every hour using a Spectronic 21D spectrophotometer (Milton Roy). To estimate 
growth rates, cells were cultured to their maximal OD600nm values. For RNA extraction 
experiments, the cells were harvested at early logarithmic phase (OD600nm of 0.15 for all carbon 
sources) by combining the culture with 2 volumes of RNAprotect® bacterial reagent (Qiagen), 
followed by centrifugation at 8,000 × g for 10 min at room temperature. The resulting cell pellets 
were stored at – 80 C until RNA extraction. In the subsequent steps, the cell pellets were treated 
with lysozyme and proteinase K for 30 minute at room temperature, and the total RNA was 
extracted with the RNeasy mini kit (Qiagen) with the optional on-column DNase treatment step. 
The RNA was eluted with DEPC-treated nuclease-free water and stored at – 80 C until 
sequencing. 
 
Transcriptional analysis by RNA sequencing.  
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For RNA-Seq analyses, RNA isolated from two biological replicates were used for each 
growth condition. Bacterial ribosomal RNAs were removed from 10 µg of total RNA with the 
MicrobExpress kit (LifeTechnologies). The enriched mRNA fraction was converted to RNA-Seq 
libraries using the TruSeq Stranded RNA Sample Prep kit from Illumina. The barcoded libraries 
were pooled in equimolar concentration and the pool was analyzed by quantitative PCR and 
sequenced on one lane for 101 cycles on a HiSeq2000 using a TruSeq SBS sequencing kit version3. 
Fastq files were generated and demultiplexed with the bcl2fastq v1.8.4 Conversion Software 
(Illumina, Inc.). RNAseq library statistics are shown in Table 6.5.  
The RNA-Seq data were analyzed using CLC genomics workbench version 5.5.1 from 
CLC Bio (Cambridge, MA). The three genomic scaffold sequences of C. polysaccharolyticus 
DSM 13641 (GenBank accession numbers: NZ_KE386493.1, NZ_KE386494.1, and 
NZ_KE386495.1) were used as the reference genome, and RNA-Seq reads were mapped onto the 
reference sequences using the CLC software. Reads were only assembled if the fraction of the read 
that aligned with the reference genome was greater than 0.9 and if the read matched other regions 
of the reference genome at less than 10 nucleotide positions. The RNA-Seq output files were 
analyzed for statistical significance by using the proportion-based test of Baggerly et al.182 The 
RNAseq data has been deposited in the NCBI server with accession data (SRP Number 
SRP048659). 
 
Recombinant protein production and purification 
E. coli BL21-CodonPlus(DE3)-RIPL cells harboring a recombinant plasmid bearing either 
the gene for CpMnBP1 (CalpoDRAFT_1212, Genbank Accesion number: AGA35557.1) or 
variants, were cultured in 10 mL lysogeny broth (LB) medium containing 100 g mL-1 sodium-
ampicillin and 50 g mL-1 chloramphenicol for approximately 8 hours at 37 °C with vigorous 
shaking.  The initial 10 mL cultures were used to inoculate LB (1 L) containing the two antibiotics, 
at the same concentrations stated above, in a 2.8 L Fernbach flask.  The cultures were incubated at 
37 °C at 200 rpm until the absorbance at 600 nm reached 0.3 (after approximately 2.5 hours). 
Gene expression in E. coli cultures was then induced with the addition of IPTG (0.1 mM, final 
concentration).  The temperature was decreased to 16 °C, and the cultures were allowed to incubate 
for an additional 16 hours with shaking at 200 rpm.  Cell pellets were harvested from the cultures 
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by centrifugation at 4,651  g for 30 minutes at 4 °C, washed with 35 mL binding buffer (50 mM 
Tris, 300 mM NaCl, pH 7.5), and frozen as cell pellets at -80 °C. 
Frozen cell pellets were thawed and re-suspended in 35-mL ice-cold binding buffer and 
passed through an EmulsiFlex C-3 homogenizer (Avestin, Ottawa, Canada) to release the cell 
contents.  The cell lysates were clarified by centrifugation at 12,857  g for 20 min at 4 °C, and 
the supernatant containing the soluble fraction was recovered. The supernatant was incubated at 
65 °C for 30 min and centrifuged at 20,000 × g for 15 min at 4 °C to pellet the precipitated heat-
labile E. coli proteins. The supernatant was loaded onto an immobilized metal ion affinity resin 
(Talon resin, Novagen) pre-equilibrated with binding buffer (50 mM Tris-HCl, 300 mM NaCl, 20 
mM imidazole, pH 7.5), and the bound proteins were washed with 10 column volumes of binding 
buffer and eluted with an elution buffer (50 mM Tris-HCl, 300 mM NaCl, 250 mM imidazole, pH 
7.5). The eluted protein fractions were pooled, concentrated and exchanged into 50 mM citrate-
HCl buffer (pH 5.5) for further purification by ion exchange chromatography. The protein was 
loaded onto a cation exchange column (5-ml HiTrap SP HP column, GE Healthcare) equilibrated 
with a citrate buffer (binding buffer-50 mM citrate-HCl, pH 5.5), and a gradient elution was 
applied by using the binding buffer supplemented with 1M NaCl. Preparation of selenomethionine 
(SeMet)-labeled CpMnBP1 was carried out by repression of methionine synthesis in defined media 
and the resultant protein was purified as above but with the inclusion of reducing agent in all 
buffers. 
 
Site-directed mutagenesis 
Site directed mutagenesis was carried out with the QuickChange Multi Site-directed 
Mutagenesis Kit according to the instruction of the manufacturer (Agilent Technologies). 
 
Substrate binding assay using isothermal titration calorimetry   
The substrate binding activity of CpMnBP1 with different oligosaccharides was 
determined at 25 °C or 65 °C using a VP-ITC microcalorimeter (Microcal Inc., Northampton, MA) 
as described previously (16). Protein was purified by size exclusion chromatography using a 
SuperdexTM 200 HiloadTM 16/6 column, and subsequently diluted to a concentration of 50 μM in 
citrate buffer (50 mM sodium citrate, pH 5.5). Mannose and manno-oligosaccharides (M1-M6) 
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and glucose and cello-oligosaccharides (G1-G6) were prepared at a final concentration of 0.5 mM. 
The ligands were individually injected into the reaction cell containing CpMnBP1 in 24 or 28 
successive 10-μl aliquots at 300 sec intervals and 20 sec duration. Binding data for CpMnBP1 
variants utilized mannotetraose as the ligand. The resulting data were analyzed by non-linear 
regression with a single site model (MicroCal Origin), and thermodynamic parameters were 
calculated using the Gibbs free energy equation (ΔG = ΔH - TΔS), and the relationship, ΔG = -RT 
lnKa. 
 
Structure determination of the CpMnBP1-oligosaccharide complexes 
CpMnBP1 was purified as described above but with a size exclusion chromatographic step 
(SuperdexTM 200 HiloadTM 16/60 size exclusion column) using a final buffer composed of 20 mM 
HEPES pH 7.5, 100 mM KCl. Crystallization attempts with the full-length protein proved fruitless. 
Treatment of full-length CpMnBP1 with trypsin yielded a stable fragment from which the 
polyhistidine tag (and additional cloning artefacts) and the first 14 amino acids of the full-length 
protein were excised. This stable fragment was further purified by size exclusion chromatography, 
prior to screening attempts for crystallization. 
Initial crystallization conditions were obtained by sparse-matrix sampling method using 
commercial screens. Crystals of both complexes were grown using the hanging vapor drop 
diffusion method. Briefly, for crystallization of the CpMnBP1-mannotriose complex, 1 l of 
protein at 20 mg/ml concentration, was incubated with 5 mM oligosaccharide for 2 hours on ice, 
and the complex was mixed with 1 l of precipitant solution (30% polyethylene glycol 1500, 100 
mM KCl and 20 mM HEPES, pH 7.5) and equilibrated over a well containing the precipitant 
solution at 9 °C. Crystals grew within 2 weeks and were briefly soaked in precipitant solution 
supplemented with 10% ethylene glycol prior to vitrification by direct immersion in liquid 
nitrogen. Crystallization of the CpMnBP1-mannobiose complex was carried out using SeMet 
labeled protein.  
Flash-cooled crystals of native CpMnBP1 in complex with mannotriose diffracted X-rays 
to 2.2 Å resolution at an insertion device synchrotron beam line (LS-CAT Sector 21 ID-F, 
Advanced Photon Source, Argonne, IL). These crystals occupy space group P21 with unit cell 
parameters a=63.3 Å, b=101.6 Å, c=67.8 Å and =116.7o, with two molecules in the 
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crystallographic asymmetric unit.  A four-fold redundant data set was collected to 2.2 Å resolution 
with an overall Rmerge=9.0% and I/(I)=2 in the highest resolution shell.  All data were indexed 
and scaled using the HKL2000 package. Crystals of SeMet CpMnBP1-mannobiose complex 
diffract to 1.4 Å and occupy space group P21 with unit cell parameters a=53.7 Å, b=62.3 Å, c=60.0 
Å and =116.7o. For crystallographic phase determination, a four-fold redundant data set was 
collected to 1.5 Å resolution near the Se absorption edge (wavelength=0.97856) with an overall 
Rmerge=5.5% and I/(I)=6 in the highest resolution shell. A second data set was collected to a 
slightly higher resolution (1.4 Å) away from the Se edge (wavelength=1.07812) and used for 
crystallographic refinement. 
Crystallographic phases were determined by single wavelength anomalous scattering. The 
heavy atom substructure was determined using HySS and refinement of heavy atom parameters 
using Phaser,124 as implemented in the PHENIX software package,88 yielded a Figure of Merit of 
0.469. Solvent flattening and non-crystallographic symmetry averaging yielded experimental 
maps of exceptional quality, allowing nearly the entire polypeptide chain to be automatically 
traced using Buccaneer.125 Further manual fitting using COOT90 was interspersed with rounds of 
refinement using REFMAC5.91 Cross-validation, using 5% of the data for the calculation of the 
free R factor was utilized throughout model building process in order to monitor building bias. 
When a near complete model of the polypeptide was obtained, further crystallographic refinement 
was carried out against the 1.4 Å resolution data set. Clear density for the oligosaccharide could 
be observed in the initial experimental maps and the ligand was manually built into the model only 
after the free R factor dropped below 30%.  
Phases for the CpMnBP1-mannotriose complex were determined by the molecular 
replacement method using the atomic coordinates of the protein obtained from the CpMnBP1-
mannobiose complex. Manual fitting, using COOT, was interspersed with rounds of REFMAC5 
refinement until the free R factor dropped below 30%. The coordinates for the oligosaccharide 
were manually built and subject to further rounds of refinement, until convergence. The 
stereochemistry of all of the models was routinely monitored throughout the course of refinement 
using PROCHECK.92 Relevant data collection and refinement parameters are provided in Table 1. 
The refined coordinates have been deposited in the Protein Data Bank183 with accession codes 
4RGF (CpMnBP1-mannobiose complex) and 4R9G (CpMnBP1-mannotriose complex). 
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Results 
Identification of a gene cluster for mannan utilization 
Multiple enzymatic activities are necessary to catabolize mannans (Figure 6.1) and genes 
encoding several of these activities can be identified within a putative mannan utilization gene 
cluster in C. polysaccharolyticus.184 However, the gene coding for the extracellular enzyme 
(CpMan5A) that may be responsible for the initial hydrolysis of the polysaccharide185 is located 
outside of this reported gene cluster, elsewhere in the genome. This strategy is in agreement with 
our previous observation that in a gene cluster for xylan degradation by C. polysaccharolyticus, 
the gene coding for the endoxylanase is located outside of the xylo-oligosaccharide metabolism 
gene cluster.180  
 
Growth of C. polysaccharolyticus with monosaccharides and polysaccharides 
C. polysaccharolyticus was previously shown to ferment glucose and mannose186 and to 
degrade mannan polysaccharides184,185 into oligosaccharides that can then be hydrolyzed into 
shorter oligosaccharides and the monomeric sugar mannose.184 The manno-oligosaccharide 
cleaving enzyme Man5B characterized in this bacterium is likely located intracellularly, since this 
protein seems to lack an identifiable signal peptide. To gain insight into the machinery employed 
for manno-oligosaccharide transport into the cells of C. polysaccharolyticus, we cultured the cells 
on defined medium containing the polysaccharide glucomannan or galactomannan as carbohydrate 
source to identify the genes uniquely upregulated (in the presence of these polysaccharides) 
compared to the monosaccharides glucose and mannose. Here, we show that the bacterium can 
utilize both polysaccharides (Figure 6.2A). The doubling time during growth with glucomannan 
(GluMan) or galactomannan (GalMan) was 2.4-fold faster relative to mannose, the major 
monosaccharide component of mannan (Figure 6.2A, Table 6.3). In contrast, the doubling time 
with glucose as the carbon source was comparable to that for the polysaccharides. These results 
indicate that while C. polysaccharolyticus can ferment free mannose, the cells possess mechanisms 
optimized for energy capture from mannan polysaccharides. To understand the molecular 
mechanism for mannan utilization, we employed an unbiased whole genome RNA-sequencing 
approach. 
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The genes most highly induced by mannan map to the man5B-containing mannan utilization 
cluster 
The mannan utilization genes in C. polysaccharolyticus were identified by applying RNA 
sequencing (RNA-Seq) analysis to transcripts extracted from cells grown on the monosaccharide 
and polysaccharide amended minimal medium (i.e., with either glucose, mannose, glucomannan, 
or galactomannan). The RNA was extracted from cells at early log phase of growth, and the relative 
expression values for the genes were quantified by RNA-Seq. The expression of four genes were 
induced greater than 100-fold during growth with glucomannan relative to mannose, and all of 
these genes mapped to the man5B containing gene cluster.184 The cluster included the putative 
ABC transporter components (CpMnBP1, 126-fold; permease1, 286-fold; permease2, 337-fold) 
and the putative GH130 manno-oligosaccharide phosphorylase (137-fold) (Table 2). The putative 
transcriptional regulator was also induced 11.9-fold (Table 2, CalpoDRAFT_1213). Interestingly, 
the magnitude of induction of man5B was rather low (2.46-fold), although the absolute expression 
values for this gene agreed well among the biological replicates, and the relative expression 
comparison yielded a very low P-value (7.6 x 10-33). To evaluate the likelihood of these genes 
being co-transcribed on a single messenger RNA molecule (polycistronic mRNA), we performed 
read mapping on the entire genome and compared the coverage over the gene cluster for the 
glucomannan and mannose experiments. A large number of reads mapped to the ABC transporter 
genes in the case of the glucomannan grown cells, whereas very few reads mapped to the ABC 
transporter in the mannose grown cells (Figure 6.2B), consistent with the expression data presented 
in Table 2. Although there were some fluctuations in coverage over the genes, overall the coverage 
was continuous over the entire region encompassing the transcriptional regulator 
(CalpoDRAFT_1213) through the GH130 gene (CalpoDRAFT_1209) (Figure 6.2B). These 
observations suggest that the genes in this region are arranged in an operon, although further 
experiments are necessary to validate this hypothesis.  
A similar upregulation of the man5B encoding gene cluster was observed during growth of 
C. polysaccharolyticus on galactomannan compared to growth on mannose. In fact, the fold 
changes during growth on galactomannan compared to mannose were higher than those for growth 
on glucomannan compared with mannose (Table 6.2). Thus, the RNA-Seq results identified this 
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cluster of genes as being involved in mannan degradation, or as part of a transcriptional program 
induced by C. polysaccharolyticus during growth on mannans. 
 
CalpoDRAFT_1212 (MnBP1) encodes a substrate-binding component of a putative ABC 
transport complex that is specific for manno-oligosaccharides 
Upregulation of the gene encoding CpMnBP1 was observed for growth on either 
glucomannan or galactomannan (Table 6.2 and Fig. 6.2B), suggesting that a mechanism exists 
whereby both the linear and decorated manno-oligosaccharides produced by the extracellular 
CpMan5A can be transported across the plasma membrane and into the cell, for subsequent 
processing by the manno-oligosaccharide utilization genes, such as CpMan5B and the GH130 
enzyme. The putative ATP-binding cassette (ABC), composed of the three genes encoding a solute 
binding protein and tandem repeats of the corresponding permease components is, therefore, the 
likely candidate for the transport of the manno-oligosaccharides. In agreement with this 
hypothesis, the components (solute-binding protein and permease) of a putative ABC transporter 
(CalpoDRAFT_0072, CalpoDRAFT_0073, and CalpoDRAFT_0074), located upstream of the 
Man5A encoding gene, together with a GH130 gene (CalpoDRAFT_0075) were among the top 30 
upregulated genes during growth on galactomannan (Table 6.2 and Figure 6.2C). The gene 
encoding Man5A was only slightly upregulated during galactomannan utilization, suggesting that 
another mannanase may be present in the genome or the Man5A encoding gene is mostly 
constitutively expressed.      
The analysis above shows that the gene encoding CpMnBP1 (CalpoDRAFT_1212, Table 
6.2 and Figure 6.2B) was upregulated during growth on the two mannan polysaccharides used as 
energy sources in culturing C. polysaccharolyticus. To evaluate whether the ABC transporter is 
specific for manno-oligosaccharides, the gene encoding CpMnBP1 was cloned, expressed in E. 
coli, and the purified recombinant protein was tested for manno-oligosaccharide binding activity. 
The binding activity of purified CpMnBP1 (Figure 6.3) was quantified against various substrates 
using isothermal titration calorimetry (ITC). CpMnBP1 did not show any appreciable binding to 
mannose (data not shown), but bound tightly to manno-oligosaccharides with degrees of 
polymerization ranging from two to five, with increased binding correlated to increases in the 
oligosaccharide length  (Table 6.4). In ITC experiments using glucose and cello-oligosaccharides, 
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no significant binding was detected (data not shown), indicating that CpMnBP1 binds specifically 
to manno-oligosaccharides. Notably, CpMnBP1 demonstrated tight affinity for α-galactosyl 
mannotriose, a likely product generated extracellularly by the endo-acting degradation of 
galactomannan by a mannanase, such as CpMan5A. These results suggest that CpMnBP1 is part 
of an ABC transporter that is specific for both linear, as well as branched manno-oligosaccharides. 
  
The molecular basis for manno-oligosaccharide recognition by CpMnBP1 
In order to elucidate the molecular rationale for manno-oligosaccharide specificity, we 
determined the co-crystal structures of CpMnBP1 in complex with mannobiose (1.4 Å resolution) 
and with mannotriose (2.2 Å resolution,). The overall structure of CpMnBP1 consists of the di-
domain architecture that is common to oligopeptide- and oligosaccharide-specific solute-binding 
components of ABC transporters (Figure 6.4A). The first domain consists of residues Lys-15 
through Val-136 and residues Leu-303 through Asn-358, and the second domain includes Asn-
137 to Ser-302, and Asp-359 to the C-terminus. Both structures lack the first 14 amino acids, which 
were excised using trypsin in order to facilitate crystallization. Based on the structure-based 
classification of solute-binding proteins, CpMnBP1 belongs to the carbohydrate and peptide-
specific B cluster. 
A DALI search94 against the Protein Data Bank183 reveals several maltose- and trehalose-
specific solute-binding proteins to be the closest homologs, including the trehalose/maltose-
binding protein from Thermococcus litoralis (PDB code 1EU8, Z-score=37.1, r.m.s.d. of 2.9 Å 
over 370 aligned C atoms), the maltodextrin-binding component from Thermoactinomyces 
vulgaris (PDB code 2ZYM, Z-score=36.9, r.m.s.d. of 2.4 Å over 355 aligned C atoms), and the 
acarbose solute receptor from Streptomyces glaucescens (PDB code 3K00, Z-score=36.5, r.m.s.d. 
of 2.5 Å over 355 aligned C atoms). As with other solute-binding proteins, the homology exists 
only at the structural level, as CpMnBP1 shares less than 23% identity in primary sequences with 
these other proteins.  
In contrast with other solute-binding proteins, CpMnBP1 engages the manno-
oligosaccharide ligand through the non-reducing end (Figures 6.4B and C). The orientation of the 
mannobiose molecule in the 1.4 Å resolution co-crystal structure was unambiguous, and the 
hydrogen bonding interactions described below are consistent with the non-reducing end of the 
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mannan as the major binding determinant in CpMnBP1 (Figure 6.4B). The sugar-binding cleft is 
capped at one end by two -helices that converge, and residue Val341, located at the end of one 
of the helices, closes off where the terminal, non-reducing mannose is bound. This mannose 
residue is engaged between two aromatic residues (Trp25 and Trp272) that sandwich the pyranose. 
The penultimate mannose is similarly stacked against two aromatic residues (Trp86 and Trp272). 
These aromatic stacking interactions explain why CpMnBP1 requires a degree of polymerization 
of at least two manno-oligosaccharides for effective binding. Additional units of 1,4--linked 
mannose would only engaged through minimal hydrogen-bonding interactions, as reflected by the 
lack of a large increase in binding affinity for polymers of lengths between 3 and 5.  
The specificity of CpMnBP1 for manno-oligosaccharides and the inability to engage other 
sugar polymers can also be understood in the context of the co-crystal structures. In addition to the 
stacking interactions described above, a number of polar residues occupy the length of the 
oligosaccharide-binding cleft, where they engage in specific interactions with mannose units. The 
first binding site, which harbors the non-reducing end of the oligosaccharide, O-2NR of the terminal 
mannose is within hydrogen bonding distance with the indole nitrogen of Trp25 (2.9 Å) and with 
the carboxyamide oxygen of Asn307 (2.6 Å); O-3NR interacts with the carboxyamide nitrogen of 
Asn307 (2.9Å) and Asn343 (2.7 Å); and O-4NR is engaged by the oxygen of Asp129 (2.8 Å) and 
Asn343 (3.1 Å). These interactions likely dictate specificity for the non-reducing end of the chain. 
The next mannose unit is engaged through interactions between O-6 and Arg139 (3.2 Å), O-5 and 
Gln191 (3.1 Å), and O-2 (2.7 Å) with the backbone carbonyl of Asn251. Additional mannose units 
are engaged through minimal interactions, most of which are mediated through intervening solvent 
molecules. Although the binding cleft can accommodate mannose chains with a degree of 
polymerization up to five (Table 6.4), there are very few polar or aromatic residues in the vicinity 
of these additional sites. 
 In order to delineate the contributions of residues to ligand binding, we generated Ala mutants 
of residues involved in stacking interactions with the non-reducing end (Trp25 and Trp272), as 
well as those involved in hydrogen-bonding interactions (Gln191 and Asn307), and measured the 
binding of these variants to mannotetraose using ITC (Figure 6.5 and Table 6.4). The Trp272Ala 
variant demonstrated the loss of all binding affinity, while the Trp25Ala bound manno-
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oligosaccharides but with a 100-fold loss in affinity. Deletion of Asn307 results in a 17-fold loss 
in affinity while the Gln191Ala mutant is not significantly compromised. 
As noted, CpMnBP1 can also engage decorated manno-oligosaccharides with high affinity, 
and the co-crystal structures provide a rationale for this tolerance. A superposition with various 
solute-binding proteins, based on a structural alignment of secondary structural elements, reveals 
that the CpMnBP1 ligand-binding site is flanked by a large loop spanning residues Gly247 through 
Pro258 (Figure 6.6A and B). In all other members of the oligosaccharide cluster B, the ligand-
binding site is enclosed by a helix that runs parallel to the orientation of the binding cavity (Figures 
6.6B, C, D, and E). This helix occludes the binding cavity, and provides a hydrophobic cavity 
where the oligosaccharide or peptide is sequestered. The lack of this “capping helix” in CpMnBP1 
results in a ligand-binding site that is open to solvent, which can presumably accommodate manno-
oligosaccharides that contain branch decorations.  
Despite the lack of this secondary structural element, the ligand-binding site is extensively 
defined, and a cavity that can accommodate branching decorations may be modeled into this cleft 
(Figure 6.7). Lastly, we note that our calorimetric analysis demonstrates that CpMnBP1 engages 
polymeric mannose ligands with an affinity that is several orders of magnitude weaker (Ka around 
106 M-1) than is observed with other solute-binding proteins and their cognate ligands (typically 
with Ka in the range of 10
9 M-1) (Table 6.4). Presumably, this weaker binding is a result of the 
fairly open nature of the ligand binding cleft in CpMnBP1. Calorimetric analysis shows that 
CpMnBP1 binds to a branched substrate (α-galactosyl mannotriose) with an affinity similar to that 
of the undecorated counterpart (mannotriose) (Figure 6.6), suggesting that tight ligand affinity is 
compromised in order to accommodate tolerance for decorated manno-oligosaccharides.  
 
Discussion 
Mannan is a major form of hemicellulose, the second most abundant polysaccharide in 
nature after cellulose. Microbes have, therefore, developed sets of enzymes that allow them to 
release the monomeric sugars in mannans for fermentation to generate energy and cellular building 
blocks. C. polysaccharolyticus, formerly Thermoanaerobacterium polysaccharolyticum, is a 
versatile polysaccharide-degrading anaerobic bacterium. This thermophilic bacterium elaborates 
enzymes of potential biotechnological application, especially in the emerging biofuel industry.  C. 
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polysaccharolyticus was isolated from a waste pile from a corn canning factory in Illinois, USA.186 
Aside from C. polysaccharolyticus, only two other members of this genus (C. zeae and C. fijienses) 
have been successfully cultured.187 Based on 16S rDNA sequence phylogeny, C. 
polysaccharolyticus and its relatives are distantly related to the thermophilic and anaerobic genera 
Thermoanaerobacterium and Thermoanaerobacter.186 Growth on mannan polysaccharides and 
subsequent transcriptome sequencing allowed us to identify two gene clusters as the main loci 
upregulated during mannan metabolism by C. polysaccharolyticus. We have named the two gene 
clusters the Man5A and the Man5B gene clusters in recognition of the two hydrolytic enzymes 
previously characterized from these gene clusters.184,185 Our previous biochemical analysis of the 
man5A gene product, a large modular polypeptide suggests that it is anchored on the cell surface 
through three surface layer homology peptides located at the C-terminus of the polypeptide.185  
We postulate that the gene product of CalpoDRAFT_1213 or the transcriptional regulator 
in the Man5B gene cluster (Figure 6.2B) senses the manno-oligosaccharides released by Man5A 
or other endo-mannanases in the C. polysaccharolyticus genome and facilitates transcription of 
other genes located in the same cluster. The Man5B polypeptide lacks an obvious signal peptide 
and is likely located in the cytoplasm. The man5b gene is also located upstream of the 
transcriptional regulator, and based on the RNAseq data it may be regulated differently or 
expressed constitutively to catalyze the hydrolysis of the manno-oligosaccharides produced by 
CpMan5A. Our previous biochemical analysis demonstrated that CpMan5B does not hydrolyze 
mannobiose, but does hydrolyze mannotriose, mannotetraose, and mannopentaose to mannose and 
mannobiose. Furthermore, CpMan5B released mannose from galactosyl-mannotriose.184,188 
Interestingly, within each of the Man5A and Man5B gene clusters is located a putative GH130, a 
newly characterized glycoside hydrolase family. The two polypeptides encoded by the GH130 
genes share 99 % identity and they lack identifiable signal peptides.  The gene products, therefore, 
likely function together with Man5B in the cytoplasm to degrade the manno-oligosaccharides 
released from mannan by Man5A. We hypothesized that the GH130 polypeptides possess manno-
oligosaccharide phosphorylase activity and thus release D-mannosyl 1-phosphate (Man1P) 
from manno-oligosaccharides. This metabolic pathway for mannan has been described for 
Bacteroides fragilis 189 and Ruminoccocus albus 7,190 where phosphomannose mutase and 
mannose-6-phosphate isomerase convert the Man1P to fructose-6-phosphate, which can then enter 
155 
 
the glycolytic pathway for metabolism. Our preliminary biochemical analysis of the recombinant 
form of the GH130 located in the Man5B gene cluster confirmed that it possesses manno-
oligosaccharide phosphorylase activity (unpublished data), and based on the high identity with the 
homolog in the Man5A cluster, the two GH130 proteins are likely to harbor the same enzymatic 
activity. Thus, the upregulation of the GH130 alone (Figure 6.2B and Figure 6.2C) may be 
sufficient for channeling the manno-oligosaccharides, released by Man5A and other mannanases, 
into the glycolytic pathway for metabolism.  
It is also important to note that the RNAseq analysis of the two GH130 is not entirely clear 
in the present report, since the two genes (GH130 located in Man5A and Man5B gene clusters) 
are 98% identical at the nucleotide level. Irrespective of the confounding data presented by their 
almost identical nucleotide sequence, the results suggest that the GH130 genes are critical for 
mannan utilization by C. polysaccharolyticus.  
Aside from the hydrolytic enzymes, each gene cluster contains the components of a 
putative multi-protein membrane integral ATP-dependent transporter, i.e., CalpoDRAFT_1210, 
CalpoDRAFT_1211 and CalpoDRAFT_1212 for the Man5B gene cluster and 
CalpoDRAFT_0072, CalpoDRAFT_0073 and CalpoDRAFT_0074 for the Man5A gene cluster 
(Table 2 and Figure 2B and 2C). A plausible periplasmic substrate-binding domain of the ABC 
transporter in the Man5B gene cluster (CpMnBP1) specifically binds manno-oligosaccharides and 
was upregulated during fermentation of both glucomannan and galactomannan (Table 2). The 
results thus suggest that the ABC transport system is for the internalization of manno-
oligosaccharides, and CpMnBP1 may be a cognate solute binding protein of the transporter. This 
system is analogous to the mechanism for xylan utilization employed by C. polysaccharolyticus, 
suggesting a conserved strategy for polysaccharide fermentation by this organism. Furthermore, 
other Gram-positive bacteria possessing SLH repeat-associated polysaccharide utilization 
functions have been shown to employ a similar strategy for xylan utilization 191. This observation 
suggests that the route described for sugar processing by C. polysaccharolyticus is widespread in 
bacteria. 
The most similar protein to CpMnBP1 in the GenBank database is a putative extracellular 
solute-binding protein from Thermoanaerobacter mathranii (Tmath_1701), which shares just 37% 
amino acid sequence identity. To the best of our knowledge, the only solute-binding protein of an 
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ABC transporter with manno-oligosaccharide binding properties is the MalE1 protein from 
Thermotoga maritima. MalE1 optimally binds mannotetraose, and its expression is induced by 
mannans. Despite the similar manno-oligosaccharide binding activity, TmMalE1 and CpMnBP1 
share only 26% amino acid sequence identity. Unlike typical oligosaccharide-specific solute-
binding proteins, CpMnBP1 engages mannan sugars through the non-reducing end. While 
unexpected, such a binding mode is not without precedent as the family 32 carbohydrate-binding 
module from C. thermocellum is demonstrated to similarly engage manno-oligosaccharides 
through the nonreducing end 192. Likewise, structural studies of the family 6 carbohydrate-binding 
module reveal that -1,3-glucan chains are targeted through the nonreducing end of the saccharide 
193. 
The inversion in binding mode provides a rationale for understanding why CpMnBP1 does 
not bind cello- or xylo-oligosaccharides with any appreciable affinity. Docking of the cellotriose 
model with the non-reducing end poised at the end of the cleft results in clashes with the Trp 
residues that form the aromatic sandwich. Likewise, docking of a xylotriose model results in 
similar clashes, providing an explanation of why CpMnBP1 precludes the binding of these sugars. 
One possible reason why CpMnBP1 binds to the non-reducing ends of manno-oligosaccharides 
may be to facilitate the import of structurally diverse mannan degradation products, such as branch 
decorations on the -1,4-linked mannose backbone. Calorimetric studies demonstrate that 
decorated substrates bind with equal affinity to CpMnBP1, and the open nature of the binding site 
allows for capture of branched substrates. The results of the mutational data can be similarly 
reconciled in the context of the crystal structures. The severe loss in binding affinity with the 
Trp272Ala mutant, compared to the 100-fold loss in the Trp25Ala variant, is probably the 
consequence of Trp272 forming one entire face of the aromatic stacking platform, while the role 
of Trp25 in forming the other face is redundant with Trp86. Likewise, the nearly 17-fold loss in 
activity with the Asn307Ala variant (compared to the insignificant loss with mutations at other 
hydrogen-bonding residues) may be due to Asn307 engaging in interactions with multiple 
hydroxyls of the substrate. 
The manno-oligosaccharide degradation gene cluster described here encodes the necessary 
constellation of activities required for manno-oligosaccharide hydrolysis and import of the 
resultant oligosaccharide products across the cell membrane. Moreover, the manno-
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oligosaccharide-specific response regulator is predicted to coordinate the expression of these genes 
in response to high extracellular concentration of mannans. Thus, the entire gene cluster can be 
utilized as a cassette for the transfer of manno-oligosaccharide degradation activity into 
ethanologenic organisms for bioenergy production.
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Figures 
 
 
 
 
 
 
Figure 6.1 Chemical structure of acetylated galacto-glucomannan demonstrating the 
complexity of the polysaccharide. The various enzymatic activities necessary for depolymerization 
into monomeric sugars are shown in shaded boxes. 
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Figure 6.2 Growth on mannan substrates and their sugar components and transcriptome map 
of the highly induced gene clusters. A: Growth of C. polysaccharolyticus on mannan 
polysaccharides and monomeric sugars with time.  B and C: Transcriptional analysis showing 
RNAseq coverage of two gene clusters (B: Man5B cluster and C: Man5A cluster), which contained 
the most highly upregulated genes during growth of C. polysaccharolyticus with galactomannan, 
glucomannan, glucose and mannose. Gene annotations and open reading frame numbers were 
determined by the Joint Genome Institute (JGI). 
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Figure 6.3 Isothermal titration calorimetry (ITC) of linear and branched manno-
oligosaccharide binding by CpMnBP1. Binding isotherms and representative curves for CpMnBP1 
showing that the affinity for linear mannotriose (A) is similar to that for the branched ligand α-
galactosyl mannotriose (B).  
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Figure 6.4 Co-crystal structures of CpMnBP1-mannooligosaccharide complexes. (A) Ribbon 
diagram of the overall structure of CpMnBP1 showing the two-domain architecture common to all 
solute-binding proteins, colored in green and pink. The mannobiose ligand is shown as a yellow 
ball-and-stick figure. (B) Difference Fourier electron density maps (contoured at 3 over 
background) calculated with coefficients Fobs – Fcalc at the ligand-binding site for the CpMnBP1-
mannobiose complex. The map was calculated from model phases with the coordinates of the 
ligand removed prior to a round of simulated annealing crystallographic refinement. The 
coordinates of the final refined model are superimposed. The color scheme for the protein residues 
follows as per panel A and residues that interact with the oligosaccharide are shown as stick 
figures. (C). Difference Fourier electron density maps (contoured at 3 over background) at the 
ligand-binding site for the CpMnBP1-mannotriose complex. 
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Figure 6.5 Isothermal titration calorimetry (ITC) of mannotetraose binding by variants of 
CpMnBP1. Binding isotherms and representative curved for CpMnBP1 showing that the affinity 
for mannotetraose to the following CpMnBP1 variants (A) Trp272Ala (B) Trp25Ala (C) 
Gln191Ala, and (D) Asn307Ala.  
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Figure 6.6 Comparison of the ligand pockets of various solute-binding proteins. A close-up 
view of the active site and a solvent accessible surface representation of the solute-binding pockets 
of (A,B) CpMnBP1 (in pink and green), in comparison with those of (C, D) the trehalose/maltose 
binding protein from Thermococcus litoralis (in brown, PDB code 1EU8), and (E, F) the xylan 
binding protein from C. polysaccharolyticus (in green, PDB code 4G68). The bound 
oligosaccharides are shown in CPK representation and the “capping helix” or equivalent structural 
element are colored in blue. 
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Figure 6.7 Model for binding of branched substrates by CpMnBP1. (A) A close-up view of 
the active site and (B) the solvent accessible surface of a hypothetical model of a branched 
mannotriose ligand bound in the ligand-binding pocket of CpMnBP1. The oligosaccharide is 
shown in CPK representation with the branching carbon atoms colored in cyan. 
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Tables 
 
Table 6.1 Data collection, phasing and refinement statistics 
 
 CpMnBP1-Mannobiose CpMnBP1-Mannotriose 
      
Data collection   
Space Group P21 P21 
a, b, c (Å),  (o) 53.7, 62.2, 60.0, 116.5 63.3, 101.7, 67.8, 116.7 
Resolution (Å)1 50-1.4 (1.42-1.4) 50-2.2 (2.28-2.2)  
Rsym (%)
2 8.4 (19.9) 8.3 (44.1) 
I/σ(I) 12.3 (4.8)  14.3 (2.0) 
Completeness (%) 98.2 (96.1)  96.2 (80.9) 
Redundancy 3.2 (3.0) 2.7 (1.9) 
 
Phasing Statistics 
FOM (after DM) 
 
Refinement 
0.469 (0.659)  
Resolution (Å) 25.0-1.4  25.0-2.2 
No. reflections 64,702 35,483 
Rwork / Rfree
4 18.3/21.3  20.1/26.5 
 
Number of atoms 
  
Protein 2948 6052  
Oligosaccharide 23  66 
Water  631  382 
 
B-factors 
  
Protein 14.2  32.5  
Oligosaccharide  9.2 24.7 
Water  28.1 36.8 
 
R.m.s deviations 
  
Bond lengths (Å) 0.004 0.01 
Bond angles () 0.983 1.36 
 
1. Highest resolution shell is shown in parenthesis. 
2. Rsym =  |(Ii - <Ii> |  Ii where Ii = intensity of the ith reflection and <Ii> = mean intensity. 
3. Mean figure of merit (acentric and centric) 
4. R-factor = (|Fobs|-k|Fcalc|)/ |Fobs| and R-free is the R value for a test set of reflections consisting of a 
random 5% of the diffraction data not used in refinement. 
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Table 6.2 C. polysaccharolyticus genes expressed greater than 10-fold on galactomannan 
relative to mannose. 
 
   
 GalMan/
Man 
GluMan/
Man 
JGI Locus # 
Genbank 
accession # 
Predicted Annotation 
CAZy Family Fold 
Change 
Fold 
Change 
CalpoDRAFT_1210 WP_026486531.1 ABC transport system, permease  392 337 
CalpoDRAFT_1211 WP_026486532.1 ABC transport system, permease  331 286 
CalpoDRAFT_1212 
(MnBP1) 
WP_026486533.1 
ABC transporter, solute-binding 
protein 
 217 126 
CalpoDRAFT_1209 WP_026486530.1 
mannooligosaccharide 
phosphorylase 
GH130 155 137 
CalpoDRAFT_0074 WP_026485573.1 ABC transport system, permease  52.7 -2.56 
CalpoDRAFT_0073 WP_026485572.1 ABC transport system, permease  40.2 -3.69 
CalpoDRAFT_0072 WP_026485571.1 
ABC transporter, solute-binding 
protein 
 35.5 -5.62 
CalpoDRAFT_0077 WP_026485576.1 hypothetical protein  29.0 -3.05 
CalpoDRAFT_1696 WP_026486920.1 ABC transport system, permease  24.4 -17.2 
CalpoDRAFT_1695 WP_026486919.1 ABC transport system, permease  22.1 -16.7 
CalpoDRAFT_0076 WP_026485575.1 man5A CBM16/GH5 21.9 -3.81 
CalpoDRAFT_0075 WP_026485574.1 
mannooligosaccharide 
phosphorylase 
GH130 20.0 -1.99 
CalpoDRAFT_0941 WP_026486300.1 FkbM family methyltransferase  19.2 14.9 
CalpoDRAFT_1697 WP_026486921.1 
ABC transporter, solute-binding 
protein 
 18.0 -61.5 
CalpoDRAFT_2316 WP_026487474.1 hypothetical protein  15.8 5.04 
CalpoDRAFT_1694 WP_026486918.1 beta-galactosidase GH2 13.4 -19.7 
CalpoDRAFT_0665 WP_026486058.1 
adenosylmethionine-8-amino-7-
oxononanoate aminotransferase 
 13.2 3.64 
CalpoDRAFT_0940 WP_026486299.1 glycosyl transferase GT4/GT2 13.0 11.1 
CalpoDRAFT_2141 WP_026487319.1 ABC transport system, permease  12.4 -2.39 
CalpoDRAFT_1996 WP_026487187.1 
galactose-1-phosphate 
uridylyltransferase 
 12.4 -1.32 
CalpoDRAFT_1213 WP_026486534.1 LacI family transcriptional regulator  11.9 11.9 
CalpoDRAFT_2317 WP_026487475.1 glycosyl transferase GT2 11.7 4.46 
CalpoDRAFT_2142 WP_026487320.1 ABC transport system, permease  11.6 -1.77 
CalpoDRAFT_2318 WP_026487476.1 hypothetical protein  11.0 4.42 
CalpoDRAFT_0872 WP_026486242.1 argininosuccinate synthase  10.9 2.42 
CalpoDRAFT_1692 WP_026486916.1 ABC transport system, permease  10.8 -40.2 
CalpoDRAFT_1844 WP_026487052.1 ammonium transporter  10.8 2.77 
CalpoDRAFT_0871 WP_026486241.1 argininosuccinate lyase  10.5 2.28 
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Table 6.3 Bacterial Growth Characteristics under Various Substrates. 
 
 
 
Growth 
Substrate 
OD600 
maximum 
Growth ratea 
(h-1) 
Doubling timeb 
(h) 
Glucose 0.59 ± 0.009 0.37 ± 0.04 1.9 ± 0.2 
Mannose 0.43 ± 0.007 0.19 ± 0.04 3.9 ± 0.8 
Glucomannan 0.57 ± 0.02 0.46 ± 0.1 1.6 ± 0.5 
Galactomannan 0.57 ± 0.008 0.45 ± 0.08 1.6 ± 0.3 
 
a Growth rates were calculated using the following equation: µ=ln(ODt2/ODt1)/(t2-
t1) 
b Doubling times (or generation times) were calculated using the following 
equation: G=ln(2)/µ 
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Table 6.4 Binding parameters for Wild-Type and Mutant CpMnBP1 interaction with 
oligosaccharides. 
 
 N Ka (x 106) 
G 
(kJ/mol) 
H 
(kJ/mol) 
S 
(kJ/mol) 
Mannobiose 0.94±0.002 3.30±0.184 -37.2 -81.9±0.34 -44.66 
Mannotriose 1.08±0.001 6.39±0.275 -38.9 -70.6±0.17 -31.69 
Mannotetraose 1.14±0.003 8.77±0.975 -39.8 -83.7±0.47 -43.91 
Mannotetraose 
(65 oC) 
0.862±0.008 1.86±0.39 -40.6 -138.9±2.2 -98.33 
Mannopentaose 0.861±0.002 9.32±0.882 -39.6 -79.5±0.41 -39.92 
Trp272Ala n.d. n.d. n.d. n.d. n.d. 
Trp25Ala 0.751±0.05 0.028±0.003 -25.3 -78.6±7.58 -53.27 
Gln191Ala 0.835±0.003 6.44±0.685 -38.8 -72.3±0.47 -33.43 
Asn307Ala 0.680±0.015 0.116±0.009 -28.9 -79.5±2.52 -50.65 
 
n.d. – could not be determined as isotherms did not indicate any significant binding. 
Data for mutants were collected using mannotetraose as the ligand. 
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Table 6.5     RNAseq mapping results 
 
 
RNAseq 
Sample ID 
Total reads 
Reads after 
Trimminga Uniquely mapped 
readsb (%) 
Non-specifically mapped 
reads (%) 
Unmapped 
reads (%) 
(avg. length) (avg. length)  
Glu_1 
27,144,132 
(100 nt) 
27,142,479 
(98.1 nt) 
21896756 
(80.7%) 
146706 
(0.5%) 
5099017 
(18.8%) 
Glu_2 
23398702 
(100 nt) 
23397193 
(98.1 nt) 
19166231 
(81.9%) 
160003 
(0.7%) 
4070959 
(17.4%) 
Man_1 
18539716 
(100 nt) 
18538613 
(97.9 nt) 
14737872 
(79.5%) 
297683 
(1.6%) 
3503058 
(18.9%) 
Man_2 
19986983 
(100 nt) 
19985820 
(98.1 nt) 
16100278 
(80.6%) 
297604 
(1.5%) 
3587938 
(18.0%) 
GluMan_1 
19371626 
(100 nt) 
19370646 
(98.1 nt) 
14145889 
(73.0%) 
141438 
(0.7%) 
5083319 
(26.2%) 
GluMan_2 
19134272 
(100 nt) 
19132985 
(98.3 nt) 
15344904 
(80.2%) 
131959 
(0.7%) 
3656122 
(19.1%) 
GalMan_1 
21673902 
(100 nt) 
21670903 
(98.0 nt) 
17476983 
(80.6%) 
112665 
(0.5%) 
4081255 
(18.8%) 
GalMan_2 
25329774 
(100 nt) 
25328422 
(98.0 nt) 
19904504 
(78.6%) 
117245 
(0.5%) 
5306673 
(21.0%) 
a Reads were trimmed using CLC Genomics Workbench v5.5.1 with a quality score limit of 0.05 and maximum number of ambiguities of 2 
b Reads were mapped to the C. polysaccharolyticus KMTHCJ genome using CLC Genomics Workbench v5.5.1 with a minimum length fraction 
of 0.9, a minimum similarity fraction of 0.8, and maximum number of hits for a read of 10. 
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Chapter 7 Xylan utilization in human gut commensal bacteria is orchestrated by unique 
modular organization of polysaccharide-degrading enzymesvi 
 
Introduction 
The human lower gastrointestinal tract is home to trillions of bacteria that equip humans 
with biological activities that are absent in human cells.194–196 The microbes within the human 
lower gut perform a wide variety of functions important for normal physiology, including 
promoting maturation of the immune system,197 development of the gastrointestinal tract (GIT),198 
and improving energy capture from dietary components.199 Moreover, dysbiosis of the microbiota 
is associated with various diseases including inflammatory bowel disease,200 obesity,201 and 
atherosclerotic cardiovascular disease.202,203 The importance of the microbial community in the 
GIT to human health has prompted analysis of gut bacteria on a massive scale. Using recent 
advances in DNA sequencing technologies, investigators have captured the diversity of organisms 
in these complex microbial assemblages204,205 and have generated enormous catalogs of microbial 
genes.194,196,206 However, the rapid accumulation of DNA sequences has far surpassed our ability 
to assign function to genes. Indeed, approximately 75% of genes encoded by the gut microbiota 
have gene products that cluster into unknown orthologous groups or represent entirely novel 
protein families.196 
One of the most important functional roles specific to the lower gut microbiota is the 
degradation and fermentation of dietary fiber that is resistant to digestion by human enzymes. The 
enzymes involved in breaking down polysaccharides are members of carbohydrate active enzymes 
(CAZymes) and are categorized into families of carbohydrate binding modules (CBMs), 
carbohydrate esterases (CEs), glycoside hydrolases (GHs), glycoside transferases (GTs), or 
polysaccharide lyases (PLs).207 The CAZy gene catalog of the human genome pales in comparison 
with that of the gut microbiota, which exceeds the total number of human CAZymes by at least 
600-fold.208 This observation suggests that humans rely heavily on their gut microbes to extract 
energy from dietary carbohydrates,209 especially in their lower gastrointestinal tract. Despite the 
                                                          
vi This chapter is adapted from the following published article: 
Zhang, M.*, Chekan, J. R.*, Dodd, D.*, Hong, P.-Y., Radlinski, L., Revindran, V., Nair, S. K., Mackie, R. I., and 
Cann, I. (2014) Xylan utilization in human gut commensal bacteria is orchestrated by unique modular organization of 
polysaccharide-degrading enzymes. Proc. Natl. Acad. Sci. U. S. A. 111, E3708–17 
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importance of these genes in energy capture by the gut microbiota, very little is known of the 
function of their encoded polypeptides.  
Xylan is the second most abundant structural polysaccharide in plant cell walls and is 
particularly high in cereal grains, a significant component of the human diet.210 Moreover, the 
digestibility rates of xylan in the human GIT are estimated at about 72%211. Of the bacteria in the 
human gut, the genus Bacteroides possesses the most expanded glycolytic gene repertoires that 
target xylan degradation.212,213 These organisms employ a highly specialized system consisting of 
a core set of polysaccharide binding proteins, outer membrane transporters, and glycolytic 
enzymes to cleave large polysaccharides into oligosaccharides that are then transported by TonB-
dependent transporters into the periplasm. An arsenal of glycolytic enzymes then converts the 
oligosaccharides into fermentable monosaccharides.214 The xylan utilization system (XUS) 
appears to be conserved across xylan-degrading Bacteroidetes from different gastrointestinal 
systems,213,215 but the roles of individual genes in the gene cluster have not been defined. 
Xylan degradation is not universally shared by the Bacteroidetes in the human gut, rather 
this capacity varies among different species and even between different strains. As recently 
reviewed,213 human gut Bacteroides which have the capacity to degrade xylan include strains of 
B. eggerthii, B. cellulosilyticus, B. intestinalis, B. ovatus, and B. xylanisolvens. Partial genome 
sequences for several strains of these bacteria are present in the publicly available databases, such 
as the NCBI GenBank. Among these xylanolytic bacteria, B. ovatus ATCC 8483 and B. intestinalis 
DSM 17393 stand out from all other gut bacteria sequenced to date as having the most highly 
expanded complement of CAZymes.216 B. intestinalis DSM 17393 was isolated from fecal samples 
of Japanese volunteers using a selective medium for polyamine producing bacteria.217 The 
organism has a large (~60 kb) region of its genome dedicated to xylan degradation. B. ovatus 
ATCC 8483 is an abundant human commensal bacterium, genetically distinct from B. intestinalis 
DSM 17393 but also contains a large number of xylan-degrading genes. A recent study 
demonstrated that a large number of B. ovatus xylanolytic genes are induced during growth with 
xylan.212 Furthermore, a hybrid two component system regulator whose periplasmic sensing 
domain binds xylo-oligosaccharides was identified adjacent to the highly induced xylanolytic 
genes, suggesting a role in the transcriptional response to xylan. Despite the vast diversity of xylan-
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degrading genes in these two organisms, very little is known about the specific roles of the 
individual genes in xylan utilization. 
In the current study, we used whole transcriptome sequencing to guide the study of genes 
with roles in xylan degradation by the two human gut commensal bacteria B. intestinalis DSM 
17393 and B. ovatus ATCC 8483. The most highly up-regulated genes encode BiXyn10A and 
BACOVA_04390, two polypeptides with an unusual modular organization that is widespread, 
especially in the human lower gut Bacteroidetes. The transcriptome data from another gut 
Bacteroidetes (the ruminal bacterium Prevotella bryantii B14) showed that a gene encoding a 
polypeptide with similar architecture to BiXyn10A and BACOVA_04390 is the most highly up-
regulated CAZy gene when the bacterium is metabolizing xylan.215 BiXyn10A and 
BACOVA_04390 are linked to a xylan utilization core cluster of genes that seem invariant in the 
genomes of xylan degrading Bacteroidetes. Here, we present the structure/function analyses of 
BiXyn10A, a member of the Bacteroidetes cardinal xylan degradation enzymes, and show that the 
enzyme and its homologs harbor a novel group of carbohydrate binding modules that impact their 
capacity to degrade xylans. Our results provide an important framework for understanding xylan 
catabolism in the Bacteroidetes, a significant group of human gut commensal bacteria.  
 
Experimental Procedures 
Materials 
The human gut bacterial isolate Bacteroides intestinalis DSM 17393 was obtained from 
the German Collection of Microorganisms and Cell Cultures (DSMZ) and Bacteroides ovatus 
ATCC 8483 was obtained from the American Type Culture Collection (ATCC). Escherichia coli 
XL10 and BL21-CodonPlus(DE3) RIPL competent cells and the PicoMaxx high-fidelity DNA 
polymerase were purchased from Stratagene (La Jolla, CA). The pET-46 Ek/LIC kit was obtained 
from Novagen (San Diego, CA). The QIAprep Spin Miniprep, RNAprotect, RNase-free DNase, 
and RNeasy kits were obtained from Qiagen (Valencia, CA). The Talon Metal Affinity resin was 
obtained from Clontech Laboratories Inc. (Mountain View, CA). The QuikChange Lightening 
Multi-Site Directed Mutagenesis kit was obtained from Agilent (Santa Clara, CA). The xylo-
oligosaccharides, glucotetraose A-C, xyloglucanoheptaose, arabinan (sugar beet), debranched 
arabinan (sugar beet), konjac glucomannan, lichenan (Icelandic moss), galactan (potato), 
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arabinogalactan (larch), xyloglucan (tamarind seed) 1,4-β-D-mannan and medium viscosity wheat 
arabinoxylan (WAX) were purchased from Megazyme (Bray, Ireland). Carboxymethyl cellulose 
was purchased from Acros Organic (Fair Lawn, NJ). Laminarin, oat spelt xylan, and all other 
reagents were of the highest possible purity and were purchased from Sigma-Aldrich (St. Louis, 
MO). 
 
Growth of B. intestinalis DSM 17393, B. ovatus ATCC 8483 and isolation of RNA 
B. intestinalis or B. ovatus cells were cultured anaerobically at 37 C in a modified basal 
cellulolytic (BC) medium218 (Table 7.1) with 0.5% w/v glucose. At an optical density of ~1, 100 
l of culture was inoculated into the modified BC medium in duplicate with either 0.5% w/v wheat 
arabinoxylan or xylose as the main carbohydrate source. The optical density at 600 nm wavelength 
was monitored using a Spectronic 20D (ThermoFisher Scientific, Waltham, MA) over a period of 
27 h. At mid-log phase of growth (OD600nm = 0.4), 50 ml of each culture was removed, combined 
with two volumes of RNAprotect, and RNA was extracted using the RNeasy mini kit based on the 
manufacturer’s protocol. The optional on-column DNase treatment was performed to ensure total 
removal of DNA. The RNA was then quantitated using a Qubit RNA assay kit (Invitrogen, Grand 
Island, NY) and stored at -80C until RNA-sequencing as described in our earlier report.215 
 
Library preparation, RNA sequencing, and expression analysis 
Ribosomal RNA was removed from 1g of total RNA using the Ribo-Zero rRNA removal 
Meta-bacteria kit (Epicentre Biotechnologies, Madison, WI). The mRNA-enriched fraction was 
converted to indexed RNAseq libraries with the TruSeq RNA Sample Prep kit (Illumina, San 
Diego, CA), and the final libraries were pooled in equimolar concentrations and quantitated by 
qPCR (Library Quantification kit, Kapa Biosystems, Woburn, MA). 
Four libraries were prepared from two biological replicates of each culture medium 
(WAX1, WAX2, Xyl1, and Xyl2) and RNAseq data were analyzed using CLC Genomics 
Workbench v5.0 (CLC Bio, Cambridge, MA) as outlined in our previous report215. The RNAseq 
output files were then analyzed for statistical significance by using the proportion-based test of 
Baggerly et al.182 A summary of the read mapping statistics is provided in Table 7.2. 
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Gene cloning, site-directed mutagenesis, gene expression and protein purification 
All genes cloned for expression were amplified from Bacteroides intestinalis DSM 17393 
genomic DNA by PCR using the primers listed in Table 7.3 (constructs listed in Figure 7.1). The 
cloning of the correct PCR amplicons into pET-46b vector, over-expression of the genes and site-
directed mutagenesis were as described in our earlier report.215 The recombinant proteins in the 
cell lysates were purified with Talon metal affinity resin215 and the purity was assessed by SDS-
PAGE. The protein concentrations were determined by the method of Gill and von Hippel based 
on the molecular mass and computed extinction coefficients.219 
 
Hydrolysis of polysaccharides 
Hydrolysis of xylo-oligosaccharides and the natural substrates, wheat arabinoxylan (WAX) 
and oat spelt xylan (OSX) by BiXyn10A was performed at 37 °C for 16 or 24 h in citrate buffer 
(50 mM citrate, 150 mM NaCl, pH 5.5). Hydrolysis of the natural substrates, wheat arabinoxylan 
(WAX) and oat spelt xylan (OSX) by the BiXyn10A WT and its mutants were performed at 37 °C 
for 48 h in citrate buffer (50 mM citrate, 150 mM NaCl, pH 5.5) to determine the influence of 
residues essential for binding of the CBMs in BiXyn10A on hydrolysis of xylan. The end products 
of hydrolysis were analyzed by thin-layer chromatography (TLC), reducing sugar assays, and high 
performance anion exchange chromatography (HPAEC), all as described previously.184 
 
Affinity gel electrophoretic mobility assays (AGE) 
Assays to monitor the binding activity of the proteins were performed according to Tomme 
et al220 with minor modifications. The stacking gel contained 3% acrylamide in 1.5M Tris-HCL 
buffer (pH 8.3). Each protein (1 g) was loaded in a native gel (12% acrylamide) containing WAX 
(0.1%) or a control gel without WAX, and the gels were electrophoresed simultaneously at 4 °C 
at 100 V for 6 hours. The gels were then stained with Coomassie Brilliant Blue G-250 for protein 
visualization. 
 
Isothermal Titration Calorimetry (ITC) 
The ITC measurements were performed using a VP-ITC microcalorimeter with a 1.4 mL 
cell volume from MicroCal Inc. (Northampton, UK). The proteins were exchanged into phosphate 
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buffer (50 mM sodium phosphate, 150 mM NaCl, pH of 7.0) by dialysis, and the oligosaccharide 
ligands were dissolved in the same buffer. The proteins (50 µM) were then injected with 28 
successive 10-µl aliquots of 2 mM ligand at 300 second intervals. The data were fitted to a 
nonlinear regression model using a single binding site (MicroCal Origin software). The 
thermodynamic parameters were calculated using the Gibbs free energy equation (G=H-TS), 
and the relationship G=-RTlnKa. 
 
Crystallography Studies 
Both BiXyn10A CBM1 and PbXyn10C CBM were crystallized by screening with sparse 
matrix conditions followed by optimization. Specifically, BiXyn10A CBM1 crystals were 
optimized to 42 mg/mL at 23 C using a mother liquor of 2.5 M ammonium sulfate and 0.1 M 
bicine pH 9.0. Crystals were soaked in mother liquor containing 30% (wt/vol) threitol prior to 
vitrification in liquid nitrogen. Co-crystals of BiXyn10A CBM1 with xylohexaose were grown at 
23 C with 30 mg/mL protein and 5 mM xylohexaose with a mother liquor of 1.6 M sodium citrate 
tribasic dehydrate pH 6.5.  Crystals were directly frozen into liquid nitrogen. PbXyn10C CBM was 
optimized to yield crystals at 4 C and 5 mg/mL protein using mother liquor containing 2.0 M 
ammonium sulfate, 0.1 M sodium chloride, and 0.1 M sodium cacodylate pH 6.5.  Briefly before 
vitrification, crystals were soaked in 30% (wt/vol) trehalose to serve as a cyroprotectant. X-ray 
diffraction data were collected at the Life Science Collaborative Access Team, Sector 21, Argonne 
National Laboratory for crystals of both BiXyn10A CBM1 and PbXyn10C CBM. 
 
Structure Determination and Refinement 
To phase BiXyn10A CBM1, anomalous signal was collected from crystals soaked with 1 
mM 4-chloromercuribenzoic acid (PCMB) for 4 hours at 23 C. After soaking, PCMB-derived 
crystals were treated identical to native crystals. PbXyn10C CBM was phased using 
selenomethionine containing protein crystals grown at 4 C with 30 mg/mL protein containing a 
mother liquor of 1.2 M sodium phosphate monobasic, 0.8 M potassium phosphate dibasic, 0.2 M 
lithium sulfate, and 0.1 M CAPS pH 10.5 vitrified in mother liquor containing 20% (wt/vol) 
threitol. Data was indexed and scaled using HKL2000 or autoPROC.87  Phasing was accomplished 
using the AutoSol package from the software PHENIX suite.88 Solutions from AutoSol were 
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automatically built using ARP/warp.89 The structures were further refined using a combination of 
COOT,90 REFMAC5,91 and PHENIX refine.88 
 
Synergy of BiXyn10A with other up-regulated enzymes 
The capacity to depolymerize xylan polysaccharides by the gene products of the three most 
highly up-regulated genes was examined with WAX and OSX as substrates by measuring release 
of reducing ends at 37 °C for 24 h. Reactions were initiated by addition of enzymes (50 nM each, 
final concentration) and reaction end products were subjected to HPAEC as described in our earlier 
report.215 Arabinose, xylose, xylobiose, and xylotriose were injected as standards. 
 
Results 
Transcriptional analysis of B. intestinalis DSM 17393 and B. ovatus ATCC 8483 reveals an 
extensive repertoire of carbohydrate active enzymes 
Within the human gut bacterium B. intestinalis DSM 17393, 67 genes are highly up-
regulated during growth on the complex polysaccharide wheat arabinoxylan (WAX) (Table 7.4) 
compared to growth on the monosaccharide xylose. Twenty-six of the up-regulated genes are 
predicted to encode CAZymes belonging to GH and CE families, and a number of the encoded 
proteins exhibited unusual modular arrangements (Figure 7.2A). Most of the up-regulated 
CAZymes possess N-terminal signal peptides, suggesting that they are transported to the periplasm 
or outer membrane during xylan metabolism. The most highly induced CAZy gene 
(BACINT_04215) was up-regulated by 170-fold and encodes a modular enzyme defined by a 
GH10 polypeptide interrupted by an amino acid sequence with low similarity to hitherto 
characterized polypeptides. The next most highly up-regulated gene encodes a GH43 protein 
(BACINT_00570), followed by two genes encoding polypeptides with unusual arrangements of 
GH43 and GH10 modules. The arrangement of the catalytic modules between these two bi-
modular proteins has been flipped, with one having a GH43/GH10 arrangement (BACINT_00569) 
and the other a GH10/GH43 arrangement (BACINT_04202). An unexpected architectural 
arrangement common to the polypeptides encoded by several of the up-regulated genes consisted 
of GH modules inserted within or linked to CE modules, suggesting that the corresponding gene 
products attack both the ester-linked side chains and the sugar backbone. Thus the transcriptome 
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analysis revealed a great diversity in the modularity of the polysaccharides encoded by B. 
intestinalis genes, indicating a highly versatile capacity in xylan degradation. 
A total of 63 genes were up-regulated by B. ovatus ATCC 8483 during growth on xylan 
relative to xylose (Table 7.5). These genes included a similarly expansive complement of CAZy 
genes possessing unique domain arrangements to B. intestinalis DSM 17393 (Figure 7.2B). 
Notable differences between the induced CAZy gene sets include the lack of GH8 enzyme 
induction by B. ovatus ATCC 8483, a reduced number of GH10 endo-xylanases, and the presence 
of two GH115 α-glucuronidases not encoded by B. intestinalis DSM 17393. Importantly, the most 
highly induced CAZy gene for both B. ovatus ATCC 8483 and B. intestinalis DSM 17393 encodes 
an enzyme having the same predicted domain arrangement (BACINT_04215, BACOVA_04390). 
Understanding of the biochemistry of BACINT_04215 and BACOVA_04390 should enhance our 
understanding of xylan hydrolysis and fermentation by the two gut bacteria, and in the ensuing 
analysis we focused on the B. intestinalis homolog.  
 
The most highly up-regulated CAZy gene encodes an endo-xylanase 
In B. intestinalis, the most highly up-regulated genes are contained within a single 
transcriptional unit comprising BACINT_04220-04215 (Figue 7.3A). This gene cluster consists of 
two tandem repeats of SusC and SusD orthologs, predicted to encode TonB-dependent outer 
membrane porins (XusA/C) and polysaccharide binding proteins (XusB/D), respectively. 
Downstream of these genes is a hypothetical protein, followed by Bixyn10A. Given the unique 
domain architecture of BiXyn10A (Figure 7.2A) and the fact that it is the most highly induced 
CAZy gene, we characterized the biochemical properties of this protein. The gene product of 
Bixyn10A was purified to near homogeneity and incubated with the WAX substrate used in the 
RNAseq experiment and also with the insoluble substrate oat spelt xylan (OSX). As shown in 
Figure 7.3B, the polypeptide released reducing ends from both substrates. End product analysis, 
using thin layer chromatography, revealed oligosaccharides (Figure 7.3C), verifying that the 
protein possesses endo-xylanase activity. A mutation in a glutamate (E654A) corresponding to the 
highly conserved catalytic nucleophile in GH10 proteins abolished hydrolytic activity on xylan 
substrates (Figure 7.3B-D), indicating that catalytic activity was restricted to the GH10 sequence, 
and independent of the 250 amino acid insertion sequence. 
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Delineation of two novel CBMs in the unknown region of Xyn10A 
To identify the function of the amino acid sequence interrupting BiXyn10A, we expressed 
the coding sequence of the cryptic 250 amino acid polypeptide and purified the corresponding 
product for biochemical characterization (TM1, Figure 7.4A and B). Based on initial 
bioinformatics studies suggesting that the insertion sequence is a CBM, we carried out native gel 
analysis to evaluate potential carbohydrate binding activity. An extensive library of soluble 
polysaccharides was used as substrates, as described in the materials and methods. As shown in 
Figure 7.4C, addition of WAX to the gel retarded the migration of TM1, while the control protein 
bovine serum albumin (BSA) migrated to the same position in the two gels, irrespective of the 
presence of WAX (Figure 7.4C, control and WAX). These results showed that the insertion 
sequence is a hitherto uncharacterized CBM. CBMs are usually about 90-120 amino acids in 
length. Therefore, the insertion sequence was unusually large for a single CBM. Bioinformatic 
analysis coupled with truncational and biochemical analyses demonstrated that the unknown 
region contains two CBMs, which we designated BiXyn10A CBM1 and BiXyn10A CBM2. The 
evidence for the two different CBMs is presented in Figue 7.4C (control and WAX), where we 
demonstrate binding to the WAX infused gel by TM2 and TM3. Lichenan and to a lesser extent, 
laminarin, retarded the migration of TM1 and TM3, however the migration of TM2 appeared 
unaffected (Figure 7.4C). This suggested that CBM2 differs in its binding specificity compared to 
CBM1. Very minor changes in migration were seen for TM3 with xyloglucan and konjac 
glucomannan (Figure 7.4C), whereas galactan, arabinogalactan, carboxymethyl cellulose, and 
linear or debranched arabinan did not alter the migration pattern of TM1, TM2 or TM3, suggesting 
that these polysaccharides are not recognized by the CBMs in BiXyn10A (Figure 7.5).  
 
Isothermal titration calorimetry (ITC) demonstrates different specificities of CBM1 and 
CBM2 for oligosaccharides 
 ITC was used to investigate the binding of the CBMs to xylose and xylo-oligosaccharides, 
as xylose constitutes the backbone of WAX. The CBM1 did not show detectable binding to xylose 
(X1), xylobiose (X2), xylotriose (X3), or xylotetraose (X4). However, the protein bound with 
increasing affinity as the chain length increased from xylopentaose (X5) to xylohexaose (X6) 
(Table 7.6, Figure 7.6A). Additional binding experiments with mixed β-1,3/β-1,4 linked gluco-
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oligosaccharides derived from lichenan, and xyloglucanoheptaose derived from xyloglucan 
showed no detectable binding for CBM1 (Figures 7.7A). The CBM2, in contrast, exhibited binding 
activity to X3, with the association constant increasing as the chain length of the oligosaccharide 
increased (Table 7.7, Figure 7.6B). In addition, binding was detected for CBM2 with both lichenan 
and xyloglucan-derived oligosaccharides, although binding to these oligosaccharides were weaker 
when compared to binding to xylo-oligosaccharides (Figure 7.7B). 
 
The CBMs in BiXyn10A contribute to hydrolysis of xylan substrates 
Scanning alanine mutagenesis of aromatic amino acid residues in the two CBMs identified 
W176 and W249 in CBM1 and W363 in CBM2 as amino acids for which alanine substitutions 
abolished binding to xylan (Figure 7.8) and xylo-oligosaccharides (Figure 7.9). To investigate the 
role of the CBMs in the enzymatic activity of BiXyn10A, the three mutations were created in the 
full-length polypeptide (Figure 7.10A) and enzymatic activity examined through kinetic analysis, 
where we measured total release of reducing sugars as we varied concentration of the substrates. 
On OSX, single mutations led to less than half the estimated catalytic efficiency of the wild-type 
enzyme, and the triple mutant exhibited a value lower than a third of the estimate for the wild-type 
protein (Table 7.8). Although a similar effect was observed with the mutants on WAX as substrate, 
in all cases the mutations reduced the estimated catalytic efficiency to only about half that of the 
wild-type enzyme (Table 7.9). The changes in the estimated catalytic efficiencies mostly derived 
from reduced kcat due to the mutations.  
Endo-xylanases cleave substrates in a random fashion. Therefore, components of the end 
products of hydrolysis were also examined for variations due to the presence of the mutations. 
Given that some of the end products may contain side chains, we focused our analysis on the most 
reliable estimate, i.e., determination of xylose concentrations in the mixture by HPLC analysis. 
Other than the triple mutant, which reduced xylose release, the mutations had no significant effect 
on the amount of xylose produced by BiXyn10A on the soluble substrate WAX (Figure 7.10B, 
WAX). While the W249A in CBM1 and W363A in CBM2 led to statistically significant increases 
in xylose release from OSX, the triple mutant led to a highly significant decrease in xylose in the 
end products (Figure 7.10B, OSX).  Thus, mutations that impacted the substrate binding activity 
of the CBMs decreased the hydrolytic activity of the enzyme on xylan substrates and also the 
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composition of the end products. The mutations did not lead to gross changes in the secondary 
structure of the protein as revealed by circular dichroism scans (Table 7.10-7.12).  
 
Phylogenetic distribution of the novel CBM and functional characterization of homologs  
A search of the non-redundant GenBank database with the novel CBM sequence as the 
query retrieved nearly one hundred homologs. Phylogenetic analysis revealed broad distribution 
of this CBM in the Bacteroidetes largely derived from the gut microbial community (Figure 
7.11A). The novel CBM was invariably found in association with GH10 proteins, and are either 
inserted as a single CBM module (e.g., the ruminal bacterium Prevotella bryantii B14 Xyn10C, 
EFI72438.1|136-303|) or tandem CBM repeats as seen for BiXyn10A. The level of amino acid 
sequence homology among the CBMs varied dramatically with some proteins sharing 99% identity 
and others exhibiting 12% identity. Remarkably, this pattern of divergence was noted even 
between two CBMs within a single polypeptide. For example, the two CBMs in BACINT_04197 
(EDV05054.1) share 71% amino acid sequence identity whereas the two CBM repeats in 
BiXyn10A (EDV05072.1) share just 12% identity. 
The broad diversity at the primary sequence level, confirmed by the low bootstrap values 
in the phylogenetic tree (Figure 7.11A), suggested that these CBMs have diverged to perform 
different functions. To evaluate this possibility, representative CBMs (indicated by arrows, Figure 
7.11A) from the different lineages were selected for analyses. Each selected CBM was expressed 
in E. coli and purified (Figure 7.12A) for electrophoretic mobility analysis. The electrophoretic 
mobility of 5 out of 7 newly studied proteins were dramatically retarded in the presence of soluble 
WAX (Figure 7.11B) but not CMC (Figure 7.12B) indicating that these proteins bind to xylan. 
The two new proteins that did not exhibit binding (EDV03684.1 and EDV014052.1) were present 
at the top of both gels, suggesting that the native gel conditions did not support migration of the 
proteins. The ITC analysis revealed that of the five proteins that bound to xylan, four bind to 
xylopentaose (EDV05054.1, EDO10010.1, EEC54455.1, and ADE81777.1) (Figure 7.12). 
Interestingly, the CBM from Prevotella bryantii B14 Xyn10C (Pbr_0377) bound to soluble WAX 
(Figure 7.11B, EFI72438.1) but not to xylopentaose (Figure 7.12C, EFI72438.1) indicating that 
its binding preference was different to the remaining CBMs that bound both polysaccharide and 
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oligosaccharides. Thus, despite the diversity in amino acid sequence, the new CBM family likely 
binds mostly to xylans. 
 
Structural characterization of BiXyn10A CBM1 and P. bryantii B14 Xyn10C CBM 
 Crystallization attempts were carried out on each of the nine recombinant CBMs, with only 
BiXyn10A CBM1 and PbXyn10C CBM yielding diffraction quality crystals. Crystallographic 
phases were independently determined using single wavelength anomalous diffraction for each 
apo CBM, and the structures were subsequently refined to 1.8 Å (apo BiXyn10A CBM1), and 1.68 
Å (apo PbXyn10C CBM). In addition, the co-crystal structure of BiXyn10A CBM1 bound to 
xylohexaose was determined to 1.14 Å resolution (Table 7.13). 
 Despite limited conservation in primary amino acid sequence (15% identity), the structures 
of the two CBMs are architecturally similar and consisted of a characteristic β-sandwich fold 
(Figure 7.13A and B). A structure-based search of the Protein Data Bank using the Dali Server94 
with BiXyn10A CBM1 identified the closest homolog as a CBM4 engineered to bind xylans from 
Rhodothermus marinus  (X-2; 18% sequence identity; RMSD of 2.4 Å over 138 aligned C atoms, 
PDB: 2Y6L) (Figure 7.14B).  
The co-crystal structure of BiXyn10A CBM1 with xylohexaose reveals continuous density 
for only three of the six sugars of the oligosaccharide (Figure 7.13C). Binding of the 
oligosaccharide by CBM1 is facilitated by three -stacking interactions, namely sandwiching of 
the reducing end between Trp176 and Trp249, and stacking of the non-reducing end with His210. 
These observations are in agreement with the mutagenesis studies described above that indicate 
the importance of the two tryptophan residues in engaging the xylo-oligosaccharide ligand. Other 
important hydrogen bonding interactions are provided by Glu178, which interacts with the 
hydroxyls of the center xylose, and Gln282 and Gln213, which form hydrogen bonds with the non-
reducing end sugar (Figure 7.13C).  An additional, water-mediated hydrogen bond occurs between 
Arg252 and the xylose at the non-reducing end. Lastly, while PbXyn10C CBM was crystallized 
in the absence of substrate, a structure-based alignment with BiXyn10A CBM1 shows 
conservation of the binding site. Notably, the amino acids predicted to be responsible for the -
stacking interactions, Tyr 209 and Trp 201 in PbXyn10C CBM are located on the opposite side of 
the binding pocket as Trp 176 and 249 from BiXyn10A CBM1.  
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When compared to the few available CBM structures with a xylan substrate bound, 
BiXyn10A CBM1 engages the oligosaccharide in a novel manner; in particular, the polypeptide 
induced a bend in the bound oligosaccharide (Figure 7.14A). A loop consisting of residues 247-
252 and an -helix encompassing residues 209-211 pinch the ligand to create the bend. The 
binding mode for the sugar is in contrast with that observed for other iso-functional CBMs, such 
as the engineered X-2 (R. marinus CBM4) and CjXyn10C CBM15 of Cellvibrio japonicus 
(1GNY). In each of these structures, the oligosaccharide binds in an extended fashion, orthogonal 
to the direction of the -strands of the CBM (Figure 7.14B and C). 
 
BiXyn10A functions synergistically with gene products of other up-regulated genes to release 
fermentable sugars 
To determine the hydrolytic potential of the enzymes encoded by the most highly up-
regulated genes during WAX fermentation, the top three most highly up-regulated genes were 
expressed in their recombinant forms (Figure 7.15) and examined as an enzyme mix for their 
hydrolytic products on WAX and OSX. In each case, several oligosaccharides and also the 
monosaccharides xylose and arabinose were released. Addition of BiXyl3A (Figure 7.2A, 
BACINT_00926), a GH3-xylosidase, to the enzyme mixture led to detection of largely 
monosaccharides (xylose and arabinose) from WAX and OSX (Figure 7.16A and B).       
 
Discussion 
Members of the phylum Bacteroidetes are among the most abundant organisms in the distal 
human gastrointestinal tract.208 These bacteria possess a remarkable repertoire of genes targeted at 
the utilization of dietary and host-derived polysaccharides,221 which allow for successful 
competition in the gut microbial community. The polysaccharide-targeting genes are arranged in 
clusters termed polysaccharide utilization loci (PULs), which characteristically contain genes 
encoding outer membrane porins, polysaccharide binding proteins, and hydrolytic enzymes in 
addition to transcriptional regulators that govern expression of genes in the corresponding PUL.214 
The Bacteroidetes PULs target specific substrates,212 confer competitive advantages in presence 
of the substrate in the diet,222 and are often within integrative and conjugative elements, permitting 
their transfer among Bacteroidetes in the GIT.223 
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Xylan degradation is increasingly being recognized as an important process in the gut and 
is the subject of intense research as a prebiotic dietary supplement.224 The genome sequences of 
gut bacteria have revealed a large diversity of xylan-degrading enzymes, with the Bacteroidetes 
clearly equipped with the most extensive enzyme systems.213 In particular, the genome of B. 
intestinalis DSM 17393 encodes the greatest abundance of CAZy gene families,216 and our study 
suggests that B. intestinalis has the most elaborate xylan-specific gene repertoire among the 
bacteria with genomes sequenced to date. The xylan-specific transcriptome of B. intestinalis DSM 
17393 consists of nearly 70 genes. Twenty two of these genes map to ~60 kb contiguous region 
on the genome comprised of 2 large PULs each containing an individual hybrid two component 
system regulator (HTCS) (Figure 7.17). The proteins encoded by the genes in this cluster are highly 
modular in their polypeptide architecture and many of these structures are entirely novel.  
The genes that make up the core xylan utilization system in human gut and ruminant 
Bacteroidetes consist of two tandem repeats of SusC/SusD orthologs (XusA-XusD) followed by a 
hypothetical protein (XusE) and finally an endo-xylanase gene (homologous to Xyn10C from P. 
bryantii B14).
215,225 Recently it has been demonstrated that the core xylan utilization genes in the 
human gut symbiont, Bacteroides cellulosilyticus WH2 are critical to fitness in the gut of mice fed 
a polysaccharide rich diet.226 Furthermore, in Bacteroides intestinalis DSM 17393 (current study), 
Bacteroides ovatus ATCC 8683212 (and the current study), Bacteroides cellulosilyticus WH2,226 
and Prevotella bryantii B14,
215 these genes are the most highly up-regulated when the bacteria are 
grown on xylan. However, the biochemical and functional properties of proteins encoded by the 
core genes are poorly understood.  
The modular GH10 proteins within these core clusters are 180-325 amino acids longer than 
other GH10 proteins, indicating the presence of additional domains in these enzymes. A previous 
study of the homolog from P. bryantii B14 (Xyn10C) demonstrated that the protein contains a 
catalytic endo-xylanase module that is disrupted by a 160 amino acid sequence of unknown 
function.227 Another GH10 endo-xylanase from a strain of Prevotella ruminicola was disrupted by 
a segment of 280 amino acids consisting of an imperfect tandem of 130 amino acids.227 We 
demonstrate that these proteins contain either single, or tandem repeats of a CBM that binds to 
xylans. Instead of the usual N- or C-terminal location to the GH domain, the CBMs are integrated 
into a loop present in the GH10 catalytic module. The binding activity of the CBMs is partially 
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mediated by tryptophan residues, and mutation of these residues diminishes enzymatic activity on 
the two xylans used as substrates in the present study. The reduction in activity, especially for the 
triple mutant, was more pronounced on OSX than on WAX (Figure 7.10B, Table 7.8 and Table 
7.9), suggesting that the CBM improves enzymatic activity by targeting the enzyme to insoluble 
xylan. Analogous to Xyn10A, the alpha-amylase (SusG) from the prototypical starch utilization 
system in Bacteroides thetaiotaomicron also possesses a catalytic domain (GH13) interrupted by 
a carbohydrate binding module (CBM58).228 Although the biological significance of having a 
CBM emanating from a loop within the catalytic domain is not clear, the presence of two such 
examples within the Bacteroides spp. suggest there may be an evolutionary benefit. This may be 
borne out by future studies which seek to address specific interactions within the outermembrane 
complexes that consist of transporters, polysaccharide binding proteins, and hydrolytic enzymes. 
While structural alignments with other CBMs demonstrate a common fold, the BiXyn10A 
CBM1-xylohexaose co-crystal structure reveals a distinct strategy for engaging oligosaccharide 
substrates. Specifically, the aromatic residues that typically mediate stacking interactions to 
engage oligosaccharide ligands are located nearly orthogonal to each other, resulting in the 
inducement of a bend in the bound sugar. Several lines of evidence support the assignment of the 
CBMs to a new family. 1) The primary amino acid sequences show low conservation with defined 
CBM families. 2) Structural comparisons of CBMs with other characterized CBMs reveal that the 
xylan substrate binds in a novel orientation with unique amino acids. 3) The CAZy database 
currently groups these proteins into a “non classified” category of CBMs. 
The current study provides important molecular insights into the glycolytic capacity of gut 
bacteria. Beyond the sheer number of enzymes produced by B. intestinalis, a salient point is the 
degree to which these polypeptides are assembled into multi-functional proteins. This is most 
notable for the GH10 proteins, where all 6 proteins display some degree of modularity. The GH10 
protein architectures include C-terminal (GH10-CE1, GH10-GH43) or N-terminal (GH43-GH10) 
appendages as well as two genes with CBM insertions within the GH10 catalytic domain (Figure 
7.2A). The GH10 and GH43 fusion proteins in the Bacteroidetes with the GH43/GH10 
arrangement (BACINT_00569, Figure 7.2A) are currently found only in strains of B. intestinalis 
and B. cellulosilyticus (GenBank accession EEF89781.1 and CDB72001.1), while genes encoding 
GH10/GH43 polypeptides (BACINT_04202) are found in strains of B. intestinalis, B. 
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cellulosilyticus, B. oleiciplenus, B. clarus (human isolates) and B. gallinarum (chicken cecum). 
The most similar protein to BACINT_04202 is a protein from B. intestinalis CAG:564 (GenBank 
accession CCY87565.1) which shares >99% amino acid sequence identity over the GH10 and 
GH43 domains, but just 30% identity over the region joining the two domains (Figure 7.18). 
Analysis of the nucleotide sequence identified two 16 bp inverted repeats in the BACINT_04202 
gene corresponding to the amino acid region joining the two domains (Figure 7.19). Although 
further studies are needed, this observation suggests that integrative and conjugative elements 
serve as a driving force in the evolution of multidomain enzymes in these organisms. 
The other genes that were up-regulated over a hundred-fold (BACINT_00570 and 
BACINT_00569, Figure 7.2A) were expressed and the proteins biochemically analyzed for xylan 
hydrolysis. BACINT_00570 hydrolyzed xylo-oligosaccharides, mostly into xylobiose and 
xylotriose, and on wheat arabinoxylan cleaved only the side-chain arabinose, suggesting an 
enzyme with both -xylosidase and arabinofuranosidase activities in a single catalytic domain. 
The recombinant BACINT_00569 released xylo-oligosaccharides and arabinose from WAX, and 
site-directed mutagenesis demonstrated that the endo-xylanase and arabinofuranosidase activities 
reside in different catalytic domains, i.e., in the GH10 and GH43 catalytic domains, respectively. 
While an enzyme mixture from the top three highly up-regulated genes (Figure 7.2A) released a 
mixture of oligosaccharides and monosaccharides, addition of the enzyme encoded by 
BACINT_00926, a protein determined in our previous report to function as a -xylosidase,218 led 
to depolymerization of both the soluble and insoluble xylans to their unit monosaccharides (xylose 
and arabinose). Both sugars are fermentable by the bacterium to generate energy and building 
blocks. Thus the gene products of only four of the highly up-regulated genes completely 
depolymerized the complex substrate into fermentable sugars. 
The gut microbial community is a complex environment where the interplay of diet and 
host factors, and microbial community dynamics converge to define the specific niche of gut 
microbes. While the true physiological contributions of the xylan degradation genes in the context 
of the human gut microbial community remain to be completely unraveled, our data show that a 
human colonic commensal bacterium has evolved an elaborate mechanism to depolymerize one of 
the recalcitrant polysaccharides found in nature. Furthermore, our results demonstrate that fiber 
digestion in the human lower gut microbial community represents a new paradigm, other than the 
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ruminant and termite gut environments, for prospecting of plant cell wall degrading enzymes, an 
integral part of the emerging biofuel industry. 
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Figures 
 
 
Figure 7.1 Primers used to amplify designated truncational mutants in this study. The 
nucleotide sequences for the individual primers are provided in Table 7.3. The BACINT_04215 
truncational mutants, the primers used, and the amino acid regions constructed are as follows: WT 
(P1-P6, 33-746); TM1 (P2-P5, 138-477); TM2 (P2-P3, 138-301); TM3 (P4-P5, 302-477). The 
amino acid regions amplified for the remaining genes are as follows: BACINT_02810 CBM 2 
(305-484); BACOVA_00247 CBM, 123-358; BACINT_04197 CBM1, 140-329; PBR_0377 
CBM, 133-306; BACOVA_04390 CBM1, 138-330; BACEGG_01298 CBM2, 265-471; 
PRU_2739 CBM2, 278-442. 
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Figure 7.2 Carbohydrate active enzyme encoding genes up-regulated on soluble WAX 
compared with xylose. Each B. intestinalis DSM 17393 (A) or B. ovatus ATCC 8483 (B) gene that 
was overexpressed at least 5-fold was used as a query in a BLASTp search of the non-redundant 
(nr) database at GenBank. Genes were assigned to CAZy207 families if they exhibited significant 
similarity (E-value <1 × 10−5) to biochemically characterized proteins already catalogued in a 
CAZy family. The CAZy annotations were verified using the dbCAN server229 and additional 
domains were predicted using both Pfam230 and the conserved domain database (CDD).231 Signal 
peptides and lipoprotein signal sequences were predicted using SignalP v4.0232 and LipoP v1.0233 
respectively. 
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Figure 7.3 Identification of BACINT_04125 as the most highly up-regulated CAZyme 
encoding gene and functional assignment as an endo-xylanase (Xyn10A). (A) Transcriptome map 
showing RNAseq coverage of the PUL containing BACINT_04215. (B-C) Demonstration of 
endo-xylanase activity. BACINT_04215 WT and its E654A mutant were incubated with WAX or 
OSX or xylo-oligosaccharides for 16 h, and the products were analyzed using a reducing sugar 
assay (B) and by thin layer chromatography (C). In (D), the hydrolytic action on oligosaccharides 
was analyzed by thin layer chromatography. 
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Figure 7.4 Truncational analysis of Xyn10A reveals two carbohydrate binding modules in 
tandem in the polypeptide. (A) Domain organization of Xyn10A wild-type (WT) and truncational 
mutants (TM). (B) Purification of Xyn10A WT and truncational mutants. (C) Affinity gel 
electrophoresis of BiXyn10A tandem CBMs (TM1), CBM1 (TM2) and CBM2 (TM3). Native 
polyacrylamide gels were prepared with or without polysaccharides (0.1% w/v), and 2 g of each 
truncational mutant or 1 g of bovine serum albumin (BSA) was loaded and electrophoresed at 
100 V for 6 h at 4 °C. The proteins were then visualized by staining with Coomassie Brilliant Blue 
G-250. Polysaccharides used in the assays were medium viscosity soluble wheat arabinoxylan 
(WAX), konjac glucomannan (KGM), laminarin, lichenan, and xyloglucan. 
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Figure 7.5 Affinity Gel Electrophoresis. Native polyacrylamide gels were prepared with or 
without 0.1% w/v polysaccharide, and 2 g of each truncational mutant or 1 g of bovine serum 
albumin (BSA) was loaded and electrophoresed at 100 V for 6 h at 4 °C. The proteins were then 
visualized by staining with Coomassie Brilliant Blue G-250. Polysaccharides used were 
carboxymethyl cellulose (CMC), potato galactan, sugar beet arabinan, debranched (DB) arabinan, 
and larch arabinogalactan. 
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Figure 7.6 Representative ITC data for binding of (A) CBM1 and (B) CBM2 with xylo-
oligosaccharides as the ligand. All experiments were carried out in 50 mM sodium phosphate 
buffer, pH 7.0 at 25°C. 
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Figure 7.7 Representative ITC data for binding of (A) CBM1 and (B) CBM2 with lichenan 
and xyloglucan derived oligosaccharides as the ligand. Linkages within the ligands are as follows: 
Glucotetraose A, Glcβ1-3Glcβ1-4Glcβ1-4Glc; Glucotetraose B, Glcβ1-4Glcβ1-4Glcβ1-3Glc, 
Glucotetraose C, Glcβ1-4Glcβ1-3Glcβ1-4Glc; Xyloglucanoheptaose, X3Glc4. All experiments 
were carried out in 50 mM sodium phosphate buffer, pH 7.0 at 25°C. 
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Figure 7.8 Affinity gel electrophoresis. Native polyacrylamide gels were prepared with or 
without 0.1% wheat arabinoxylan (WAX). Two µg of each protein or 1 µg of bovine serum 
albumin (BSA) was loaded and electrophoresed at 100 V for 6 h at 4°C. (A) CBM1 and its mutants. 
(B) CBM2 and its mutants. 
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Figure 7.9 Representative ITC data for binding of (A) CBM1 W176A, (B) CBM1 W249A and 
(C) CBM2 W363A, with xylo-oligosaccharides as the ligand. All experiments were carried out in 
50 mM sodium phosphate buffer, pH 7.0 at 25°C. 
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Figure 7.10 Mutation of critical residues in CBM1 and CBM2 diminishes BiXyn10A-mediated 
hydrolysis of xylans. (A) Domain organization of BiXyn10A, with asterisks indicating locations 
within the gene where site-specific mutations were introduced. (B) BiXyn10A WT, the individual 
site-directed mutants, or the triple mutant (W176A/W249A/W363A) were incubated with WAX 
or OSX at 37°C for 48 h, and the xylose released during hydrolysis was quantified by HPLC as 
indicated in “Experimental Procedures.” *,p<0.05, ***,p<0.001 
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Figure 7.11 Phylogenetic tree of insertion sequences detected in GH10 polypeptides and xylan 
binding activities of representatives. (A) A phylogenetic tree based on amino acid sequences 
aligned using ClustalW,85 was constructed by the maximum likelihood algorithm in MEGA6.234 
Bootstraps were performed with 1,000 replicates. The sequence IDs are color coded according to 
whether they represent a single CBM sequence or are part of a pair of repeated CBM sequences in 
which case a designation of CBM1 for N-terminal CBM, and CBM2 for C-terminal CBM is used. 
The proteins indicated by arrows were cloned, expressed, purified and subsequently assessed for 
xylan binding activity. The Genbank accession numbers or locus IDs in this tree are as follows: 
EJP31444.1 (glycoside hydrolase family 10, Prevotella sp. MSX73), EFC76216.1 (glycoside 
hydrolase family 10, Prevotella buccae D17), EFU31470.1 (glycoside hydrolase family 10, 
Prevotella buccae ATCC 33574), EEF88961.1 (putative glycoside hydrolase family 10, 
Bacteroides cellulosilyticus DSM 14838), EFI38462.1 (glycoside hydrolase family 10,  
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Figure 7.11 (cont.) 
 
Bacteroides sp. 3_1_23), CBK67953.1 (Beta-1,4-xylanase, Bacteroides xylanisolvens XB1A), 
EGK05990.1 (hypothetical protein HMPREF9456_02254, Dysgonomonas mossii DSM 22836), 
EHO73033.1 (hypothetical protein HMPREF9944_00626, Prevotella maculosa OT 289), 
EFI72438.1 (glycoside hydrolase family 10, Prevotella bryantii B14, PBR_0377), EEF88944.1 
(glycoside hydrolase family 10, Bacteroides cellulosilyticus DSM 14838), EDV05054.1 
(glycoside hydrolase family 10, Bacteroides intestinalis DSM 17393, BACINT_04197), 
EDO10010.1 (glycoside hydrolase family 10, Bacteroides ovatus ATCC 8483, 
BACOVA_04390), AFL84731.1 (beta-1,4-xylanase, Belliella baltica DSM 15883), 
WP_010528479.1 (carbohydrate-binding CenC domain protein, Thermophagus  xiamenensis), 
ACX30647.1 (XynB19 precursor, Sphingobacterium sp. TN19), EEC54455.1 (putative glycoside 
hydrolase family 10, Bacteroides eggerthii DSM 20697, BACEGG_01298), EFB34367.1 
(putative glycoside hydrolase family 10, Prevotella copri DSM 18205), EFA43871.1 (glycoside 
hydrolase family 10, Prevotella bergensis DSM 17361), EFI48293.1 (carbohydrate binding 
domain-containing protein, Prevotella oris C735), EDV05072.1 (putative glycoside hydrolase 
family 10, Bacteroides intestinalis DSM 17393, BACINT_04215), EIY38981.1 (hypothetical 
protein HMPREF1062_00490, Bacteroides cellulosilyticus CL02T12C19), EDY95689.1 (putative 
glycoside hydrolase family 10, Bacteroides plebeius DSM 17135), ADF51103.1 (family 10 
glycoside hydrolase, Zunongwangia profunda SM-A87), EGK02428.1 (hypothetical protein 
HMPREF9455_01698, Dysgonomonas gadei ATCC BAA-286), ADY53105.1 (carbohydrate-
binding CenC domain protein, Pedobacter saltans DSM 12145), EJL65303.1 (beta-1,4-xylanase, 
Flavobacterium sp. CF136), WP_010417124.1 (carbohydrate-binding CenC domain protein, 
Anaerophaga thermohalophila), AEV98992.1 (endo-1,4-beta-xylanase, Niastella koreensis 
GR20-10), CCH01345.1 (endo-1,4-beta-xylanase, Fibrella aestuarina BUZ 2), ADB38141.1 
(glycoside hydrolase family 10, Spirosoma linguale DSM 74), CCH00356.1 (glycoside hydrolase 
family 10, Fibrella aestuarina BUZ 2), ADE81777.1 (endo-1,4-beta-xylanase, Prevotella 
ruminicola 23, PRU_2739), EDO14052.1 (putative glycoside hydrolase family 10, Bacteroides 
ovatus ATCC 8483, BACOVA_00247), EEZ05210.1 (hypothetical protein 
HMPREF0102_00209, Bacteroides sp. 2_1_22), EIY59304.1 (hypothetical protein 
HMPREF1069_04286, Bacteroides ovatus CL02T12C04), EDO10798.1 (hypothetical protein 
BACOVA_03431, Bacteroides ovatus ATCC 8483), EFS31249.1 (hypothetical protein 
BSGG_1949, Bacteroides sp. D2), EEF86710.1 (hypothetical protein BACCELL_05690, 
Bacteroides cellulosilyticus DSM 14838), EDV03684.1 (putative glycoside hydrolase family 10, 
Bacteroides intestinalis DSM 17393, BACINT_02810), EDO14247.1 (putative glycoside 
hydrolase family 10, Bacteroides ovatus ATCC 8483), EIY28996.1 (hypothetical protein 
HMPREF1062_03304, Bacteroides cellulosilyticus CL02T12C19). (B) Affinity gel 
electrophoresis of selected proteins. Native polyacrylamide gels were prepared with or without 
0.1% wheat arabinoxylan (WAX), and 2 g of each protein or 1 g of bovine serum albumin 
(BSA) was loaded and electrophoresed at 100 V for 6 h at 4 °C. The proteins were then visualized 
by staining with Coomassie Brilliant Blue G-250. 
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Figure 7.12 The detection of binding activity of selected proteins with CMC and xylo-
oligosaccharides. (A) SDS-PAGE showing the purified proteins. The proteins were purified as 
described in materials and methods. Two µg of protein was loaded on the 12% polyacrylamide gel 
and stained with Coomassie brilliant blue G-250.  (B) Affinity gel electrophoresis. Native 
polyacrylamide gels were prepared with or without 0.1% carboxymethyl cellulose (CMC). Two 
µg of each protein or 1 µg of bovine serum albumin (BSA) was loaded and electrophoresed at 100 
V for 6 h at 4°C. (C) ITC data for binding activity of selected proteins with xylopentaose as the 
ligand. All experiments were carried out in 50 mM sodium phosphate buffer, pH 7.0 at 25°C. 
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Figure 7.13 Overall structures of BiXyn10A CBM1 and PbXyn10C CBM. (A) The overall 
structures of (A) BiXyn10A CBM1 and (B) PbXyn10C CBM contain the typical β-sandwich fold. 
(C) Stereoview of xylotriose bound to BiXyn10A CBM1. 
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Figure 7.14 BiXyn10A CBM1 binds xylotriose in a novel conformation. (A-C) The BiXyn10A 
CBM1, R. marinus X-2 CBM4, and CjXyn10C CBM15, respectively, with bound xylo-
oligosaccharide.  BiXyn10A CBM1 binds xylotriose in a bent conformation, while the R. marinus 
X-2 CBM4 (B) and C. japonicus Xyn10C CBM15 (C) bind xylopentaose in a linear manner. 
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Figure 7.15 SDS-PAGE analysis of the purified recombinant proteins BACINT_04215 
(BiXyn10A), BACINT_00569, BACINT_00570, and BACINT_00926 (BiXyl3A). Two μg of 
each of the proteins was resolved on a 12% SDS-polyacrylamide gel and stained with Coomassie 
brilliant blue G-250. 
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Figure 7.16 BiXyn10A functions synergistically with the most highly up-regulated gene products to degrade xylans. (A) WAX and 
(B) OSX hydrolysis in the presence of the indicated combinations of enzymes were carried out in citrate buffer at 37°C for 24 h. The 
end products of the reactions were resolved by HPAEC by comparison of peaks with retention times of arabinose (A1) and xylose (X1). 
Control reactions were composed of the same constituents in the absence of enzymes. These experiments were performed in triplicate 
and representative results are shown. 
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Figure 7.17 Genomic organization of the major xylan utilization locus in Bacteroides intestinalis DSM 17393. ORF numbers 
indicated within each of the genes correspond to those listed in the GenBank database. Numbering indicates the nucleotide position 
along the genome. Annotations were made using a hybrid approach with dbCAN, RAST, and Pfam as described in the text.  
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Figure 7.18 Amino acid sequence alignment of BACINT_04202 and the most similar protein (CCY87565.1) from B. intestinalis 
CAG:564. The amino acid sequences were obtained from GenBank, aligned with ClustalW, and then visualized using ESPript 3.0. 
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Inverted Repeat 1 
 385            390            395            400            405 
 |              |              |              |              | 
 Q  L  T  I  D  N  S  M  Q  R  D  S  A  A  N  C  Q  L  S  T  V  N  C  Q  L 
CAATTGACAATTGACAATTCTATGCAGCGTGACAGCGCAGCCAATTGTCAATTGTCAACTGTCAATTGTCAATTG 
       |         |         |         |         |         |         | 
       1160      1170      1180      1190      1200      1210      1220 
Inverted Repeat 2 
 385            390            395            400            405 
 |              |              |              |              | 
 Q  L  T  I  D  N  S  M  Q  R  D  S  A  A  N  C  Q  L  S  T  V  N  C  Q  L 
CAATTGACAATTGACAATTCTATGCAGCGTGACAGCGCAGCCAATTGTCAATTGTCAACTGTCAATTGTCAATTG 
       |         |         |         |         |         |         | 
       1160      1170      1180      1190      1200      1210      1220 
 
 
Figure 7.19 Analysis of the inverted repeats in BACINT_04202.  The nucleotide sequence for 
BACINT_04202 was analyzed for inverted and direct repeats using UGENE.235 Two pairs of 
inverted repeats with 23 (IR1) and 43 (IR2) nucleotide spacers were identified with partial overlap 
at the 5′ end. Shaded regions represent the inverted repeats. Top numbers indicate amino acid 
position and the bottom numbers indicate nucleotide positions. 
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Table 7.1     Anaerobic medium for culturing Bacteroides intestinalis DSM 17393 and Bacteroides 
ovatus ATCC 8483 
Ingredients Concentration in Media (mg/L) 
Xylosea 5000 
Wheat arabinoxylan (medium viscosity, 22 cSt)a 5000 
Clarified rumen fluid 200 mL 
Yeast extract 500 
Tryptone 1000 
Resazurin (0.1% w/v) 1.0 mL 
Cysteine-HCl (2.5%, w/v) 10 mL 
Hemin (0.1% w/v) 1.0 mL 
Sodium sulfide (2.5%, w/v) 5.0 mL 
Sodium carbonate (8%, w/v) 30 mL 
  
Mineral solution 1 (mL/L) 75 mL 
        KH2PO4 (6 g/L)  
  
Mineral solution 2 (mL/L) 75 mL  
        KH2PO4 (6 g/L)  
        (NH4)2SO4 (12 g/L)  
        NaCl (12 g/L)  
        MgSO4·7H2O (1.2 g/L)  
        CaCl2·2H2O  (1.2 g/L)  
  
Trace element solution (mL/L) b 10 mL  
        Nitrilotriacetic acid (1.5 g/L)  
        MgSO4·7H2O (3 g/L)  
        MnSO4·2H2O (0.5 g/L)  
        NaCl (1 g/L)  
        FeSO4·7H2O  (0.1 g/L)  
        CoCl2 (0.1 g/L)  
        CaCl2·2H2O  (0.1 g/L)  
        ZnSO4 (0.1 g/L)  
        CuSO4·5H2O  (0.01 g/L)  
        AlK(SO4)2 (0.01 g/L)  
        H3BO3  (0.01 g/L)  
        Na2MoO4·2H2O  (0.01 g/L)  
  
Vitamin solution (mL/L) 5.0 mL 
        Thiamine-HCl (200 mg/L)  
        Riboflavin (200 mg/L)  
        Pyridoxine-HCl (200 mg/L)  
Para-aminobenzoic acid (10 mg/L)  
Biotin (2.5 mg/L)  
Folic acid (2.5 mg/L)  
Calcium pantothenate (200 mg/L)  
Nicotinamide (200 mg/L)  
Vitamin B12 (1 mg/L)  
  
VFA solution (mL/L) 10 mL 
        Acetic acid (16.8% v/v)  
        Propionic acid (6.68% v/v)  
        n-butyric acid (3.96% v/v)  
Isobutyric acid (0.8% v/v)  
n-valeric acid (0.92% v/v)  
Isovaleric acid (0.92% v/v)  
D,L-2-methylbutyric acid (0.8% v/v)  
a  Either xylose or soluble wheat arabinoxylan were used as the sole carbohydrate source. 
b  Trace element solution was prepared as described by Balch et al.236 Nitrilotriacetic acid was first dissolved by adjusting the pH to 6.5 
with KOH. Next, the remaining trace elements were added, the pH was adjusted to 7.0 with KOH, and then the volume was brought to 1 L 
with milliQ H2O. 
  
208 
 
Table 7.2   RNAseq mapping results 
RNAseq Sample ID 
Total reads 
(avg. length) 
Reads after 
Trimminga 
(avg. length) 
Uniquely 
mapped readsb 
(%) 
Non-specifically 
mapped reads 
(%) 
Unmapped 
reads 
(%) 
BACINT_WAX1 10,101,023 
(100 nt) 
10,100,976  
(94.7 nt) 
8,597,177 
(85.1%) 
8,786  
(0.09%) 
1,495,013 
(14.8%) 
BACINT_WAX2 22,325,130  
(100 nt) 
22,325,047  
(94.8 nt) 
18,839,356 
(84.4%) 
20,881  
(0.09%) 
3,464,810 
(15.5%) 
BACINT_Xylose1 17,076,556  
(100 nt) 
17,076,484  
(94.7 nt) 
14,281,134 
(83.6%) 
14,737  
(0.09%) 
2,780,613 
(16.3%) 
BACINT_Xylose2 11,009,018 
(100 nt) 
11,008,962  
(94.9 nt) 
9,142,140 
(83.0%) 
9,677  
(0.09%) 
1,857,145 
(16.9%) 
BACOVA_WAX1 21,824,448  
(100 nt) 
21,824,352  
(95.1 nt) 
16,738,339 
(76.7%) 
125,379  
(0.6%) 
4,960,634 
(22.7%) 
BACOVA_WAX2 27,234,520  
(100 nt) 
27,234,391  
(95.3 nt) 
20,244,307 
(74.3%) 
105,564  
(0.4%) 
6,884,520 
(25.3%) 
BACOVA_Xylose1 11,265,889  
(100 nt) 
11,265,845  
(95.1 nt) 
9,240,294 
(82.0%) 
58,302  
(0.5%) 
2,025,551 
(18.0%) 
BACOVA_Xylose2 15,992,242  
(100 nt) 
15,992,175  
(95.0 nt) 
12,609,816 
(78.8%) 
60,094  
(0.4%) 
3,322,265 
(20.8%) 
a Reads were trimmed using CLC Genomics Workbench v5.0 with a quality score limit of 0.05 and maximum number of ambiguities of 2. 
b Reads were mapped to the B. intestinalis DSM 17393 or B. ovatus ATCC 8483 genome using CLC Genomics Workbench v5.0 with a 
minimum length fraction of 0.9, a minimum similarity fraction of 0.8, and maximum number of hits for a read of 10. 
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Table 7.3     Primers used in this study. 
Gene name Primer name Orientation Sequence (5'  3') 
   
Cloninga   
BACINT_04215 P1 Forward GACGACGACAAGATGGTGGACGACAAACCGTTGGCATTCGAAG 
BACINT_04215 P2 Forward GACGACGACAAGATGAATAACAAGTTTTTGAATTCGTTGATT 
BACINT_04215 P3 Reverse GAGGAGAAGCCCGGTTAAGCCTCAGAATGAGTAATCTTAACATA 
BACINT_04215 P4 Forward GACGACGACAAGATGGCTCCGGTTATGGAAATCTTTACCGAC 
BACINT_04215 P5 Reverse GAGGAGAAGCCCGGTTAGAGAGGAATAGAATTGCCCTTAGTTAC 
BACINT_04215 P6 Reverse GAGGAGAAGCCCGGTTATTTTCCAGCCAATCCATCAGC 
BACINT_02810 P1 Forward GACGACGACAAGATGGCTTCGGGAGGCGCACAATATTTTC 
BACINT_02810 P2 Reverse GAGGAGAAGCCCGGTTAGTAAGCATGCCACTC 
BACOVA_00247 P1 Forward GACGACGACAAGATGAATAATGGGACATTAGTG 
BACOVA_00247 P2 Reverse GAGGAGAAGCCCGGTTACTTAGTTGCAGCAAC 
BACINT_04197 P1 Forward GACGACGACAAGATGCAGCAGAAACAAATGTAC 
BACINT_04197 P2 Reverse GAGGAGAAGCCCGGTTAGTCGGCAAACGAAG 
PBR_0377 P1 Forward GACGACGACAAGATGTCTCAGCAGCAAGTAGC 
PBR_0377 P2 Reverse GAGGAGAAGCCCGGTTACTTTACTTCTTCGGTC 
BACOVA_04390 P1 Forward GACGACGACAAGATGACTAATCAGAATGCGAG 
BACOVA_04390 P2 Reverse GAGGAGAAGCCCGGTTAAAAATCTCCGTTAGAAATC 
BACEGG_01298 P1 Forward GACGACGACAAGATGGTAGGCAAACATACTGGTG 
BACEGG_01298 P2 Reverse GAGGAGAAGCCCGGTTAGCAGGCTTCCATC 
PRU_2739 P1 Forward GACGACGACAAGATGAGCTATGACGGTACTCTTG 
PRU_2739 P2 Reverse GAGGAGAAGCCCGGTTACTCTGTCAGAGGCAG 
    
Mutagenesisb   
BACINT_04215 Y173A Forward GAAATAGACTATTCTACTGCGGGCGCTAGTTTTTGGAACGAAGTAAA
TGAA 
BACINT_04215 F175A Forward GACTATTCTACTGCGGGCTATAGTGCTTGGAACGAAGTAAATGAAGA
AG 
BACINT_04215 W176A Forward CTATTCTACTGCGGGCTATAGTTTTGCGAACGAAGTAAATGAAGAAG 
BACINT_04215 W249A Forward GAATTTTGGTGTAGGACCTGCGAGTGGTAGAGCAGAAGGT 
BACINT_04215 W263A Forward AAGGTTCTTTTTCTTTCAACACAGAAGCGAAAGAGTATGAGTTTTCAT
TCAAAG 
BACINT_04215 W363A Forward CAGCAGGTGGTGGTGTAAATAGTGCGGATACTCAGTTCTT 
BACINT_04215 W421A Forward GGATGTGCTGTTGATTTTACTACAGAAGCGCAACATTTTGAAAAAACT
ATAAC 
BACINT_04215 W445A Forward GAAAACATGCAGACTTTTGCAGCGAATCTTGATGTAGGTGTGCC 
BACINT_04215 E654A Forward TGGTAAACTGGTAAAGATATCAGCACTTGATATGGGTTATATAGATG 
a Underlined sequences indicate the incorporated T4 exonuclease digestion sites. Italicized nucleotides indicate translational stop codons 
inserted at the end of the construct. The primer names correspond to those mentioned in the text and shown in Figure 1. 
b Primers were designed using the Agilent Technologies QuikChange primer design tool. Underlined sequences indicate the substituted 
codon. 
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Table 7.4     Genes up-regulated greater than five-fold during growth of B. intestinalis DSM 17393 
with WAX compared to xylose assessed by RNAseq and listed by magnitude of induction.a 
ORF Annotationb Fold change CAZy Designation 
BACINT_04218 SusC-like 214 - 
BACINT_04220 SusC-like 182 - 
BACINT_04215 endo-xylanase 170 GH10/CBM 
BACINT_04216 hypothetical protein 167 - 
BACINT_04219 SusD-like 142 - 
BACINT_00570 beta-xylosidase 135 GH43 
BACINT_00569 arabinofuranosidase/endo-xylanase 132 GH43/GH10 
BACINT_04217 SusD-like 98.1 - 
BACINT_04201 Na/sodium co-transporter 97.0 - 
BACINT_04202 endo-xylanase/arabinofuranosidase 90.0 GH10/GH43 
BACINT_04199 beta-galactosidase 87.5 GH35 
BACINT_04200 esterase 85.1 GH2/CE6 
BACINT_04198 hypothetical protein 78.4 - 
BACINT_04203 beta-xylosidase 71.0 GH43 
BACINT_04213 endo-xylanase 70.1 GH5 
BACINT_04204 oxidoreductase 65.6 - 
BACINT_04205 alpha-glucuronidase 62.5 GH67 
BACINT_04214 hypothetical protein 60.7 - 
BACINT_04196 hypothetical protein 41.9 - 
BACINT_01180 hypothetical protein 41.7 - 
BACINT_01179 hypothetical protein 41.4 - 
BACINT_04197 endo-xylanase 39.2 GH10/CBM 
BACINT_04195 SusD-like 36.4 - 
BACINT_02768 beta-xylosidase 34.2 GH43 
BACINT_04194 SusC-like 32.1 - 
BACINT_00076 xylanase-esterase 28.8 GH10/CE1 
BACINT_02774 SusC-like 28.2 - 
BACINT_02773 SusD-like 26.3 - 
BACINT_02772 SusC-like 25.8 - 
BACINT_02776 hypothetical protein 25.2 - 
BACINT_01178 hypothetical protein 23.7 - 
BACINT_02767 arabinofuranosidase 22.9 CBM4/GH51 
BACINT_02775 SusD-like 22.5 - 
BACINT_02771 hypothetical protein 21.8 - 
BACINT_00908 SusC-like 21.4 - 
BACINT_00927 exo-xylanase 19.7 GH8 
BACINT_02777 beta-xylosidase 19.7 GH43 
BACINT_00926 beta-xylosidase 19.2 GH3 
BACINT_02766 beta-xylosidase 19.1 GH43 
BACINT_00907 SusD-like 18.7 - 
BACINT_01181 hypothetical protein 17.5 - 
BACINT_02782 L-arabinose isomerase 17.5 - 
BACINT_04210 exo-xylanase 17.2 GH8 
BACINT_04212 esterase 16.8 CE1 
BACINT_02783 xylulose kinase 15.3 - 
BACINT_04706 hypothetical protein 15.1 - 
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Table 7.4 (cont.)   
    
ORF Annotationb Fold change CAZy Designation 
BACINT_01183 hypothetical protein 14.4 - 
BACINT_02784 hypothetical protein 14.4 - 
BACINT_04211 alpha-rhamnosidase 14.3 CE6/GH95 
BACINT_02786 arabinofuranosidase 14.3 GH51 
BACINT_02781 L-ribulose-5-phosphate 4-epimerase 14.2 - 
BACINT_02785 alpha-glucosidase 13.8 GH97 
BACINT_01095 beta-xylosidase 13.5 GH43/CBM6 
BACINT_01182 hypothetical protein 13.4 - 
BACINT_01094 esterase 13.1 CE1 
BACINT_01184 hypothetical protein 12.8 - 
BACINT_02779 Na/sodium cotransporter 10.8 - 
BACINT_04223 hypothetical protein 10.7 GH115 
BACINT_02780 ADP-ribose pyrophosphorylase 10.7 - 
BACINT_02778 aldose 1-epimerase 9.92 - 
BACINT_00772 hypothetical protein 9.14 - 
BACINT_04222 esterase 7.91 GH2/CE6 
BACINT_01185 hypothetical protein 7.47 - 
BACINT_03137 hypothetical protein 7.16 - 
BACINT_01190 hypothetical protein 6.78 - 
BACINT_01096 hypothetical protein 6.17 - 
BACINT_01186 hypothetical protein 5.89 - 
a B. intestinalis DSM 17393 was cultured in a synthetic medium with either soluble wheat arabinoxylan (WAX) or xylose as the sole 
carbohydrate source. RNA was then extracted and RNAseq experiments were performed as described in experimental procedures. 
b Open reading frame assignments and gene annotations were from the Joint Genome Institute’s Integrated Microbial Genomes database 
(http://img.jgi.doe.gov/cgi-bin/w/main.cgi). 
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Table 7.5     Genes up-regulated greater than five-fold during growth of B. ovatus ATCC 8483 with 
WAX compared to xylose assessed by RNAseq and listed by magnitude of induction.a 
ORF Annotationb Fold change CAZy Designation 
BACOVA_04393 SusC-like 341 - 
BACOVA_04390 endo-xylanase 335 GH10/CBM 
BACOVA_04389 Esterase 319 GH2/CE6 
BACOVA_04384 hypothetical protein 312 - 
BACOVA_03427 SusD-like 300 - 
BACOVA_03422 alpha-glucosidase 294 GH31 
BACOVA_03425 beta-xylosidase 286 GH43 
BACOVA_04386 beta-xylosidase 286 GH43 
BACOVA_04385 alpha-glucuronidase 256 GH67 
BACOVA_04387 endo-xylanase 244 GH10 
BACOVA_03426 SusC-like 241 GH35 
BACOVA_03423 alpha-glucosidase 234 GH97 
BACOVA_03428 SusC-like 217 - 
BACOVA_03424 beta-xylosidase 201 GH43/CBM6 
BACOVA_03431 hypothetical protein 201 - 
BACOVA_04391 hypothetical protein 194 - 
BACOVA_03433 endo-beta-galactosidase 171 GH98/CBM35 
BACOVA_03429 SusD-like 166 - 
BACOVA_03432 endo-xylanase 164 GH30 
BACOVA_03421 beta-xylosidase 163 GH43 
BACOVA_03417 beta-xylosidase 158 GH43 
BACOVA_04392 SusD-like 145 - 
BACOVA_04388 Na/sugar cotransporter 112 - 
BACOVA_03434 alpha-glucuronidase 105 GH115 
BACOVA_03436 beta-xylosidase 94.0 GH43/CBM6 
BACOVA_01707 hypothetical protein 71.2 - 
BACOVA_03430 hypothetical protein 58.6 - 
BACOVA_03435 Esterase 49.2 CE6/CE1 
BACOVA_03449 alpha-glucuronidase 43.6 GH115 
BACOVA_01708 alpha-arabinofuranosidase 42.1 GH51 
BACOVA_03450 Esterase 41.3 GH2/CE6 
BACOVA_01709 hypothetical protein 36.6 - 
BACOVA_01715 aldose 1-epimerase 29.6 - 
BACOVA_01714 Na/sugar cotransporter 21.8 - 
BACOVA_01710 xylulose kinase 20.0 - 
BACOVA_03419 beta-xylosidase 19.8 GH3 
BACOVA_01713 ADP-ribose pyrophosphatase 19.5 - 
BACOVA_01711 L-arabinose isomerase 19.2 - 
BACOVA_01712 L-ribulose-5-phosphate 4-epimerase 16.9 - 
213 
 
Table 7.5 (cont.)   
ORF Annotationb Fold change CAZy Designation 
BACOVA_03637 hypothetical protein 15.7 - 
BACOVA_04183 hypothetical protein 11.8 - 
BACOVA_03438 hypothetical protein 10.2 - 
BACOVA_01199 SusD-like 9.63 - 
BACOVA_03483 alpha-arabinofuranosidase 9.00 GH51 
BACOVA_03440 hypothetical protein 8.17 - 
BACOVA_01866 hypothetical protein 8.12 - 
BACOVA_03443 SusC-like 8.00 - 
BACOVA_03447 hypothetical protein 7.98 - 
BACOVA_03437 HTCS regulator 7.83 - 
BACOVA_01865 hypothetical protein 7.69 - 
BACOVA_03444 SusD-like 7.59 - 
BACOVA_03446 hypothetical protein 7.38 - 
BACOVA_01864 hypothetical protein 7.06 - 
BACOVA_03445 hypothetical protein 7.03 - 
BACOVA_03439 hypothetical protein 6.87 - 
BACOVA_03484 alpha-glucosidase 6.59 GH97 
BACOVA_01868 hypothetical protein 6.41 - 
BACOVA_01867 hypothetical protein 6.28 - 
BACOVA_01869 hypothetical protein 5.83 - 
BACOVA_04621 site-specific recombinase 5.75 - 
BACOVA_04960 hypothetical protein 5.62 - 
BACOVA_01497 hypothetical protein 5.23 - 
BACOVA_05005 pectate lyase 5.02 PL1 
a B. ovatus ATCC 8483 was cultured in a synthetic medium with either soluble wheat arabinoxylan (WAX) or xylose as the sole carbohydrate 
source. RNA was then extracted and RNAseq experiments were performed as described in experimental procedures. 
b Open reading frame assignments and gene annotations were from the Joint Genome Institute’s Integrated Microbial Genomes database 
(http://img.jgi.doe.gov/cgi-bin/w/main.cgi). 
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Table 7.6     Affinity of BiXyn10A CBM1 for xylo-oligosaccharides a,b 
Substrate N 
Ka x 103 
(M-1) 
G 
(kJ/mol) 
H 
(kJ/mol) 
TS 
(kJ/mol) 
X1 N.D. N.D. N.D. N.D. N.D. 
X2 N.D. N.D. N.D. N.D. N.D. 
X3 N.D. N.D. N.D. N.D. N.D. 
X4 N.D. N.D. N.D. N.D. N.D. 
X5 0.78 ± 0.17 2.51 ± 0.01 -19.4 -68.9 ± 17.3 -49.5 
X6 0.82 ± 0.15 5.00 ± 0.23 -21.1 -56.9 ± 11.4 -35.8 
a Values are reported as means ± standard errors from the mean for two or three independent experiments. 
b N.D. indicates that no binding was detected. 
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Table 7.7     Affinity of BiXyn10A CBM2 for xylo-oligosaccharides a,b 
Substrate N 
Ka x 103 
 (M-1) 
G 
(kJ/mol) 
H 
(kJ/mol) 
TS 
(kJ/mol) 
X1 N.D. N.D. N.D. N.D. N.D. 
X2 N.D. N.D. N.D. N.D. N.D. 
X3 1.18 ± 0.28 2.11 ± 0.01 -19.0 -37.9 ± 8.46 -18.8 
X4 0.91 ± 0.20 4.25 ± 0.23 -20.8 -51.8 ± 12.4 -31.1 
X5 0.82± 0.08 10.3 ± 0.41 -27.1 -52.6 ± 5.1 -25.4 
X6 1.23 ± 0.04 11.0 ± 0.23 -23.1 -33.9 ± 1.2 -10.8 
a Values are reported as means ± standard errors from the mean for two or three independent 
experiments. 
b N.D. indicates that no binding was detected. 
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Table 7.8     Kinetic properties of BiXyn10A and 
mutants with OSXa 
Protein 
kcat 
(s-1) 
KM 
(ml mg-1) 
kcat/KM 
(ml mg-1 s-1) 
WT 54 ± 6 7.4 ± 2 7.4 ± 2 
W176A 32 ± 7 11 ± 5 2.9 ± 1 
W249A 39 ± 6 11 ± 4 3.4 ± 1 
W363A 27 ± 2 8.8 ± 2 3.1 ± 0.7 
W176A/W249A/W363A 15 ± 1 6.7 ± 1 2.2 ± 0.4 
a  BiXyn10A wild type and mutants were incubated with OSX and initial rates of 
reducing sugar release were monitored at different substrate concentrations. The rate 
of reducing sugar release was plotted against the substrate concentration and non-
linear regressions were used to estimate the kinetic parameters. Experiments were 
performed in triplicate and the data are represented as means ± standard deviations. 
 
  
217 
 
Table 7.9     Kinetic properties of BiXyn10A and 
mutants with WAXa 
Protein 
kcat 
(s-1) 
KM 
(ml mg-1) 
kcat/KM 
(ml mg-1 s-1) 
WT 93 ± 6 1.7 ± 0.4 57 ± 10 
W176A 70 ± 4 2.7 ± 0.5 26 ± 5 
W249A 57 ± 2 1.5 ± 0.2 37 ± 5 
W363A 57 ± 3 2.0 ± 0.3 29 ± 5 
W176A/W249A/W363A 69 ± 3 2.1 ± 0.3 33 ± 5 
a  BiXyn10A wild type and mutants were incubated with WAX and initial rates of 
reducing sugar release were monitored at different substrate concentrations. The rate 
of reducing sugar release was plotted against the substrate concentration and non-
linear regressions were used to estimate the kinetic parameters. Experiments were 
performed in triplicate and the data are represented as means ± standard deviations. 
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Table 7.10     CD spectroscopy analysis of CBM1 and its mutants 
with abolished substrate binding a 
Protein 
-helices 
(%) 
β-strands 
(%) 
β-turns 
(%) 
unordered 
(%) 
CBM1 1 ± 1 49 ± 1 21 ± 0 26 ± 0 
CBM1 W176A 2 ± 1 47 ± 1 22 ± 1 26 ± 1 
CBM1 W249A 3 ± 1 46 ± 2 22 ± 1 27 ± 3 
a  CD spectra were recorded in the far-UV range utilizing a J-815 CD spectropolarimeter. 
The spectra were recorded from 190 to 260 nm at a scan rate of 50 nm/s and a 1-nm 
wavelength step with five accumulations. Each reaction was performed three times, and the 
data are represented as means  standard deviations of the means. The spectra were uploaded 
onto the DICHROWEB on-line server and analyzed as described in supplemental materials 
and methods. 
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Table 7.11     CD spectroscopy analysis of CBM2 and its mutant 
with abolished substrate bindinga 
Protein 
-helices 
(%) 
β-strands 
(%) 
β-turns 
(%) 
unordered 
(%) 
CBM2 2 ± 1 38 ± 0 23 ± 6 34 ± 0 
CBM2 W363A 2 ± 1 39 ± 1 22 ± 1 35 ± 1 
a  CD spectra were recorded in the far-UV range utilizing a J-815 CD spectropolarimeter. The 
spectra were recorded from 190 to 260 nm at a scan rate of 50 nm/s and a 1-nm wavelength step 
with five accumulations. Each reaction was performed three times, and the data are represented as 
means  standard deviations of the means. The spectra were uploaded onto the DICHROWEB on-
line server and analyzed as described in supplemental materials and methods.  
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Table 7.12     CD spectroscopy analysis of BiXyn10A and its 
mutants a 
Protein 
-helices 
(%) 
β-strands 
(%) 
β-turns 
(%) 
unordered 
(%) 
WT 10 ± 0 37 ± 1 22 ± 0 31 ± 1 
E634A 10 ± 2 37 ± 2 22 ± 1 30 ± 1 
W176A 10 ± 2 35 ± 2 22 ± 1 30 ± 0 
W249A 11 ± 1 35 ± 1 22 ± 1 31 ± 1 
W363A 10 ± 2 37 ± 2 22 ± 1 31 ± 1 
W176A/W249A/W363A 10 ± 2 37 ± 2 22 ± 0 30 ± 1 
a  CD spectra were recorded in the far-UV range utilizing a J-815 CD spectropolarimeter. The spectra 
were recorded from 190 to 260 nm at a scan rate of 50 nm/s and a 1-nm wavelength step with five 
accumulations. Each reaction was performed three times, and the data are represented as means  
standard deviations of the means. The spectra were uploaded onto the DICHROWEB on-line server 
and analyzed as described in supplemental materials and methods. 
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Table 7.13     Crystallographic Statistics for BiXyn10A CBM1 and PbXyn10C CBM 
 
 BiXyn10A 
CBM1 
BiXyn10A CBM1-
X6 
PBXyn10C CBM 
Cell Dimensions    
     Space group P21212 P212121 P3121 
     a, b, c (Å) 53.738, 90.657, 
30.998 
36.868, 57.044, 
85.371 
68.683, 68.683, 
111.471 
     α, β, γ, (o) 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 120.0 
     Resolution 22.79-1.80 
(1.83-1.80) 
57.049-1.144 
(1.148-1.144) 
15.83-1.68 (1.71-
1.68) 
     Total Reflections 112,403 513,642 161,095 
     Unique reflections 14,401 (695) 65,859 (4,183) 35,308 (1,720) 
     Rsym (%) 9.0 (59.5) 6.4 (74.7) 5.0 (74.4) 
     I/σ 21.5 (2.38) 16.2 (2.3) 26.5 (2.0) 
     Completeness (%) 100.0 (100.0) 100.0 (99.8) 99.9 (99.8) 
     Redundancy 7.8 (6.5) 7.8 (6.4) 4.6 (4.6) 
Phasing    
     Figure of Merit 0.414  0.260 
 
Refinement    
    Resolution (Å) 22.79-1.801 47.44-1.14 15.83-1.68 
     No. reflections 14,363 62,558 33,795 
     Rwork/Rfree 0.1588/0.1856 0.1603/0.1783 0.1858/0.2078 
No. of atoms    
     Protein 1125 1127 1268 
     Water 190 311 418 
B-factors    
     Protein 16.52 13.64 14.51 
     Sugar  21.74  
     Water 29.14 33.56 30.31 
Ramachandran analysis    
     Favored 98.58 97.9 98.09 
     Allowed 1.42 2.1 1.91 
     Outliers 0.0 0.0 0.0 
RMSD    
     Bond lengths (Å) 0.006 0.0313 0.006 
     Bond angels (o) 1.024 2.362 1.168 
PDB Code 4MGS 4QPW 4MGQ 
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